WO2017083351A1 - Heterologous expression of taurine in microorganisms - Google Patents
Heterologous expression of taurine in microorganisms Download PDFInfo
- Publication number
- WO2017083351A1 WO2017083351A1 PCT/US2016/061081 US2016061081W WO2017083351A1 WO 2017083351 A1 WO2017083351 A1 WO 2017083351A1 US 2016061081 W US2016061081 W US 2016061081W WO 2017083351 A1 WO2017083351 A1 WO 2017083351A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microorganism
- taurine
- seq
- naturally occurring
- polynucleotide
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 493
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 424
- 229960003080 taurine Drugs 0.000 title claims abstract description 212
- 230000014509 gene expression Effects 0.000 title claims description 70
- 230000000694 effects Effects 0.000 claims abstract description 199
- 102000004190 Enzymes Human genes 0.000 claims abstract description 197
- 108090000790 Enzymes Proteins 0.000 claims abstract description 197
- 239000002243 precursor Substances 0.000 claims abstract description 41
- 239000002028 Biomass Substances 0.000 claims abstract description 32
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 27
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 claims abstract description 24
- JTJIXCMSHWPJJE-UHFFFAOYSA-N sulfoacetaldehyde Chemical compound OS(=O)(=O)CC=O JTJIXCMSHWPJJE-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 532
- 102000040430 polynucleotide Human genes 0.000 claims description 532
- 239000002157 polynucleotide Substances 0.000 claims description 532
- 108010058198 sulfoalanine decarboxylase Proteins 0.000 claims description 137
- 102100026278 Cysteine sulfinic acid decarboxylase Human genes 0.000 claims description 129
- 102000008214 Glutamate decarboxylase Human genes 0.000 claims description 123
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims description 123
- 108090000623 proteins and genes Proteins 0.000 claims description 86
- 102000020018 Cystathionine gamma-Lyase Human genes 0.000 claims description 68
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 claims description 68
- 102100040149 Adenylyl-sulfate kinase Human genes 0.000 claims description 64
- 108060008243 Cysteate synthase Proteins 0.000 claims description 54
- 108020004705 Codon Proteins 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 235000018102 proteins Nutrition 0.000 claims description 46
- 108010006152 Serine racemase Proteins 0.000 claims description 40
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 39
- 241000589323 Methylobacterium Species 0.000 claims description 38
- -1 Tpa Proteins 0.000 claims description 37
- 238000004519 manufacturing process Methods 0.000 claims description 36
- 206010010071 Coma Diseases 0.000 claims description 35
- 102100035717 Serine racemase Human genes 0.000 claims description 35
- 102000015295 Cysteine Dioxygenase Human genes 0.000 claims description 34
- 108010039724 Cysteine dioxygenase Proteins 0.000 claims description 34
- 235000021466 carotenoid Nutrition 0.000 claims description 31
- 241000588722 Escherichia Species 0.000 claims description 30
- 241000235070 Saccharomyces Species 0.000 claims description 29
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 27
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 27
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 27
- 101000915771 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) 3-mercaptopropionate dioxygenase Proteins 0.000 claims description 26
- 108010054404 Adenylyl-sulfate kinase Proteins 0.000 claims description 24
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 20
- 230000037430 deletion Effects 0.000 claims description 18
- 238000012217 deletion Methods 0.000 claims description 18
- 230000012010 growth Effects 0.000 claims description 16
- 108010008433 taurine pyruvate aminotransferase Proteins 0.000 claims description 14
- 101710088194 Dehydrogenase Proteins 0.000 claims description 11
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 claims description 11
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims description 11
- 108020001633 phosphosulfolactate synthase Proteins 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 108030003151 Sulfoacetaldehyde acetyltransferases Proteins 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 230000003834 intracellular effect Effects 0.000 claims description 9
- 241000589344 Methylomonas Species 0.000 claims description 8
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 8
- COMVEZIIQHBEJL-UHFFFAOYSA-N 2-hydroxy-2-sulfopropanoic acid Chemical compound OC(=O)C(O)(C)S(O)(=O)=O COMVEZIIQHBEJL-UHFFFAOYSA-N 0.000 claims description 7
- GACDQMDRPRGCTN-KQYNXXCUSA-N 3'-phospho-5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](OP(O)(O)=O)[C@H]1O GACDQMDRPRGCTN-KQYNXXCUSA-N 0.000 claims description 7
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 claims description 7
- 108010041155 Taurine dehydrogenase Proteins 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 6
- 241000235648 Pichia Species 0.000 claims description 6
- 108030002845 Taurine dioxygenases Proteins 0.000 claims description 6
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 6
- DXGPVSAOAACJKU-UHFFFAOYSA-N (1-carboxy-2-sulfoethoxy)-oxido-oxophosphanium Chemical compound P(=O)(=O)OC(C(=O)O)CS(=O)(=O)O DXGPVSAOAACJKU-UHFFFAOYSA-N 0.000 claims description 5
- 101710191344 3-mercaptopropionate dioxygenase Proteins 0.000 claims description 5
- 239000004201 L-cysteine Substances 0.000 claims description 5
- 235000013878 L-cysteine Nutrition 0.000 claims description 5
- 241000589350 Methylobacter Species 0.000 claims description 5
- 241000589345 Methylococcus Species 0.000 claims description 5
- 241000589354 Methylosinus Species 0.000 claims description 5
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 claims description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 5
- 108030003516 Sulfopyruvate decarboxylases Proteins 0.000 claims description 5
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 5
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 4
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 4
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 4
- 241001533203 Methylomicrobium Species 0.000 claims description 4
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 4
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 4
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 4
- 235000013793 astaxanthin Nutrition 0.000 claims description 4
- 239000001168 astaxanthin Substances 0.000 claims description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 4
- 229940022405 astaxanthin Drugs 0.000 claims description 4
- 235000013734 beta-carotene Nutrition 0.000 claims description 4
- 239000011648 beta-carotene Substances 0.000 claims description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 4
- 229960002747 betacarotene Drugs 0.000 claims description 4
- 235000012682 canthaxanthin Nutrition 0.000 claims description 4
- 239000001659 canthaxanthin Substances 0.000 claims description 4
- 229940008033 canthaxanthin Drugs 0.000 claims description 4
- 235000012680 lutein Nutrition 0.000 claims description 4
- 239000001656 lutein Substances 0.000 claims description 4
- 229960005375 lutein Drugs 0.000 claims description 4
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 4
- 235000012661 lycopene Nutrition 0.000 claims description 4
- 239000001751 lycopene Substances 0.000 claims description 4
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 4
- 229960004999 lycopene Drugs 0.000 claims description 4
- 229960003151 mercaptamine Drugs 0.000 claims description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 4
- 235000010930 zeaxanthin Nutrition 0.000 claims description 4
- 239000001775 zeaxanthin Substances 0.000 claims description 4
- 229940043269 zeaxanthin Drugs 0.000 claims description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 4
- 241000186063 Arthrobacter Species 0.000 claims description 3
- 241000862974 Hyphomicrobium Species 0.000 claims description 3
- 241000589325 Methylobacillus Species 0.000 claims description 3
- 241000187654 Nocardia Species 0.000 claims description 3
- 241001057811 Paracoccus <mealybug> Species 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 241000190932 Rhodopseudomonas Species 0.000 claims description 3
- 241000223252 Rhodotorula Species 0.000 claims description 3
- 241000589506 Xanthobacter Species 0.000 claims description 3
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 claims description 2
- 102000016680 Dioxygenases Human genes 0.000 claims description 2
- 108010028143 Dioxygenases Proteins 0.000 claims description 2
- 108090000820 Rhodopsin Proteins 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 102000004330 Rhodopsin Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 33
- 238000009629 microbiological culture Methods 0.000 abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 94
- 210000004027 cell Anatomy 0.000 description 93
- 229920001184 polypeptide Polymers 0.000 description 71
- 108090000765 processed proteins & peptides Proteins 0.000 description 71
- 102000004196 processed proteins & peptides Human genes 0.000 description 71
- 108010022348 Sulfate adenylyltransferase Proteins 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 35
- 230000037361 pathway Effects 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 29
- 244000144974 aquaculture Species 0.000 description 29
- 238000009360 aquaculture Methods 0.000 description 29
- 150000001413 amino acids Chemical class 0.000 description 28
- 101150095937 cuyA gene Proteins 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 239000002609 medium Substances 0.000 description 18
- 241000251468 Actinopterygii Species 0.000 description 17
- 150000001747 carotenoids Chemical class 0.000 description 17
- 230000000813 microbial effect Effects 0.000 description 17
- 230000035772 mutation Effects 0.000 description 17
- 235000019688 fish Nutrition 0.000 description 16
- 229910052799 carbon Inorganic materials 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 150000003505 terpenes Chemical class 0.000 description 12
- 241000589308 Methylobacterium extorquens Species 0.000 description 11
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 229960001153 serine Drugs 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 108060004316 L-cysteine desulfidase Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 8
- 102000004523 Sulfate Adenylyltransferase Human genes 0.000 description 8
- 108030003593 Sulfinoalanine decarboxylases Proteins 0.000 description 8
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 8
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 8
- 238000012239 gene modification Methods 0.000 description 8
- 230000005017 genetic modification Effects 0.000 description 8
- 235000013617 genetically modified food Nutrition 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical class O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 108030006654 L-cysteate sulfo-lyases Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000006652 catabolic pathway Effects 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 6
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 6
- 230000012846 protein folding Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- IPFXNYPSBSIFOB-UHFFFAOYSA-N isopentyl pyrophosphate Chemical compound CC(C)CCO[P@](O)(=O)OP(O)(O)=O IPFXNYPSBSIFOB-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 235000014102 seafood Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 description 4
- 102100036608 Aspartate aminotransferase, cytoplasmic Human genes 0.000 description 4
- 108030002081 Aspartate transaminases Proteins 0.000 description 4
- 102100023162 L-serine dehydratase/L-threonine deaminase Human genes 0.000 description 4
- 108010006519 Molecular Chaperones Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 125000002015 acyclic group Chemical group 0.000 description 4
- 229960004424 carbon dioxide Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000593 degrading effect Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- BUTHMSUEBYPMKJ-UHFFFAOYSA-N 3-sulfopyruvic acid Chemical compound OC(=O)C(=O)CS(O)(=O)=O BUTHMSUEBYPMKJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 241000238424 Crustacea Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 3
- 102000005431 Molecular Chaperones Human genes 0.000 description 3
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 3
- 239000007990 PIPES buffer Substances 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 description 3
- BIWLELKAFXRPDE-UHFFFAOYSA-N all-trans-zeta-carotene Natural products CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)CCC=C(C)CCC=C(C)C BIWLELKAFXRPDE-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001569 carbon dioxide Chemical class 0.000 description 3
- 229910002092 carbon dioxide Chemical class 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229950006137 dexfosfoserine Drugs 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229940076788 pyruvate Drugs 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 208000001644 thecoma Diseases 0.000 description 3
- JVBLPSSXRSHBAY-OQINAPANSA-N (5z)-3-[2-[(1r,4r)-4-hydroxy-2,6,6-trimethylcyclohex-2-en-1-yl]ethyl]-5-[(2e,4e,6e,8e,10e,12e)-13-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]-2,7,11-trimethyltrideca-2,4,6,8,10,12-hexaenylidene]furan-2-one Chemical compound C(\[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C(C=1)\OC(=O)C=1CC[C@H]1C(C)=C[C@H](O)CC1(C)C JVBLPSSXRSHBAY-OQINAPANSA-N 0.000 description 2
- ATCICVFRSJQYDV-UHFFFAOYSA-N (6E,8E,10E,12E,14E,16E,18E,20E,22E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,26,30-dodecaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C ATCICVFRSJQYDV-UHFFFAOYSA-N 0.000 description 2
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 2
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 description 2
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- QXNWZXMBUKUYMD-ITUXNECMSA-N 4-keto-beta-carotene Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C QXNWZXMBUKUYMD-ITUXNECMSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000203069 Archaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102000004031 Carboxy-Lyases Human genes 0.000 description 2
- 108090000489 Carboxy-Lyases Proteins 0.000 description 2
- 108700024124 Cysteine synthases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 241000700141 Rotifera Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- JVBLPSSXRSHBAY-QZEUTGNPSA-N Uriolide Natural products CC(=C/C=C/C=C(C)/C=C/1OC(=O)C(=C1)CCC2C(=CC(O)CC2(C)C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C JVBLPSSXRSHBAY-QZEUTGNPSA-N 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- IUUXWKRRZDDNQG-UHFFFAOYSA-N all-trans-spheroidene Natural products COC(C)(C)CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)CCC=C(C)CCC=C(C)C IUUXWKRRZDDNQG-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- WGIYGODPCLMGQH-UHFFFAOYSA-N delta-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C WGIYGODPCLMGQH-UHFFFAOYSA-N 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- QABFXOMOOYWZLZ-UKMVMLAPSA-N epsilon-carotene Chemical compound CC1=CCCC(C)(C)C1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C QABFXOMOOYWZLZ-UKMVMLAPSA-N 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000011663 gamma-carotene Substances 0.000 description 2
- 235000000633 gamma-carotene Nutrition 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 230000001418 larval effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000000065 osmolyte Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000011765 phytoene Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- CNYVJTJLUKKCGM-RGGGOQHISA-N rhodopin Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCCC(C)(C)O CNYVJTJLUKKCGM-RGGGOQHISA-N 0.000 description 2
- CNYVJTJLUKKCGM-MCBZMHSTSA-N rhodopin Natural products OC(CCC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(\C)/C)\C)/C)\C)/C)\C)/C)(C)C CNYVJTJLUKKCGM-MCBZMHSTSA-N 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 101150025220 sacB gene Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229910021654 trace metal Inorganic materials 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 150000003735 xanthophylls Chemical class 0.000 description 2
- 235000008210 xanthophylls Nutrition 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ZRCXVNZZDQGBQT-XQIHNALSSA-N (3'R)-3'-hydroxy-echinenone Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)CCC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C ZRCXVNZZDQGBQT-XQIHNALSSA-N 0.000 description 1
- ZQFURSYWJPLAJR-UHFFFAOYSA-N (3E)-1-methoxy-3,4-didehydro-1,2,7',8'-tetrahydro-psi,psi-caroten-2-one Chemical compound COC(C)(C)C(=O)C=CC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)CCC=C(C)CCC=C(C)C ZQFURSYWJPLAJR-UHFFFAOYSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- BIPAHAFBQLWRMC-LOFNIBRQSA-N (3R,3'R,6R,6'S)-Tunaxanthin Natural products CC1=CC(O)CC(C)(C)C1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CC(O)CC1(C)C BIPAHAFBQLWRMC-LOFNIBRQSA-N 0.000 description 1
- BZQRJBLJDFPOBX-GBQLTMFZSA-N (3S,3'S)-7,8-Didehydro-astaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C#CC1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C BZQRJBLJDFPOBX-GBQLTMFZSA-N 0.000 description 1
- NZEPSBGUXWWWSI-FWFPOGQTSA-N (3e,5e,7e,9e,11e,13e,15e)-18-[(2r,4s)-2,4-dihydroxy-2,6,6-trimethylcyclohexylidene]-1-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]-3,7,12,16-tetramethyloctadeca-3,5,7,9,11,13,15,17-octaen-2-one Chemical compound C([C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)C(=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C=C=C1C(C)(C)C[C@H](O)C[C@@]1(C)O NZEPSBGUXWWWSI-FWFPOGQTSA-N 0.000 description 1
- SUCKEYMKNGZJHK-ZARIWKGHSA-N (3e,5e,7e,9e,11e,13e,15e,17e)-3-(hydroxymethyl)-18-[(1r,4r)-4-hydroxy-2,6,6-trimethylcyclohex-2-en-1-yl]-1-[(4r)-4-hydroxy-2,6,6-trimethylcyclohexen-1-yl]-7,12,16-trimethyloctadeca-3,5,7,9,11,13,15,17-octaen-2-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1CC(=O)C(\CO)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C SUCKEYMKNGZJHK-ZARIWKGHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PLZRVZWMWJQZSE-DSWSVDFDSA-N 1'-<(beta-D-glucopyranosyl)oxy>-1',2'-dihydro-beta,psi-caroten-4-one Natural products CC(=C/C=C/C(=C/C=C/C(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)CCC1(C)C)/C)/C)CCCC(C)(C)OC2OC(CO)C(O)C(O)C2O PLZRVZWMWJQZSE-DSWSVDFDSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 description 1
- ZRCXVNZZDQGBQT-ZMSRUZMRSA-N 3'-Hydroxyechinenone Natural products O=C1C(C)=C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@@H](O)CC=2C)\C)/C)\C)/C)C(C)(C)CC1 ZRCXVNZZDQGBQT-ZMSRUZMRSA-N 0.000 description 1
- ZRCXVNZZDQGBQT-BANQPSJHSA-N 3'-hydroxyechinenone Chemical compound CC=1C(=O)CCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C ZRCXVNZZDQGBQT-BANQPSJHSA-N 0.000 description 1
- DFNMSBYEEKBETA-JZLJSYQFSA-N 3-Hydroxyechinenone Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C DFNMSBYEEKBETA-JZLJSYQFSA-N 0.000 description 1
- GCDPDLHIDNBTJP-BOBWQXBNSA-N 3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e,19e,21e)-24-hydroxy-3,7,12,16,20,24-hexamethylpentacosa-1,3,5,7,9,11,13,15,17,19,21-undecaenyl]-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC(O)(C)C/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)CCC1(C)C GCDPDLHIDNBTJP-BOBWQXBNSA-N 0.000 description 1
- BZQRJBLJDFPOBX-AKKQMVQHSA-N 7,8-Didehydroastaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1C#CC(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C BZQRJBLJDFPOBX-AKKQMVQHSA-N 0.000 description 1
- OFNSUWBAQRCHAV-UHFFFAOYSA-N 9-cis-antheraxanthin Natural products O1C(CC(O)CC2(C)C)(C)C12C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CC(O)CC1(C)C OFNSUWBAQRCHAV-UHFFFAOYSA-N 0.000 description 1
- YECXHLPYMXGEBI-DOYZGLONSA-N Adonixanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C YECXHLPYMXGEBI-DOYZGLONSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- OFNSUWBAQRCHAV-MATJVGBESA-N Antheraxanthin Natural products O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/[C@]23C(C)(C)C[C@H](O)C[C@@]2(C)O3)\C)/C)\C)/C)=C(C)C1 OFNSUWBAQRCHAV-MATJVGBESA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001597062 Channa argus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- 108010089629 Cysteamine dioxygenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- GCDPDLHIDNBTJP-LEMFVTKFSA-N Desoxy-flexixanthin Natural products CC(=C/C=C/C(=C/C=C/C(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)CCC1(C)C)/C)/C)C=C/CC(C)(C)O GCDPDLHIDNBTJP-LEMFVTKFSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- HNYJHQMUSVNWPV-DRCJTWAYSA-N Diatoxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1C#CC(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C HNYJHQMUSVNWPV-DRCJTWAYSA-N 0.000 description 1
- HNYJHQMUSVNWPV-QWJHPLASSA-N Diatoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C#CC1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C HNYJHQMUSVNWPV-QWJHPLASSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- PVNVIBOWBAPFOE-UHFFFAOYSA-N Dinoxanthin Natural products CC1(O)CC(OC(=O)C)CC(C)(C)C1=C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1(C(CC(O)C2)(C)C)C2(C)O1 PVNVIBOWBAPFOE-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- IWZRTQIXVDXLNL-UHFFFAOYSA-N Hydroxyneurosporene Natural products CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCCC(C)(C)O IWZRTQIXVDXLNL-UHFFFAOYSA-N 0.000 description 1
- 108010059247 Hydroxypyruvate reductase Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- YTZIWAULTIDEEY-UHFFFAOYSA-N Isomeres zeta-Carotin Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C YTZIWAULTIDEEY-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-YSEOPJLNSA-N Isorenieratene Chemical compound CC=1C=CC(C)=C(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=CC(C)=C1C ZCIHMQAPACOQHT-YSEOPJLNSA-N 0.000 description 1
- XVOYSCVBGLVSOL-REOHCLBHSA-N L-cysteic acid Chemical compound OC(=O)[C@@H](N)CS(O)(=O)=O XVOYSCVBGLVSOL-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- BIPAHAFBQLWRMC-IUSVJEKLSA-N Lactucaxanthin Natural products O[C@H]1C=C(C)[C@H](/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/[C@H]2C(C)=C[C@H](O)CC2(C)C)\C)/C)\C)/C)C(C)(C)C1 BIPAHAFBQLWRMC-IUSVJEKLSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VAZQBTJCYODOSV-UHFFFAOYSA-N Me ether-Bacteriopurpurin Natural products COC(C)(C)CC=CC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)C=CCC(C)(C)OC VAZQBTJCYODOSV-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 241000197701 Methylobacterium nodulans Species 0.000 description 1
- 241000272433 Methylobacterium populi Species 0.000 description 1
- 241001430258 Methylobacterium radiotolerans Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- ATCICVFRSJQYDV-DDRHJXQASA-N Neurosporene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C ATCICVFRSJQYDV-DDRHJXQASA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OOUTWVMJGMVRQF-NWYYEFBESA-N Phoenicoxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C OOUTWVMJGMVRQF-NWYYEFBESA-N 0.000 description 1
- 229930186185 Polyprenol Natural products 0.000 description 1
- 229920001731 Polyprenol Polymers 0.000 description 1
- WEELHWARVOLEJX-IFJHFXLNSA-N Rhodopin glucoside Natural products O(C(CCC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(\C)/C)\C)/C)\C)/C)\C)/C)(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 WEELHWARVOLEJX-IFJHFXLNSA-N 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- HKQXGRCDKWFDBE-CZJSGJJBSA-N Siphonaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)CC1=C(C)CC(O)CC1(C)CO)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C HKQXGRCDKWFDBE-CZJSGJJBSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- AXDLADCVDYBQBY-XRKCEDLHSA-N Spheroidenone Natural products COC(C)(C)C(=O)C=CC(=CC=CC(=CC=CC(=CC=CC=CC(C)C=C/C=C(C)/CCC=C(/C)CC=C(C)C)C)C)C AXDLADCVDYBQBY-XRKCEDLHSA-N 0.000 description 1
- ZSLHSVCDHQRPAB-UHFFFAOYSA-N Spirilloxanthin Natural products COC(C)(C)CC=CC(=CC=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C=CC=C(/C)CCCC(C)(C)C)C)C)C ZSLHSVCDHQRPAB-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 101100481791 Streptoalloteichus tenebrarius (strain ATCC 17920 / DSM 40477 / JCM 4838 / CBS 697.72 / NBRC 16175 / NCIMB 11028 / NRRL B-12390 / A12253. 1) tobZ gene Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- YECXHLPYMXGEBI-ZNQVSPAOSA-N adonixanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C YECXHLPYMXGEBI-ZNQVSPAOSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 description 1
- PGYAYSRVSAJXTE-CLONMANBSA-N all-trans-neoxanthin Chemical compound C(\[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C=C=C1C(C)(C)C[C@H](O)C[C@@]1(C)O PGYAYSRVSAJXTE-CLONMANBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- IGABZIVJSNQMPZ-UHFFFAOYSA-N alpha-Zeacarotene Natural products CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C IGABZIVJSNQMPZ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- OFNSUWBAQRCHAV-OYQUVCAXSA-N antheraxanthin Chemical compound C(/[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C OFNSUWBAQRCHAV-OYQUVCAXSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- NMMZEYGYFYIADS-FOHJNKRASA-N beta-Isorenieratene Chemical compound CC=1C=CC(C)=C(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NMMZEYGYFYIADS-FOHJNKRASA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- 239000011774 beta-cryptoxanthin Substances 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- IWZRTQIXVDXLNL-PZKADDIDSA-N chloroxanthin Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCCC(C)(C)O IWZRTQIXVDXLNL-PZKADDIDSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000641 cold extrusion Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- WGIYGODPCLMGQH-ZNTKZCHQSA-N delta-Carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C WGIYGODPCLMGQH-ZNTKZCHQSA-N 0.000 description 1
- 235000001581 delta-carotene Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- BIWLELKAFXRPDE-PCYOLSTGSA-N di-cis-zeta-carotene Natural products CC(C)=CCCC(C)=CCCC(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(\C)CCC=C(C)CCC=C(C)C BIWLELKAFXRPDE-PCYOLSTGSA-N 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000006932 echinenone Nutrition 0.000 description 1
- YXPMCBGFLULSGQ-YHEDCBSUSA-N echinenone Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(=O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C YXPMCBGFLULSGQ-YHEDCBSUSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000002680 epsilon-carotene Nutrition 0.000 description 1
- QABFXOMOOYWZLZ-UWXQCODUSA-N epsilon-carotene Natural products CC(=CC=CC=C(C)C=CC=C(C)C=C[C@H]1C(=CCCC1(C)C)C)C=CC=C(C)C=C[C@H]2C(=CCCC2(C)C)C QABFXOMOOYWZLZ-UWXQCODUSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 1
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 1
- LBCWAKKSVZUJKE-YGQWAKCJSA-N fucoxanthinol Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)CC12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=C=C3C(O)CC(O)CC3(C)C LBCWAKKSVZUJKE-YGQWAKCJSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- HRQKOYFGHJYEFS-BXOLYSJBSA-N gamma-carotene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-BXOLYSJBSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000001192 hot extrusion Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- BIPAHAFBQLWRMC-KLCRVCSUSA-N lactucaxanthin Chemical compound C(\[C@@H]1C(C[C@@H](O)C=C1C)(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=C[C@H]1C(C)=C[C@H](O)CC1(C)C BIPAHAFBQLWRMC-KLCRVCSUSA-N 0.000 description 1
- 235000004490 lactucaxanthin Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000001450 methanotrophic effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- OWAAYLVMANNJOG-OAKWGMHJSA-N neoxanthin Natural products CC(=C/C=C(C)/C=C/C=C(C)/C=C=C1C(C)(C)CC(O)CC1(C)O)C=CC=C(/C)C=CC23OC2(C)CC(O)CC3(C)C OWAAYLVMANNJOG-OAKWGMHJSA-N 0.000 description 1
- 235000008665 neurosporene Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000003096 polyprenols Chemical class 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- DFNMSBYEEKBETA-FXGCUYOLSA-N rac-3-Hydroxyechinenon Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DFNMSBYEEKBETA-FXGCUYOLSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 235000009514 rubixanthin Nutrition 0.000 description 1
- 239000000455 rubixanthin Substances 0.000 description 1
- ABTRFGSPYXCGMR-SDPRXREBSA-N rubixanthin Natural products O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=C(\CC/C=C(\C)/C)/C)\C)/C)\C)/C)=C(C)C1 ABTRFGSPYXCGMR-SDPRXREBSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000001606 spheroiden-2-one Nutrition 0.000 description 1
- FJOCMTHZSURUFA-AXYGSFPTSA-N spheroidene Chemical compound COC(C)(C)C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)CC\C=C(/C)CCC=C(C)C FJOCMTHZSURUFA-AXYGSFPTSA-N 0.000 description 1
- QCZWKLBJYRVKPW-LYWCOASQSA-N spheroidene Natural products COC(C)(C)CC=CC(=CC=CC(=CC=CC(=CC=CC=CC(C)C=C/C=C(C)/CCC=C(/C)CC=C(C)C)C)C)C QCZWKLBJYRVKPW-LYWCOASQSA-N 0.000 description 1
- VAZQBTJCYODOSV-HZUCFJANSA-N spirilloxanthin Chemical compound COC(C)(C)C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)\C=C\CC(C)(C)OC VAZQBTJCYODOSV-HZUCFJANSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003535 tetraterpenes Chemical class 0.000 description 1
- 235000009657 tetraterpenes Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AIBOHNYYKWYQMM-MXBSLTGDSA-N torulene Chemical compound CC(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AIBOHNYYKWYQMM-MXBSLTGDSA-N 0.000 description 1
- VAZQBTJCYODOSV-SRGNDVFZSA-N trans-Spirilloxanthin Natural products COC(C)(C)CC=C/C(=C/C=C/C(=C/C=C/C(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(C)/C=CCC(C)(C)OC)/C)/C)/C VAZQBTJCYODOSV-SRGNDVFZSA-N 0.000 description 1
- NMMZEYGYFYIADS-GGMQMQDSSA-N trans-beta-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C NMMZEYGYFYIADS-GGMQMQDSSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 101150002118 xsc gene Proteins 0.000 description 1
- OFNSUWBAQRCHAV-KYHIUUMWSA-N zeaxanthin monoepoxide Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC3=C(C)CC(O)CC3(C)C OFNSUWBAQRCHAV-KYHIUUMWSA-N 0.000 description 1
- BIWLELKAFXRPDE-XXKNMTJFSA-N zeta-Carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)\C)(\C=C\C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)/C BIWLELKAFXRPDE-XXKNMTJFSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/40—Colouring or decolouring of foods
- A23L5/42—Addition of dyes or pigments, e.g. in combination with optical brighteners
- A23L5/43—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives
- A23L5/44—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives using carotenoids or xanthophylls
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P11/00—Preparation of sulfur-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/001—Amines; Imines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention relates to recombinant production of taurine in microbial organisms, and use in feed compositions, in particular for aquaculture, animal feeds and human nutrition.
- Taurine (2-aminoethanesulfonic acid) is a 2-carbon ( )-amino acid found in a broad swath of organisms, from birds to mammals, fish to plants, fungi and bacteria (McCusker et al. (2014) JNutr Sci 3:e39). While some proteins contain taurine, it does not form peptide bonds due to the lack of a carboxyl group. In fact, taurine is the most abundant free amino acid (FAA) present in animal tissues, constituting 19% of the FAA in the brain, 50% in kidney, and 53% in muscle. (Brosnan et al. (2006) JNutr. 136(6): 16365 -16405)
- Taurine is critical in many basic cellular processes, including osmoregulation, membrane stabilization, and anti oxidation. (Honjoh et al. (2010) Amino Acids . 38(4): 1173- 1183; Takeuchi et al. (2000) Biochim Biophys Acta. 1464(2):219-230) In addition, taurine participates in a variety of more complex physiological functions, such as bile conjugation and calcium signaling. (Salze et al. (2015) Aquaculture 437:215-229). Taurine and hypotaurine have also been shown to aid in protein folding (Warskulat et al. (2007) Methods Enzymol 428:439-58; Abe et al. (2015) Amino acids 47(5):909-15; Fujii et al. (2007) J Biochem 141(5):697-707).
- taurine can be detected at high levels in a variety of fish species, some taurine has been suggested as a conditionally essential nutrient for many carnivorous fish species, from trout to snakehead, and its supplementation has been shown to increase their growth rate. (Gibson et al. (2007) Aquaculture 269(l-4):514-524; Wu et al. (2015) Aquae Nutr. 21 (2):214-222) Furthermore, it appears that taurine supplementation can complement the reduction of fishmeal in the feedstock, a critical objective for achieving a more sustainable form of aquaculture.
- taurine is often a necessary addition to feed. Inadequate levels of taurine may cause severe degenerative changes in the retina, visual cortex and brain development. Taurine has also been reported to have anti-epilepsy properties. (Ripps and Shen (2012) Molecular Vision 18:2673-2786)
- non-naturally occurring microorganisms that express one or more polynucleotide(s) expressing exogenous enzyme(s) for production of taurine.
- a non-naturally occurring microorganism expresses the following enzyme activities: (a) cysteamine (2-aminoethanethiol) di oxygenase (ADO); (b) cysteine dioxygenase (CDO), and cysteine sulfinic acid decarboxylase (CSAD) or glutamate decarboxylase (GAD); (c) 3-mercaptopropionate dioxygenase (p3MDO), and CSAD or GAD; (d) L-serine dehydratase; sulfate adenyltransferase and adenylyl-sulfate kinase (APSK), and/or 3'-phosphoadenosine 5'-phosphosulfate synthase (PAPSS 1)
- the non-naturally occurring microorganism is derived from a host cell from genera selected from Methylobacterium, Methylomonas , Methylobacter . Methylococcus , Methylosinus , Methylocyctis , Methylomicrobium, Methylomonas,
- the microorganism may be selected from Methylobacterium, Escherichia, Saccharomyces, and Bacillus.
- the non-naturally occurring microorganism is a methylotrophic bacterium.
- the non-naturally occurring microorganism may be aMethylobacterium species, such as but not limited to,
- Methylobacterium extorquens Methylobacterium extorquens.
- the one or more exogenous polynucleotide(s) is/are codon optimized for expression in the microorganism. In some embodiments, the one or more exogenous polynucleotide(s) is/are operably linked to promoter(s) for expression in the microorganism.
- the non-naturally occurring microorganism includes deletion of one or more genes that encode enzyme(s) that degrade taurine or the taurine precursor cysteate or sulfoacetaldehyde or modification of one or more genes that encode enzyme(s) that degrade taurine, cysteate, or sulfoacetaldehyde such that activity of the one or more enzyme(s) that degrade taurine, cysteate, or sulfoacetaldehyde is lower than in the microorganism parent strain from which the non-naturally microorganism is derived.
- the one or more enzyme(s) that degrade taurine, cysteate, or sulfoacetaldehyde includes taurine dehydrogenase, taurine dioxygenase, Xsc, CuyA, Tpa, and/or gamma-glutamyltransferase.
- the non-naturally occurring microorganism is genetically modified or artificially pre-selected to produce elevated levels of a carotenoid compound relative to the corresponding unmodified or unselected microorganism.
- the microorganism may produce elevated levels of one or more carotenoid compound(s) selected from ⁇ -carotene, lycopene, rhodopsin, zeaxanthin, lutein, canthaxanthin, astaxanthin, and sprilloxanthin, in comparison to the host cell from which the carotenoid producing microorganism is derived.
- the non-naturally occurring microorganism accumulates intracellular taurine and/or hypotaurine, wherein the taurine and/or hypotaurine aids in the folding of one or more native and/or heterologous protein(s), e.g., for the purpose of increased enzymatic activity and/or protein yield in comparison to the parent
- microorganism from which the non-naturally occurring microorganism is derived e.g., a parent microorganism that does not include the one or more exogenous polynucleotide(s).
- methods for producing biomass that includes taurine and/or taurine precursors such as cysteate, sulfoacetaldehyde, and/or hypotaurine.
- the methods include culturing a non-naturally occurring microorganism as described herein in a culture medium under conditions suitable for growth of the microorganism and expression of exogenous enzyme(s) for production of taurine and/or taurine precursors, wherein biomass comprising taurine and/or taurine precursors is produced in the culture.
- a feed or nutritional supplement that includes taurine- and/or taurine precursor-containing biomass produced as described herein.
- Figure 1 depicts an embodiment of a biosynthetic pathway for production of taurine from cysteamine.
- Figure 2 depicts an embodiment of a biosynthetic pathway for production of taurine from L-cysteine.
- Figure 3 depicts an embodiment of a biosynthetic pathway for production of taurine from L-cysteine.
- Figure 4 depicts an embodiment of a biosynthetic pathway for production of taurine from L-serine.
- Figure 5 depicts an embodiment of a biosynthetic pathway for production of taurine from L-phosphoserine or L-serine.
- Figure 6 depicts an embodiment of a biosynthetic pathway for production of taurine from L-cysteine.
- Figure 7 depicts an embodiment of a biosynthetic pathway for production of taurine from L-cysteine.
- Figure 8 depicts an embodiment of a biosynthetic pathway for production of taurine from pyruvate.
- Figure 9 depicts an embodiment of a biosynthetic pathway for production of taurine from phosphoenolpyruvate.
- Figure 10 depicts an embodiment of a biosynthetic pathway for production of taurine from acetyl phosphate.
- Figure 11 depicts an embodiment of a biosynthetic pathway for production of taurine from phosphoenolpyruvate.
- Figure 12 depicts an embodiment of a biosynthetic pathway for production of taurine through taurine-pyruvate aminotransferase.
- FIG. 13 depicts taurine and cysteate degradation pathways.
- the invention described herein addresses the dual challenge of producing taurine from an inexpensive feedstock, and encapsulating it to prevent dissolution in water for aquaculture.
- Microbial systems for taurine production are described as well as feed products in which the taurine is encapsulated in a natural lipid bilayer (microbial cells).
- non-naturally occurring microorganisms e.g., bacteria, yeast, Archaea, that are capable of producing taurine and/or the taurine precursor(s), e.g., hypotaurine or cysteate.
- aquaculture feeds, pet food, and nutritional supplement compositions are provided that include taurine-containing microbial biomass and a complete protein nutrition, that is, containing most or all amino acids necessary for healthy growth of the animal to which it is administered.
- the aquaculture feed compositions herein contain one or more carotenoid(s) produced by the microorganism that produces taurine and/or taurine precursor(s), e.g. , hypotaurine or cysteate.
- the microbial biomass can be blended with other ingredients to form a portion or whole of a feed, or may be consumed directly as a protein-rich powder.
- Osmolytes such as betaine, glycine, trimethylamine N-Oxide (TMAO), and taurine can aid in protein folding (Warskulat et al. (2007) Methods Enzymol 428:439-58; Abe et al. (2015) Amino acids 47(5):909-15; Fujii et al. (2007) J Biochem 141(5):697-707).
- Microorganisms engineered to accumulate intracellular taurine as a chemical chaperone could produce higher yields or more active proteins of interest.
- taurine, hypotaurine, and their precursors also promote protein activity by limiting protein inactivation through oxidation (Oliveira et al.
- nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.
- polynucleotide refers to a polymeric form of nucleotides of any length and any three-dimensional structure and single- or multi-stranded (e.g., single-stranded, double-stranded, triple-helical, etc.), which contain
- deoxyribonucleotides or ribonucleotides including modified nucleotides or bases or their analogs. Because the genetic code is degenerate, more than one codon may be used to encode a particular amino acid, and the present invention encompasses polynucleotides which encode a particular amino acid sequence. Any type of modified nucleotide or nucleotide analog may be used, so long as the polynucleotide retains the desired functionality under conditions of use, including modifications that increase nuclease resistance (e.g., deoxy, 2'-0-Me, phosphorothioates, etc.).
- modifications that increase nuclease resistance e.g., deoxy, 2'-0-Me, phosphorothioates, etc.
- Labels may also be incorporated for purposes of detection or capture, for example, radioactive or nonradioactive labels or anchors, e.g., biotin.
- polynucleotide also includes peptide nucleic acids (PNA). Polynucleotides may be naturally occurring or non-naturally occurring.
- Polynucleotide “nucleic acid,” and “oligonucleotide” are used herein interchangeably. Polynucleotides may contain RNA, DNA, or both, and/or modified forms and/or analogs thereof. A sequence of nucleotides may be interrupted by non-nucleotide components. One or more phosphodiester linkages may be replaced by alternative linking groups.
- linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(0)S ("thioate”), P(S)S ("dithioate”), (0)NR.sub.2 (“amidate”), P(0)R, P(0)OR', CO or CH.sub.2 (“formacetal”), in which each R or R is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (— 0 ⁇ ) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. Polynucleotides may be linear or circular or comprise a combination of linear and circular portions.
- polypeptide refers to a composition comprised of amino acids and recognized as a protein by those of skill in the art.
- the conventional one-letter or three- letter code for amino acid residues is used herein.
- polypeptide and protein are used interchangeably herein to refer to polymers of amino acids of any length.
- the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
- the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
- polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
- a "vector” refers to a polynucleotide sequence designed to introduce nucleic acids into one or more cell types.
- Vectors include cloning vectors, expression vectors, shuttle vectors, plasmids, phage particles, cassettes and the like.
- expression refers to the process by which a polypeptide is produced based on the nucleic acid sequence of a gene. The process includes both transcription and translation.
- expression vector refers to a DNA construct containing a DNA coding sequence (e.g., gene sequence) that is operably linked to one or more suitable control sequence(s) capable of effecting expression of the coding sequence in a host.
- control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control termination of transcription and translation.
- the vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself.
- the plasmid is the most commonly used form of expression vector. However, the invention is intended to include such other forms of expression vectors that serve equivalent functions and which are, or become, known in the art.
- a "promoter” refers to a regulatory sequence that is involved in binding RNA polymerase to initiate transcription of a gene.
- a promoter may be an inducible promoter or a constitutive promoter.
- An "inducible promoter” is a promoter that is active under environmental or developmental regulatory conditions.
- operably linked refers to a juxtaposition or arrangement of specified elements that allows them to perform in concert to bring about an effect.
- a promoter is operably linked to a coding sequence if it controls the transcription of the coding sequence.
- Under transcriptional control is a term well understood in the art that indicates that transcription of a polynucleotide sequence depends on its being operably linked to an element which contributes to the initiation of, or promotes transcription.
- Under translational control is a term well understood in the art that indicates a regulatory process which occurs after mRNA has been formed.
- a "gene” refers to a DNA segment that is involved in producing a polypeptide and includes regions preceding and following the coding regions as well as intervening sequences (introns) between individual coding segments (exons).
- the term "host cell” refers to a cell or cell line into which a recombinant expression vector for production of a polypeptide may be transfected for expression of the polypeptide.
- Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
- a host cell includes cells transfected or transformed in vivo with an expression vector.
- the term "recombinant,” refers to genetic material (i.e., nucleic acids, the polypeptides they encode, and vectors and cells comprising such polynucleotides) that has been modified to alter its sequence or expression characteristics, such as by mutating the coding sequence to produce an altered polypeptide, fusing the coding sequence to that of another gene, placing a gene under the control of a different promoter, expressing a gene in a heterologous organism, expressing a gene at a decreased or elevated levels, expressing a gene conditionally or constitutively in manner different from its natural expression profile, and the like.
- nucleic acids, polypeptides, and cells based thereon have been manipulated by man such that they are not identical to related nucleic acids, polypeptides, and cells found in nature.
- a "signal sequence” refers to a sequence of amino acids bound to the N-terminal portion of a protein which facilitates the secretion of the mature form of the protein from the cell.
- the mature form of the extracellular protein lacks the signal sequence which is cleaved off during the secretion process.
- selectable marker refers to a gene capable of expression in a host cell that allows for ease of selection of those hosts containing an introduced nucleic acid or vector.
- selectable markers include but are not limited to antimicrobial substances (e.g. , hygromycin, bleomycin, or chloramphenicol) and/or genes that confer a metabolic advantage, such as a nutritional advantage, on the host cell.
- the term “derived from” encompasses the terms “originated from,” “obtained from,” “obtainable from,” “isolated from,” and “created from,” and generally indicates that one specified material finds its origin in another specified material or has features that can be described with reference to the another specified material.
- the term “culturing” refers to growing a population of cells, e.g., microbial cells, under suitable conditions for growth, in a liquid or solid medium.
- heterologous or “exogenous,” with reference to a polynucleotide or protein, refers to a polynucleotide or protein that does not naturally occur in a specified cell, e.g., a host cell. It is intended that the term encompass proteins that are encoded by naturally occurring genes, mutated genes, and/or synthetic genes.
- homologous with reference to a polynucleotide or protein, refers to a polynucleotide or protein that occurs naturally in the cell.
- Transfection or “transformation” refers to the insertion of an exogenous polynucleotide into a host cell.
- the exogenous polynucleotide may be maintained as a non- integrated vector, for example, a plasmid, or alternatively, may be integrated into the host cell genome.
- transfecting or “transfection” is intended to encompass all conventional techniques for introducing nucleic acid into host cells. Examples of transfection techniques include, but are not limited to, calcium phosphate precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, and microinjection.
- transformed As used herein, the terms “transformed,” “stably transformed,” and “transgenic” refer to a cell that has a non-native (e.g. , heterologous) nucleic acid sequence integrated into its genome or as an episomal plasmid that is maintained through multiple generations.
- non-native e.g. , heterologous
- recovered refers to a material (e.g., a protein, nucleic acid, or cell) that is removed from at least one component with which it is naturally associated.
- these terms may refer to a material which is substantially or essentially free from components which normally accompany it as found in its native state, such as, for example, an intact biological system.
- a “signal sequence” (also termed “presequence,” “signal peptide,” “leader sequence,” or “leader peptide”) refers to a sequence of amino acids at the amino terminus of a nascent polypeptide that targets the polypeptide to the secretory pathway and is cleaved from the nascent polypeptide once it is translocated in the endoplasmic reticulum membrane.
- variant proteins encompass "variant" proteins.
- Variant proteins differ from a parent protein and/or from one another by a small number of amino acid residues. In some embodiments, the number of different amino acid residues is any of about 1, 2, 3, 4, 5, 10, 20, 25, 30, 35, 40, 45, or 50. In some embodiments, variants differ by about 1 to about 10 amino acids. Alternatively or additionally, variants may have a specified degree of sequence identity with a reference protein or nucleic acid, e.g., as determined using a sequence alignment tool, such as BLAST, ALIGN, and CLUSTAL (see, infra).
- variant proteins or nucleic acid may have at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or even 99.5% amino acid sequence identity with a reference sequence.
- analogous sequence refers to a polypeptide sequence within a protein that provides a similar function, tertiary structure, and/or conserved residues with respect to a reference protein. For example, in epitope regions that contain an alpha helix or a beta sheet structure, replacement amino acid(s) in an analogous sequence maintain the same structural element.
- analogous sequences are provided that result in a variant enzyme exhibiting a similar or improved function with respect to the parent protein from which the variant is derived.
- homologous protein refers to a protein that has similar function and/or structure as a reference protein. Homologs may be from evolutionarily related or unrelated species. In some embodiments, a homolog has a quaternary, tertiary and/or primary structure similar to that of a reference protein, thereby potentially allowing for replacement of a segment or fragment in the reference protein with an analogous segment or fragment from the homolog, with reduced disruptiveness of structure and/or function of the reference protein in comparison with replacement of the segment or fragment with a sequence from a non-homologous protein.
- wild-type As used herein, wild-type, “native,” and “naturally-occurring” proteins are those found in nature.
- wild-type sequence refers to an amino acid or nucleic acid sequence that is found in nature or naturally occurring.
- a wild-type sequence is the starting point of a protein engineering project, for example, production of variant proteins.
- phrases "substantially similar” and “substantially identical” in the context of at least two nucleic acids or polypeptides typically means that a polynucleotide, polypeptide, or region or domain of a polypeptide that comprises a sequence that has at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or even 99.5% sequence identity, in comparison with a reference (e.g., wild-type) polynucleotide, polypeptide, or region or domain of a polypeptide.
- a reference e.g., wild-type
- a region or domain of a polypeptide may contain, for example, at least about 20, 50, 100, or 200 amino acids within a longer polypeptide sequence. Sequence identity may be determined using known programs such as BLAST, ALIGN, and CLUSTAL using standard parameters. (See, e.g., Altshul et al. (1990) J. Mol. Biol. 215:403-410; Henikoff et al. (1989) Proc. Natl. Acad. Sci. 89: 10915; Karin et al. (1993) Proc. Natl. Acad. Sci. 90:5873; and Higgins et al. (1988) Gene 73:237).
- substantially identical polypeptides differ only by one or more conservative amino acid substitutions.
- substantially identical polypeptides are immunologically cross- reactive.
- substantially identical nucleic acid molecules hybridize to each other under stringent conditions (e.g., within a range of medium to high stringency).
- carotenoid is understood in the art to refer to a structurally diverse class of pigments derived from isoprenoid pathway intermediates.
- the commitment step in carotenoid biosynthesis is the formation of phytoene from geranylgeranyl pyrophosphate.
- Carotenoids can be acyclic or cyclic, and may or may not contain oxygen, so that the term carotenoids include both carotenes and xanthophylls.
- carotenoids are hydrocarbon compounds having a conjugated polyene carbon skeleton formally derived from the five-carbon compound IPP, including triterpenes (C30 diapocarotenoids) and tetraterpenes (C40 carotenoids) as well as their oxygenated derivatives and other compounds that are, for example, C35, C50, C60, C70, Cso in length or other lengths.
- C200- C30 diapocarotenoids typically consist of six isoprenoid units joined in such a manner that the arrangement of isoprenoid units is reversed at the center of the molecule so that the two central methyl groups are in a 1 ,6-positional relationship and the remaining non-terminal methyl groups are in a 1 ,5-positional relationship.
- Such C30 carotenoids may be formally derived from the acyclic C30H42 structure, having a long central chain of conjugated double bonds, by: (i) hydrogenation (ii) dehydrogenation, (iii) cyclization, (iv) oxidation, (v) esterification/glycosylation, or any combination of these processes.
- C40 carotenoids typically consist of eight isoprenoid units joined in such a manner that the arrangement of isoprenoid units is reversed at the center of the molecule so that the two central methyl groups are in a 1 ,6-positional relationship and the remaining non-terminal methyl groups are in a 1 ,5-positional relationship.
- Such C40 carotenoids may be formally derived from the acyclic C40H56 structure, having a long central chain of conjugated double bonds, by (i) hydrogenation, (ii) dehydrogenation, (iii) cyclization, (iv) oxidation, (v)
- C40 carotenoids also includes certain compounds that arise from rearrangements of the carbon skeleton, or by the (formal) removal of part of this structure. More than 600 different carotenoids have been identified in nature. Carotenoids include but are not limited to:
- hydroxyneurosporene peridinin, phytoene, rhodopin, rhodopin glucoside, 4-keto- rubixanthin,siphonaxanthin, spheroidene, spheroidenone, spirilloxanthin, torulene, 4-keto- torulene, 3-hydroxy-4-keto-torulene, uriolide, uriolide acetate, violaxanthin, zeaxanthin- ⁇ - diglucoside, zeaxanthin, and C30 carotenoids.
- carotenoid compounds include derivatives of these molecules, which may include hydroxy-, methoxy-, 0x0-, epoxy-, carboxy-, or aldehydic functional groups. Further, included carotenoid compounds include ester (e.g., glycoside ester, fatty acid ester) and sulfate derivatives (e.g., esterified xanthophylls).
- ester e.g., glycoside ester, fatty acid ester
- sulfate derivatives e.g., esterified xanthophylls
- the "isoprenoid pathway” is understood in the art to refer to a metabolic pathway that either produces or utilizes the five-carbon metabolite isopentyl pyrophosphate (IPP). As discussed herein, two different pathways can produce the common isoprenoid precursor IPP— the “mevalonate pathway” and the “non-mevalonate pathway.” The term “isoprenoid pathway” is sufficiently general to encompass both of these types of pathway. Biosynthesis of isoprenoids from IPP occurs by polymerization of several five-carbon isoprene subunits. Isoprenoid metabolites derived from IPP vary greatly in chemical structure, including both cyclic and acyclic molecules. Isoprenoid metabolites include, but are not limited to, monoterpenes, sesquiterpenes, diterpenes, sterols, and polyprenols such as carotenoids.
- isoprenoid compound refers to any compound which is derived via the pathway beginning with isopentenyl pyrophosphate (IPP) and formed by the head-to-tail condensation of isoprene units which may be of 5, 10, 15, 20, 30 or 40 carbons in length.
- isoprenoid pigment refers to a class of isoprenoid compounds which typically have strong light absorbing properties.
- feed premix refers to the crude mixture of aquaculture feed or animal/pet food components prior to processing, optionally at high temperature, into an aquaculture feed or animal or pet food composition that is in the form of pellets or flakes.
- An aquaculture feed composition is used in the production of an "aquaculture product," wherein the product is a harvestable aquacultured species (e.g., finfish, crustaceans), which is often sold for human consumption.
- aquaculture product e.g., fish, crustaceans
- salmon are intensively produced in aquaculture and thus are aquaculture products.
- Aquaculture compositions may also be used as feed for aquaculture feed organisms such as small fish like krill, rotifers, and the like, that are food sources for larger aquaculture organisms such as carnivorous fish.
- aquaculture compositions described herein can be used as feed for ornamental fish, shrimp, hobbyist aquaculture, and the like, that are not intended as food for other organisms.
- aquaculture meat product refers to food products intended for human consumption comprising at least a portion of meat from an aquaculture product as defined above.
- An aquaculture meat product may be, for example, a whole fish or a filet cut from a fish, each of which may be consumed as food. In some embodiments, such a product can be referred to as a fish or seafood product.
- biomass refers to microbial cellular material. Biomass may be produced naturally, or may be produced from the fermentation of a native host or a recombinant production host.
- the biomass may be in the form of whole cells, whole cell lysates, homogenized cells, partially hydrolyzed cellular material, and/or partially purified cellular material (e.g., microbially produced oil).
- processed biomass refers to biomass that has been subjected to additional processing such as drying, pasteurization, disruption, etc., each of which is discussed in greater detail below.
- C-l carbon substrate refers to any carbon-containing molecule that lacks a carbon-carbon bond. Examples are methane, methanol, formaldehyde, formic acid, formate, methylated amines (e.g., mono-, di-, and tri- methyl amine), methylated thiols, and carbon dioxide.
- CI metabolizer refers to a microorganism that has the ability to use a single carbon substrate as a sole source of energy and biomass. CI metabolizers will typically be methylotrophs and/or methanotrophs capable of growth.
- methylotroph means an organism capable of oxidizing organic compounds which do not contain carbon-carbon bonds. Where the methylotroph is able to oxidize CH4, the methylotroph is also a methanotroph.
- methanotroph means a prokaryote capable of utilizing methane as a substrate. Complete oxidation of methane to carbon dioxide occurs by aerobic degradation pathways.
- methanotrophs useful in the present invention include but are not limited to the genera Methylomonas, Methylobacter , Methylococcus , and
- high growth methanotrophic bacterial strain refers to a bacterium capable of growth using methane as its sole carbon and energy source.
- Non-naturally occurring microorganisms are provided for production of taurine or the taurine precursors hypotaurine, cysteate, or sulfoacetaldehyde.
- Non-naturally occurring, e.g., recombinant, microorganisms herein include, e.g., bacteria, yeast, Archaea, that have been engineered to express at least one (i.e. , one or more) enzyme(s) for biosynthesis of taurine or taurine precursors and that produce taurine or taurine precursors when cultured under conditions suitable for microbial growth and taurine production.
- Non-naturally occurring microorganisms as described herein include one or more exogenous polynucleotide(s) that encode and express one or more enzyme or enzyme activity for biosynthesis of taurine or the taurine precursors cysteate, sulfoacetaldehyde, or hypotaurine.
- the exogenous polynucleotide(s) may include one or more coding sequence for one or more enzyme or enzyme activity for biosynthesis of taurine or taurine precursors, operably linked to one or more promoter for expression in the non-naturally occurring microorganism.
- Such promoters may include, but are not limited to, P R (e.g., SEQ ID NO:42), P Lac (e.g., SEQ ID NO:41), P tac (e.g. , SEQ ID NO:39), P tacA (e.g. , SEQ ID NO:40), PmxaF (e.g. , SEQ ID NO:43), P rrnB, and P T7.
- the polynucleotide(s) are codon optimized for expression in the microorganism.
- the non-naturally occurring microorganism includes one or more exogenous and/or endogenous polynucleotide(s) that encodes one or more enzymes or enzyme activities for taurine biosynthesis, as described herein, that has been modified for improved stability and/or activity relative to the stability and/or activity of the enzyme or enzyme activity in the host cell from which it is derived or relative to the wild-type stability and/or activity of the enzyme or enzyme activity.
- the non-naturally occurring microorganism may express a variant of an enzyme of taurine biosynthesis that has greater stability and/or activity than the wild-type enzyme from which it is derived.
- the host cell from which a non-naturally occurring microorganism as described herein is derived has one or more endogenous taurine, cysteate, or sulfoacetaldehyde degrading activity, for example, but not limited to, taurine
- the non-naturally occurring microorganism includes deletion of one or more genes that encode taurine, cysteate, or sulfoacetaldehyde degrading enzyme(s).
- the host cell from which a non-naturally occurring microorganism includes modification of one or more genes that encode taurine, cysteate, or
- sulfoacetaldehyde degrading enzyme(s) such that the taurine, cysteate, or
- the host cell is Methylobacterium extorquens and the non-naturally occurring microorganism derived from the host cell includes deletion or modification of the gene that encodes gamma-glutamyltransferase in the host cell.
- the host cell comprises one or more of endogenous genes in the described pathway.
- the host cell is modified so that one or more genes producing enzymes that divert compounds and taurine precursors away from a taurine biosynthetic pathway are blocked or deleted.
- the one or more blocked or deleted genes are selected from genes involved in the degradation of taurine, cysteate, or sulfoacetaldehyde.
- the host cell is a spontaneous mutant whose rate of growth is increased relative to a corresponding non- mutant.
- the host cell is cultured under stress conditions selected from light depletion, nutrient depletion, nitrogen depletion, high salt, or a chemical that inhibits growth of the host cell, wherein the stress conditions induce changes in gene expression leading to increased taurine or taurine precursor production.
- stress conditions selected from light depletion, nutrient depletion, nitrogen depletion, high salt, or a chemical that inhibits growth of the host cell, wherein the stress conditions induce changes in gene expression leading to increased taurine or taurine precursor production.
- the non-naturally occurring microorganism or the host cell from which the non-naturally occurring microorganism is derived is genetically modified or artificially pre-selected to produce elevated levels of one or more carotenoid compound(s) relative to the corresponding unmodified or unselected microorganism.
- the one or more carotenoid compound(s) may include, but are not limited to, ⁇ -carotene, lycopene, zeaxanthin, lutein, canthaxanthin, rhodopin, astaxanthin, and/or sprilloxanthin.
- Non- limiting examples of host cells that produce elevated levels of one or more carotenoid compound(s) and methods for producing such microorganisms are provided in
- Non-limiting examples of genera from which the non-naturally occurring microorganism may be derived include Methylobacterium, Methylomonas , Methylobacter . Methylococcus , Methylosinus , Methylocyctis , Methylomicrobium, Methylomonas,
- Methylpophilus Methylobacillus , Methylobacterium, Hyphomicrobium, Xanthobacter , Bacillus, Paracoccus, Nocardia, Arthrobacter , Rhodopseudomonas , Pseudomonas, Candida, Hansenula, Pichia, Torulopsis, Rhodotorula, Escherichia, and Saccharomyces .
- microbial species from which the non-naturally occurring microorganism may be derived include Methylobacterium extorquens ⁇ e.g.
- strains AMI, DM4, CM4, PA1, or BJ001 previously Methylobacterium populi
- Methylobacterium radiotolerans Methylobacterium nodulans
- Methylobacterium spp. 4-46 Methylobacterium spp. 4-46
- Escherichia coli Escherichia coli.
- the non-naturally occurring microorganism is a methylotrophic bacterium. Conversion of cvsteamine to taurine
- a non-naturally occurring microorganism that expresses an exogenous enzyme activity of 2-aminoethanol (cysteamine) dioxygenase (ADO) (EC 1.13.11.19), which converts cysteamine to hypotaurine, for biosynthesis of taurine, as shown in Fig. 1.
- cysteamine 2-aminoethanol
- ADO 2-aminoethanol dioxygenase
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ADO comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 44, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:44.
- the polynucleotide that encodes ADO comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:45 or SEQ ID NO:57 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:45 or SEQ ID NO:57.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:57.
- the non-naturally occurring microorganism is a
- Methylobacterium Escherichia, Saccharomyces , or Bacillus microorganism that includes an exogenous polynucleotide that encodes ADO.
- a non-naturally occurring microorganism that expresses one or more exogenous enzyme activity/ies for the conversion of cysteine to taurine via the enzyme cysteine dioxygenase (CDO), for example, exogenous enzyme(s) of the CDO/CSAD or GAD pathway for biosynthesis of taurine.
- CDO cysteine dioxygenase
- the CDO/CSAD or GAD pathway for taurine biosynthesis is shown schematically in Fig. 2.
- the non-naturally occurring microorganism that expresses exogenous enzyme activities of the CDO/CSAD or GAD pathway is not of genera
- the non-naturally occurring microorganism is not of genera Saccharomyces or species Saccharomyces cerevisiae.
- CDO cysteine sulfinic acid decarboxylase
- CDO and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one or two exogenous polynucleotide(s)) in the microorganism.
- one of CDO and CSAD enzymes or enzyme activities is encoded an exogenous polynucleotide in the microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from an exogenous polynucleotide.
- the microorganism expresses an endogenous CSAD activity and CDO is encoded by an exogenous polynucleotide in the microorganism. In one embodiment, the microorganism expresses an endogenous CDO activity and CSAD is encoded by an exogenous polynucleotide in the microorganism.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: cysteine dioxygenase (CDO) (EC 1.13.11.20); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed.
- CDO and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one or two exogenous polynucleotide(s)) in the microorganism.
- one of CDO and GAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the
- the microorganism expresses an
- endogenous GAD activity and CDO is encoded by an exogenous polynucleotide in the microorganism.
- the microorganism expresses an endogenous CDO activity and GAD is encoded by an exogenous polynucleotide in the microorganism.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CDO comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 15, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 15.
- the polynucleotide that encodes CDO comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 16, SEQ ID NO:50, or SEQ ID NO:58 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 16, SEQ ID NO:50, or SEQ ID NO:58.
- the polynucleotide that encodes CDO comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 16, SEQ ID NO:50, or SEQ ID NO:58 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 16, SEQ ID NO:50, or SEQ ID NO:58.
- polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:58.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CDO comprising or consisting of the amino acid sequence depicted in SEQ ID NO:35, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:35.
- the polynucleotide that encodes CDO comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 36, SEQ ID NO: 51, or SEQ ID NO: 59 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:36, SEQ ID NO:51, or SEQ ID NO:59.
- the polynucleotide that encodes CDO comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 36, SEQ ID NO: 51, or SEQ ID NO: 59 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:36, SEQ ID NO:51, or SEQ ID NO:59.
- polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ. NO:51 or SEQ ID NO: 59.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40,45,50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40,45,50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13.
- the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14. In some embodiments,
- the polynucleotide sequence is codon optimized for expression in the microorganism.
- a non-naturally occurring Methylobacterium microorganism that includes one or more exogenous polynucleotide(s) encoding CDO and CSAD.
- a non-naturally occurring Methylobacterium microorganism includes one or more exogenous polynucleotide(s) encoding CDO and CSAD.
- microorganism includes one or more exogenous polynucleotide(s) encoding CDO and GAD.
- a non-naturally occurring Escherichia microorganism that includes an exogenous polynucleotide encoding CDO. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CDO and CSAD.
- a non-naturally occurring Saccharomyces microorganism that includes an exogenous polynucleotide encoding CDO. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CDO and CSAD.
- a non-naturally occurring Bacillus microorganism that includes an exogenous polynucleotide encoding CSAD.
- a non-naturally occurring microorganism expresses one or more exogenous enzyme activity/ies for the conversion of cysteine to taurine via the enzyme 3-mercaptopropionate dioxygenase (p3MDO), for example, exogenous enzyme(s) of the p3MDO/CSAD or GAD pathway for biosynthesis of taurine.
- p3MDO 3-mercaptopropionate dioxygenase
- the p3MDO/CSAD or GAD pathway for taurine biosynthesis is shown schematically in Fig. 3
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: 3-mercaptopropionate dioxygenase (MDO; p3MDO) (EC 1.13.11.-); and cysteine sulfinic acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed.
- p3MDO and CSAD enzymes or enzyme activities are encoded by one or more exogenous
- polynucleotide(s) e.g., one or two, exogenous polynucleotide(s)
- one of p3MDO and CSAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring
- microorganism is derived, i.e. , not expressed from an exogenous polynucleotide.
- the microorganism expresses an endogenous CSAD activity and p3MDO is encoded by an exogenous polynucleotide in the microorganism.
- the microorganism expresses an endogenous p3MDO activity and CSAD is encoded by an exogenous polynucleotide in the microorganism.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: 3-mercaptopropionate dioxygenase (MDO; p3MDO) (EC 1.13.11.-); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed.
- MDO 3-mercaptopropionate dioxygenase
- p3MDO and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one or two, exogenous polynucleotide(s)) in the microorganism.
- one of p3MDO and GAD enzymes or enzyme activities is encoded an exogenous polynucleotide in the microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from an exogenous polynucleotide.
- the microorganism expresses an endogenous GAD activity and p3MDO is encoded by an exogenous polynucleotide in the microorganism.
- the microorganism expresses an endogenous p3MDO activity and GAD is encoded by an exogenous polynucleotide in the microorganism.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes p3MDO comprising or consisting of the amino acid sequence depicted in SEQ ID NO:33, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:33.
- the polynucleotide that encodes p3MDO comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:34 or SEQ ID NO:60 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:34 or SEQ ID NO:60.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:60.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- polynucleotide sequence is codon optimized for expression in the microorganism, e.g. SEQ ID NO: 53 or SEQ ID NO:54.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13.
- the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the polynucleotide sequence is codon optimized for expression in the microorganism.
- a non-naturally occurring Methylobacterium microorganism that includes one or more exogenous polynucleotide(s) encoding p3MDO and CSAD.
- a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding p3MDO and GAD.
- a non-naturally occurring Escherichia microorganism that includes an exogenous polynucleotide encoding p3MDO.
- a non-naturally occurring Escherichia microorganism includes one or more exogenous polynucleotide(s) encoding p3MDO and CSAD.
- a non-naturally occurring Saccharomyces microorganism that includes an exogenous polynucleotide encoding p3MDO.
- a non-naturally occurring Saccharomyces microorganism includes one or more exogenous polynucleotide(s) encoding p3MDO and CSAD.
- a non-naturally occurring Bacillus microorganism that includes an exogenous polynucleotide encoding p3MDO. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding p3MDO and CSAD.
- a non-naturally occurring microorganism that expresses one or more exogenous enzyme activity/ies of the serine/sulfate pathway for biosynthesis of taurine.
- the serine/sulfate pathway for taurine biosynthesis is shown schematically in Fig. 4.
- the non-naturally occurring microorganism includes one or more mutations that cause accumulation of serine in the microorganism.
- a methylotrophic strain that uses ribulose monophosphate (RuMP) for carbon assimilation from methanol may include a deletion or mutation in HprA (hydroxypyruvate reductase), which blocks the serine cycle from being completed, resulting in serine accumulation.
- RuMP ribulose monophosphate
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: L-serine dehydratase (EC 4.3.1.17); sulfate adenyltransferase (EC 2.7.7.4) and adenylyl-sulfate kinase (APS kinase) (EC 2.7.1.25), and/or 3'- phosphoadenosine 5'-phosphosulfate synthase (PAPSS1) (EC 2.7.7.4/EC 2.7.1.25); 3'- phosphoadenylyl sulfate: 2-aminoacrylate C-sulfotransferase (PAPS-AS) (EC 2.8.2.-); and cysteine sulfinic acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed.
- L-serine dehydratase; sulfate adenyltransferase and APS kinase, and/or PAPSS 1; PAPS-AS; and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, five, six, or seven exogenous polynucleotide(s)) in the microorganism. In some embodiments, one, two, three, four, five, or six of L-serine dehydratase, sulfate
- adenyltrasnferase, APS kinase, PAPSS1, PAPS-AS, and CSAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s).
- the microorganism expresses an endogenous L- serine dehydratase activity, and sulfate adenyltransferase and APS kinase, and/or PAPSS 1, PAPS-AS, and CSAD are expressed from exogenous polynucleotide(s).
- the microorganism expresses endogenous L-serine dehydratase, sulfate adenyltransferase, and APS kinase activity, and PAPS-AS and CSAD are expressed from exogenous polynucleotide(s).
- the microorganism expresses endogenous L-serine dehydratase, sulfate adenyltransferase, APS kinase, and CSAD activities, and PAPS-AS is expressed from an exogenous polynucleotide.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: L-serine dehydratase (EC 4.3.1.17); sulfate adenyltransferase (EC 2.7.7.4) and adenylyl-sulfate kinase (APS kinase) (EC 2.7.1.25), and/or 3'- phosphoadenosine 5'-phosphosulfate synthase (PAPSS1) (EC 2.7.7.4/EC 2.7.1.25); 3'- phosphoadenylyl sulfate: 2-aminoacrylate C-sulfotransferase (PAPS-AS) (EC 2.8.2.-); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the
- L-serine dehydratase; sulfate adenyltrasnferase and APS kinase, and/or PAPSS1 ; PAPS-AS; and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, five, six, or seven exogenous polynucleotide(s)) in the microorganism.
- adenyltransferase, APS kinase, PAPSS1, PAPS-AS, and GAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s).
- the microorganism expresses an endogenous L- serine dehydratase activity, and sulfate adenyltransferase and APS kinase, and/or PAPSS 1, PAPS-AS, and GAD are expressed from exogenous polynucleotide(s).
- the microorganism expresses endogenous L-serine dehydratase, sulfate adenyltransferase, APS kinase activity, and PAPS-AS and GAD are expressed from exogenous
- the microorganism expresses endogenous L-serine dehydratase, sulfate adenyltransferase, APS kinase, and GAD activities, and PAPS-AS is expressed from an exogenous polynucleotide.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes L-serine dehydratase comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 1, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: l.
- the polynucleotide that encodes L-serine dehydratase comprises or consists of the
- the polynucleotide sequence is codon optimized for expression in the microorganism.
- the non-naturally occurring microorganism includes exogenous polynucleotides that encode sulfate adenyltransferase comprising or consisting of the amino acid sequences depicted in SEQ ID NO:3 and SEQ ID NO:5, or a variant or homolog thereof.
- the exogenous polynucleotides encode polypeptides comprising or consisting of amino acid sequences having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:3 or SEQ ID NO: 5.
- the polynucleotides that encode sulfate adenyltransferase comprise or consists of the polynucleotide sequences depicted in SEQ ID NO:4 and SEQ ID NO:6 or polynucleotides having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:4 or SEQ ID NO:6.
- the polynucleotide sequences are codon optimized for expression in the microorganism.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes APS kinase comprising or consisting of the amino acid sequence depicted in SEQ ID N0:7, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:7.
- the polynucleotide that encodes APS kinase comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:8 or SEQ ID NO:62 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:8 or SEQ ID NO:62.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. SEQ ID NO:62.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes PAPSS1 comprising or consisting of the amino acid sequence depicted in SEQ ID NO:31, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:31.
- the polynucleotide that encodes PAPSS1 comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:32 or SEQ ID NO:63 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:32 or SEQ ID NO:63.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:63.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes PAPS-AS comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 9, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:9.
- the polynucleotide that encodes PAPS-AS comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 10 or SEQ ID NO:61 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 10 or SEQ ID NO:61.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:61.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13.
- the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the polynucleotide sequence is codon optimized for expression in the microorganism.
- a non-naturally occurring Methylobacterium microorganism includes one or more exogenous polynucleotide(s) encoding: sulfate adenyltransferase and APS kinase, and/or PAPSS1 ; PAPS-AS; and CSAD.
- a non-naturally occurring Methylobacterium microorganism includes one or more exogenous polynucleotide(s) encoding PAPS-AS and CSAD.
- a non-naturally occurring Methylobacterium microorganism includes one or more exogenous polynucleotide(s) encoding: sulfate adenyltransferase and APS kinase, and/or PAPSS1 ; PAPS-AS; and GAD.
- a non-naturally occurring Methylobacterium microorganism includes one or more exogenous polynucleotide(s) encoding PAPS-AS and GAD.
- a non-naturally occurring Escherichia microorganism that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1 and PAPS-AS. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
- a non-naturally occurring Saccharomyces microorganism that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1 and PAPS-AS. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
- a non-naturally occurring Bacillus microorganism that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS 1 and PAPS-AS. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
- a non-naturally occurring microorganism expresses one or more exogenous enzyme activity/ies for the conversion of phosphoserine to taurine via the enzyme cysteate synthase, for example, enzyme(s) of the cysteate synthase (e.g., MA_3297)/CSAD or GAD pathway for biosynthesis of taurine, and/or expresses one or more exogenous enzyme activity/ies for the conversion of serine to taurine via the enzymes L-serine dehydratase, cysteate synthase (e.g. , MA_3297), and CS AD/GAD.
- enzyme(s) of the cysteate synthase e.g., MA_3297
- CSAD CSAD
- GAD pathway for biosynthesis of taurine
- exogenous enzyme activity/ies for the conversion of serine to taurine via the enzymes L-serine dehydratase, cysteate synthase (e.g. , MA_3297), and CS AD
- cysteate synthase e.g., MA_3297
- CSAD or GAD The cysteate synthase (e.g., MA_3297)/CSAD or GAD, and L-serine dehydratase cysteate synthase (e.g., MA_3297)/CSAD or GAD pathways for taurine biosynthesis are shown schematically in Fig. 5.
- Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: cysteate synthase, e.g.
- cysteate synthase, optionally L-serine dehydratase, and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, or three, exogenous polynucleotide(s)) in the microorganism.
- one of cysteate synthase, L-serine dehydratase, or CSAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from exogenous polynucleotide(s).
- the microorganism expresses endogenous CSAD and optionally L-serine dehydratase activity, and cysteate synthase (e.g., MA_3297) is encoded by an exogenous polynucleotide in the microorganism.
- the microorganism expresses an endogenous cysteate synthase and CSAD is encoded by an exogenous polynucleotide in the microorganism.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: cysteate synthase, e.g. , MA_3297 (EC 2.5.1.76); optionally L-serine dehydratase (EC 4.3.1.17); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed.
- cysteate synthase e.g. , MA_3297 (EC 2.5.1.76)
- L-serine dehydratase EC 4.3.1.17
- GAD glutamate decarboxylase
- cysteate synthase, optionally L-serine dehydratase, and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, or three, exogenous polynucleotide(s)) in the microorganism.
- exogenous polynucleotide(s) e.g., one, two, or three, exogenous polynucleotide(s)
- one of cysteate synthase, L-serine dehydratase, or GAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from exogenous polynucleotide(s).
- the microorganism expresses endogenous GAD and optionally L-serine dehydratase activity and cysteate synthase (e.g., MA_3297) is encoded by an exogenous polynucleotide in the microorganism.
- the microorganism expresses an endogenous cysteate synthase and GAD is encoded by an exogenous polynucleotide in the microorganism.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes cysteate synthase comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 17, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 17.
- the polynucleotide that encodes cysteate synthase comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 18, SEQ ID NO:52, or SEQ ID NO:64 or a
- polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 18, SEQ ID NO:52, or SEQ ID NO:64.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:52 or SEQ ID NO:64.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes L-serine dehydratase comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 1, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: l.
- the polynucleotide that encodes L-serine dehydratase comprises or consists of the
- the polynucleotide sequence is codon optimized for expression in the microorganism.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13.
- the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the polynucleotide sequence is codon optimized for expression in the microorganism.
- a non-naturally occurring Methylobacterium microorganism that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g. , MA_3297) and CSAD.
- a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g. , MA_3297) and GAD.
- a non-naturally occurring Escherichia microorganism that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g., MA_3297) and optionally L-serine dehydratase.
- a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g. , MA_3297), optionally L-serine dehydratase, and CSAD.
- a non-naturally occurring Saccharomyces microorganism that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g., MA_3297) and optionally L-serine dehydratase.
- a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g. , MA_3297), optionally L-serine dehydratase, and CSAD.
- a non-naturally occurring Bacillus microorganism that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g. , MA 3297) and optionally L-serine dehydratase.
- a non-naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g. , MA_3297), optionally L-serine dehydratase, and CSAD.
- a non-naturally occurring microorganism expresses one or more exogenous enzyme activity/ies for the conversion of cysteine to taurine via the enzymes cystathionine gamma-lyase (CGL)/ L-cysteine desulfhydrase (CD), 3'phosphoadenylyl sulfate: 2-aminoacry late C-sulfotransferase (PAPS-AS), and cysteine sulfinic acid decarboxylase (CSAD) or glutamate decarboxylase (GAD).
- This pathway for taurine biosynthesis is shown schematically in Fig. 6.
- L-cysteine desulfhydrase activity (EC 4.4.1.1) including cystathionine gamma- lyase (CGL), tryptophanase, cysteine synthases, and MalY (Awano et al. (2005) Appl Environ Microbiol 71(7):4149-52.).
- a single enzyme includes both CGL and CD activities.
- CGL and CD activities are provided by two separate enzymes.
- CD activity is provided by an enzyme and CGL activity is absent. When CGL activity is present, it may provide greater flux via production of L-cysteine, which serves as a substrate for CD activity.
- a first enzyme that includes both CGL and CD activities and a second enzyme that includes only CD activity are provided.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: cystathionine gamma-lyase (CGL)/L-cysteine desulfhydrase (CD) (EC 4.4.1.1); sulfate adenyltransferase (EC 2.7.7.4) and adenylyl-sulfate kinase (APS kinase) (EC 2.7.1.25), and/or 3'-phosphoadenosine 5'-phosphosulfate synthase (PAPSS1) (EC 2.7.7.4/EC 2.7.1.25); 3'- phosphoadenylyl sulfate: 2-aminoacrylate C-sulfotransferase (PAPS-AS) (EC 2.8.2.-); and cysteine sulfinic acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by
- CGL/CD; sulfate adenyltransferase and APS kinase, and/or PAPSS l; PAPS- AS; and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, five, six, or seven exogenous polynucleotide(s) (e.g., one, two, three, four, five, six, or seven exogenous
- polynucleotide(s)) in the microorganism in the microorganism.
- one, two, three, four, five, or six of CGL/CD, sulfate adenyltransferase, APS kinase, PAPSSl, PAPS-AS, and CSAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s).
- the microorganism expresses an endogenous activity, and sulfate adenyltransferase and APS kinase and/or PAPSSl, PAPS- AS, and CSAD are expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses endogenous CGL/CD and sulfate adenyltransferase, APS kinase activities, and PAPS-AS and CSAD activities are expressed from exogenous
- the microorganism expresses endogenous CGL/CD, sulfate adenyltransferase, APS kinase, and CSAD activities, and PAPS-AS is expressed from an exogenous polynucleotide.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: cystathionine gamma-lyase (CGL)/ L-cysteine desulfhydrase (CD) (EC 4.4.1.1); sulfate adenyltransferase (EC 2.7.7.4) and adenylyl-sulfate kinase (APS kinase) (EC 2.7.1.25), and/or 3'-phosphoadenosine 5'-phosphosulfate synthase (PAPSSl) (EC 2.7.7.4/EC 2.7.1.25); 3'- phosphoadenylyl sulfate: 2-aminoacrylate C-sulfotransferase (PAPS-AS) (EC 2.8.2.-); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous poly
- CGL/CD, sulfate adenyltransferase and APS kinase, and/or PAPSS l, PAPS-AS, and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, five, six, or seven exogenous polynucleotide(s)) in the microorganism.
- exogenous polynucleotide(s) e.g., one, two, three, four, five, six, or seven exogenous polynucleotide(s) in the microorganism.
- one, two, three, four, five, or six of CGL/CD, sulfate adenyltransferase, APS kinase, PAPSSl, PAPS-AS, and GAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from exogenous polynucleotide(s).
- the microorganism expresses an endogenous activity, and sulfate
- adenyltransferase and APS kinase, and/or PAPSS1, PAPS-AS, and GAD are expressed from exogenous polynucleotide(s).
- the microorganism expresses endogenous CGL/CD, sulfate adenyltransferase, and APS kinase activities, and PAPS-AS and GAD activities are expressed from exogenous polynucleotide(s).
- the microorganism expresses endogenous CGL/CD, sulfate adenyltransferase, APS kinase, and GAD activities, and PAPS-AS is expressed from an exogenous polynucleotide.
- the non-naturally occurring microorganism includes one or more exogenous polynucleotide(s) that encode(s) CGL/CD comprising or consisting of the amino acid sequence(s) depicted in SEQ ID NO:46, SEQ ID NO:70, and/or SEQ ID NO:72 or variant(s) or homolog(s) thereof.
- the exogenous polynucleotide(s) encode(s) polypeptide(s) comprising or consisting of amino acid sequence(s) having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:46, SEQ ID NO:70, and/or SEQ ID NO:72.
- the exogenous polynucleotide(s) encode(s) polypeptide(s) comprising or consisting of amino acid sequence(s) having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:46, SEQ ID NO:70, and/or SEQ ID NO:72.
- polynucleotide(s) that encode(s) CGL/CD comprise or consist of the polynucleotide sequence(s) depicted in SEQ ID NO:47, SEQ ID NO:65, SEQ ID NO:71 and/or SEQ ID NO:73, or polynucleotide(s) having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:47, SEQ ID NO:65, SEQ ID NO:71, and/or SEQ ID NO:73.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:65.
- the non-naturally occurring microorganism includes exogenous polynucleotides that encode sulfate adenyltransferase comprising or consisting of the amino acid sequences depicted in SEQ ID NO:3 and SEQ ID NO:5, or a variant or homolog thereof.
- the exogenous polynucleotides encode polypeptides comprising or consisting of an amino acid sequences having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:3 or SEQ ID NO:5.
- the polynucleotides that encode sulfate comprising or consisting of the amino acid sequences depicted in SEQ ID NO:3 and SEQ ID NO:5, or a variant or homolog thereof.
- the exogenous polynucleotides encode polypeptides comprising or consisting of an amino acid sequences having at least about 30, 35, 40, 45, 50, 55,
- adenyltransferase comprises or consists of the polynucleotide sequences depicted in SEQ ID NO:4 or SEQ ID NO:6 or polynucleotides having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:4 or SEQ ID NO:6.
- the polynucleotide sequences are codon optimized for expression in the microorganism.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes APS kinase comprising or consisting of the amino acid sequence depicted in SEQ ID NO:7, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:7.
- the polynucleotide that encodes APS kinase comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:8 or SEQ ID NO:62 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:8 or SEQ ID NO:62.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:62.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes PAPSS1 comprising or consisting of the amino acid sequence depicted in SEQ ID NO:31, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:31.
- the polynucleotide that encodes PAPSS1 comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:32 or SEQ ID NO:63 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:32 or SEQ ID NO:63.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:63.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes PAPS-AS comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 9, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:9.
- the polynucleotide that encodes PAPS-AS comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 10 or SEQ ID NO:61 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 10 or SEQ ID NO:61.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:61.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13.
- the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the polynucleotide sequence is codon optimized for expression in the microorganism.
- a non-naturally occurring Methylobacterium microorganism includes one or more exogenous polynucleotide(s) encoding: CGL/CD, sulfate adenyltransferase and APS kinase, and/or PAPSS1 ; PAPS-AS, and CSAD.
- a non-naturally occurring Methylobacterium microorganism includes one or more exogenous polynucleotide(s) encoding CGL/CD, PAPS-AS and CSAD.
- a non-naturally occurring Methylobacterium includes one or more exogenous polynucleotide(s) encoding CGL/CD, PAPS-AS and CSAD.
- microorganism that includes one or more exogenous polynucleotide(s) encoding: CGL/CD; sulfate adenyltransferase and APS kinase, and/or PAPSS 1, PAPS-AS, and GAD.
- a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CGL/CD, PAPS-AS and GAD.
- a non-naturally occurring Escherichia microorganism that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1 and PAPS-AS. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
- a non-naturally occurring Saccharomyces microorganism that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1 and PAPS-AS. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
- a non-naturally occurring Bacillus microorganism that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS 1 and PAPS-AS. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
- a non-naturally occurring microorganism expresses one or more exogenous enzyme activity/ies for the conversion of cysteine to taurine via the enzymes cystathionine gamma-lyase/ L-cysteine desulfhydrase, cysteate synthase (e.g. , MA_3297), and cysteine sulfinic acid decarboxylase (CSAD) or glutamate decarboxylase (GAD).
- the CGL/CD, cysteate synthase (e.g., MA_3297), CSAD or GAD pathway for taurine biosynthesis is shown schematically in Fig. 7.
- L-cysteine desulfhydrase activity (EC 4.4.1.1) including cystathionine gamma-lyase (CGL), tryptophanase, cysteine synthases, and MalY (Awano et al. (2005) Appl Environ Microbiol 71(7):4149-52.).
- a single enzyme includes both CGL and CD activities.
- CGL and CD activities are provided by two separate enzymes.
- CD activity is provided by an enzyme and CGL activity is absent. When CGL activity is present, it may provide greater flux via production of L-cysteine, which serves as a substrate for CD activity.
- a first enzyme that includes both CGL and CD activities and a second enzyme that includes only CD activity are provided.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: cystathionine gamma-lyase (CGL)/ L-cysteine desulfhydrase (CD) (EC4.4.4.1), cysteate synthase, e.g. , MA_3297 (EC 2.5.1.76); and cysteine sulfuric acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the
- CGL/CD, cysteate synthase, and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, or four exogenous polynucleotide(s)) in the microorganism.
- one or more of CGL/CD, cysteate synthase, and CSAD enzymes or enzyme activities is encoded by one or more exogenous
- polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s).
- the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s).
- microorganism expresses an endogenous CSAD activity and CGL/CD and cysteate synthase (e.g., MA_3297) are encoded by exogenous polynucleotide(s) in the
- microorganism expresses endogenous CGL/CD and CSAD activities and cysteate synthase (e.g., MA_3297) is encoded by an exogenous polynucleotide in the microorganism.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: cystathionine gamma-lyase (CGL)/ L-cysteine desulfhydrase (CD) (EC4.4.4.1), cysteate synthase, e.g. , MA_3297 (EC 2.5.1.76); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed.
- cystathionine gamma-lyase CGL
- L-cysteine desulfhydrase CD
- cysteate synthase e.g. , MA_3297 (EC 2.5.1.76)
- GAD glutamate decarboxylase
- CGL/CD, cysteate synthase, and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, or four exogenous polynucleotide(s)) in the microorganism.
- one or more of CGL/CD, cysteate synthase, and GAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e.
- the microorganism expresses an endogenous GAD activity and CGL/CD and cysteate synthase (e.g., MA_3297) are encoded by exogenous polynucleotide(s) in the microorganism.
- the microorganism expresses endogenous CGL/CD and GAD activities and cysteate synthase (e.g., MA_3297) is encoded by an exogenous polynucleotide in the microorganism.
- the non-naturally occurring microorganism includes one or more exogenous polynucleotide(s) that encode(s) CGL/CD comprising or consisting of the amino acid sequence(s) depicted in SEQ ID NO:46, SEQ ID NO:70, and/or SEQ ID NO:72 or variant(s) or homolog(s) thereof.
- the exogenous polynucleotide(s) that encode(s) CGL/CD comprising or consisting of the amino acid sequence(s) depicted in SEQ ID NO:46, SEQ ID NO:70, and/or SEQ ID NO:72 or variant(s) or homolog(s) thereof.
- the exogenous polynucleotide(s) that encode(s) CGL/CD comprising or consisting of the amino acid sequence(s) depicted in SEQ ID NO:46, SEQ ID NO:70, and/or SEQ ID NO:72 or variant(s) or homolog(s) thereof.
- polynucleotide(s) encode(s) polypeptide(s) comprising or consisting of amino acid sequence(s) having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:46, SEQ ID NO:70, and/or SEQ ID NO:72.
- the polynucleotide(s) that encode(s) CGL/CD comprise or consist of the polynucleotide sequence(s) depicted in SEQ ID NO:47, SEQ ID NO:65, SEQ ID NO:71, and/or SEQ ID NO:73 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:47, SEQ ID NO:65, SEQ ID NO:71, and/or SEQ ID NO:73.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO: 65.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes cysteate synthase comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 17, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 17.
- the polynucleotide that encodes cysteate synthase comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 18, SEQ ID NO:52, or SEQ ID NO:64 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 18, SEQ ID NO:52, or SEQ ID NO:64.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:52 or SEQ ID NO:64.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13.
- the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the polynucleotide sequence is codon optimized for expression in the microorganism.
- a non-naturally occurring Methylobacterium microorganism that includes one or more exogenous polynucleotide(s) encoding CGL/CD, cysteate synthase (e.g., MA_3297), and CSAD.
- a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CGL/CD, cysteate synthase (e.g., MA_3297), and GAD.
- a non-naturally occurring Escherichia microorganism includes one or more exogenous polynucleotide(s) encoding CGL/CD and cysteate synthase (e.g., MA_3297). In one embodiment, a non-naturally occurring
- Escherichia microorganism that includes one or more exogenous
- polynucleotide(s) encoding CGL/CD, cysteate synthase, and CSAD polynucleotide(s) encoding CGL/CD, cysteate synthase, and CSAD.
- a non-naturally occurring Saccharomyces microorganism includes one or more exogenous polynucleotide(s) encoding CGL/CD and cysteate synthase (e.g., MA_3297). In one embodiment, a non-naturally occurring
- Saccharomyces microorganism includes one or more exogenous polynucleotide(s) encoding CGL/CD, cysteate synthase, and CSAD.
- a non-naturally occurring Bacillus microorganism includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g., MA_3297) and CSAD.
- a non-naturally occurring microorganism expresses exogenous enzyme activity/ies for the conversion of pyruvate to taurine via the enzyme L-cysteate sulfo-lyase (cuyA), for example, exogenous enzyme(s) of the L-cysteate sulfo-lyase (cuyA)/CSAD or GAD pathway for biosynthesis of taurine.
- L-cysteate sulfo-lyase for example, exogenous enzyme(s) of the L-cysteate sulfo-lyase (cuyA)/CSAD or GAD pathway for biosynthesis of taurine.
- the cuyA/CSAD or GAD pathway for taurine biosynthesis is shown schematically in Fig. 8.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: L-cysteate sulfo-lyase (cuyA) (EC 4.4.1.25); and cysteine sulfinic acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the
- cuyA and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one or two exogenous polynucleotide(s)) in the microorganism.
- one of cuyA and CSAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from an exogenous polynucleotide.
- the microorganism expresses an endogenous CSAD activity and cuyA is encoded by an exogenous polynucleotide in the microorganism. In one embodiment, the microorganism expresses an endogenous cuyA activity and CSAD is encoded by an exogenous polynucleotide in the microorganism.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: L-cysteate sulfo-lyase (cuyA) (EC 4.4.1.25); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed.
- cuyA and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one or two exogenous polynucleotide(s)) in the microorganism.
- one of cuyA and GAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the
- the microorganism expresses an endogenous GAD activity and cuyA is encoded by an exogenous polynucleotide in the microorganism. In one embodiment, the microorganism expresses an endogenous cuyA activity and GAD is encoded by an exogenous polynucleotide in the microorganism.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes cuyA comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 37, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:37.
- the polynucleotide that encodes cuyA comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:38 or SEQ ID NO:66 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:38 or SEQ ID NO:66.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:66.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13.
- the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the polynucleotide sequence is codon optimized for expression in the microorganism.
- a non-naturally occurring Methylobacterium microorganism that includes one or more exogenous polynucleotide(s) encoding cuyA and CSAD.
- a non-naturally occurring Methylobacterium microorganism includes one or more exogenous polynucleotide(s) encoding cuyA and CSAD.
- microorganism includes one or more exogenous polynucleotide(s) encoding cuyA and GAD.
- a non-naturally occurring Escherichia microorganism that includes an exogenous polynucleotide encoding cuyA. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cuyA and CSAD.
- a non-naturally occurring Saccharomyces microorganism that includes an exogenous polynucleotide encoding cuyA. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cuyA and CSAD. [172] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes an exogenous polynucleotide encoding cuyA. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cuyA and CSAD.
- a non-naturally occurring microorganism that expresses one or more exogenous enzyme activity/ies for the conversion of
- phosphoenolpyruvate to taurine via the enzymes phosphosulfolactate synthase (ComA), 2- phsopho-e-sulfolactate dehydrogenase (ComB), sulfolactate dehydrogenase (ComC), and aspartate aminotransferase (AspAT), for example, one or more exogenous enzyme(s) of the ComA/ComB/ComC/AspAT/CSAD or GAD pathway for biosynthesis of taurine.
- the ComA/ComB/ComC/AspAT/CSAD or GAD pathway for taurine biosynthesis is shown schematically in Fig. 9.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: phosphosulfolactate synthase (ComA) (EC 4.4.1.19), 2- phospho-3 -sulfolactate phosphohydrolase (ComB) (EC 3.1.3.71), sulfolactate
- ComC dehydrogenase
- AspAT aspartate aminotransferase
- CSAD cysteine sulfinic acid decarboxylase
- ComA, ComB, ComC, AspAT, and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, or five exogenous polynucleotide(s)) in the microorganism.
- one or more of ComA, ComB, ComC, AspAT, and CSAD enzymes or enzyme activities is encoded by one or more exogenous
- polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s).
- the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s).
- microorganism expresses endogenous CSAD and AspAT activities, and ComA, ComB, and ComC are encoded by exogenous polynucleotide(s) in the microorganism.
- the microorganism expresses endogenous AspAT activity, and ComA, ComB, ComC, and CSAD are encoded by exogenous polynucleotide(s) in the microorganism.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: phosphosulfolactate synthase (ComA) (EC 4.4.1.19), 2- phospho-3-sulfolactate phosphohydrolase (ComB) (EC 3.1.3.71), sulfolactate
- ComC dehydrogenase
- AspAT aspartate aminotransferase
- GAD glutamate decarboxylase
- ComA, ComB, ComC, AspAT, and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, or five exogenous polynucleotide(s)) in the microorganism.
- one or more of ComA, ComB, ComC, AspAT, and GAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e.
- the microorganism expresses endogenous GAD and AsPAT activities, and ComA, ComB, and ComC are encoded by exogenous polynucleotide(s) in the microorganism.
- the microorganism expresses endogenous AsPAT activity, and ComA, ComB, ComC, and GAD are encoded by exogenous polynucleotide(s) in the microorganism.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComA comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 19, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 19.
- the polynucleotide that encodes ComA comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:20 or SEQ ID NO:67 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:20 or SEQ ID NO:67.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:67.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComB comprising or consisting of the amino acid sequence depicted in SEQ ID NO:21, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:21.
- the polynucleotide that encodes ComB comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:22 or SEQ ID NO:68 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:22 or SEQ ID NO:68.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:68.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComC comprising or consisting of the amino acid sequence depicted in SEQ ID NO:23, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:23.
- the polynucleotide that encodes ComC comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:24 or SEQ ID NO:69 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:24 or SEQ ID NO:69.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. SEQ ID NO:69.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13.
- the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14.
- the polynucleotide sequence is codon optimized for expression in the microorganism.
- a non-naturally occurring Methylobacterium microorganism that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and CSAD.
- a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and GAD.
- a non-naturally occurring Escherichia microorganism that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, and ComC. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and CSAD.
- a non-naturally occurring Saccharomyces microorganism that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, and ComC. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and CSAD.
- a non-naturally occurring Bacillus microorganism that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, and ComC. In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and CSAD. Conversion of acetyl phosphate to taurine
- a non-naturally occurring microorganism that expresses one or more exogenous enzyme activity/ies for the conversion of acetyl phosphate to taurine, for example, enzymes of the Xsc/Tpa pathway for biosynthesis of taurine.
- the Xsc/Tpa pathway of taurine biosynthesis is shown schematically in Fig. 10.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: sulfoacetaldehyde acetyltransferase (Xsc) (EC 2.3.3.15); and taurine-pyruvate aminotransferase (Tpa) (EC 2.6.1.77), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed.
- Xsc and Tpa enzymes or enzyme activities are encoded by one or more exogenous polynucleotides in the
- microorganism e.g., one or two exogenous polynucleotide(s).
- one of Xsc and Tpa enzymes or enzyme activities is encoded an exogenous polynucleotide in the microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from an exogenous polynucleotide.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes Xsc comprising or consisting of the amino acid sequence depicted in SEQ ID NO:48, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:48.
- the polynucleotide that encodes Xsc comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:49 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:49.
- the polynucleotide sequence is codon optimized for expression in the microorganism.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes Tpa comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 27, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:27.
- the polynucleotide that encodes Tpa comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:28 or SEQ ID NO:56 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:28 or SEQ ID NO:56.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:56.
- a non-naturally occurring Methylobacterium microorganism includes one or more exogenous polynucleotide(s) encoding Xsc and Tpa.
- a non-naturally occurring Escherichia microorganism includes an exogenous polynucleotide encoding Xsc and Tpa.
- a non-naturally occurring Saccharomyces microorganism that includes an exogenous polynucleotide encoding Xsc and Tpa.
- a non-naturally occurring Bacillus microorganism includes an exogenous polynucleotide encoding Xsc and Tpa.
- a non-naturally occurring microorganism that expresses one or more exogenous enzyme activity/ies for the conversion of
- phosphoenolpyruvate to taurine via the enzymes phosphosulfolactate synthase (ComA), 2- phsopho-e-sulfolactate dehydrogenase (ComB), sulfolactate dehydrogenase (ComC), sulfopyruvate decarboxylase (ComDE), and taurine-pyruvate aminotransferase (Tpa), for example, one or more exogenous enzyme(s) of the ComA/ComB/ComC, ComDE/Tpa pathway for biosynthesis of taurine. This pathway for taurine biosynthesis is shown schematically in Fig. 11.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: phosphosulfolactate synthase (ComA) (EC 4.4.1.19), 2- phospho-3 -sulfolactate phosphohydrolase (ComB) (EC 3.1.3.71), sulfolactate
- ComC dehydrogenase
- ComDE sulfopyruvate decarboxylase
- Tpa taurine-pyruvate aminotransferase
- ComA, ComB, ComC, ComDE, and Tpa enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, or five exogenous polynucleotide(s)) in the microorganism.
- one or more of ComA, ComB, ComC, ComDE, and Tpa enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from exogenous polynucleotide(s).
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComA comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 19, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 19.
- the polynucleotide that encodes ComA comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:20 or SEQ ID NO:67 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:20 or SEQ ID NO:67.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:67.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComB comprising or consisting of the amino acid sequence depicted in SEQ ID NO:21, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:21.
- the polynucleotide that encodes ComB comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:22 or SEQ ID NO:68 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:22 or SEQ ID NO:68.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:68.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComC comprising or consisting of the amino acid sequence depicted in SEQ ID NO:23, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:23.
- the polynucleotide that encodes ComC comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:24 or SEQ ID NO:69 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:24 or SEQ ID NO:69.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:69.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComDE comprising or consisting of the amino acid sequence depicted in SEQ ID NO:25, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:25.
- the polynucleotide that encodes ComDE comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:26 or SEQ ID NO:55 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:26 or SEQ ID NO:55.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:55.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes Tpa comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 27, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:27.
- the polynucleotide that encodes Tpa comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:28 or SEQ ID NO:56 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:28 or SEQ ID NO:56.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:56.
- a non-naturally occurring Methylobacterium microorganism that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and ComDE, and Tpa.
- a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, ComDE, and Tpa.
- a non-naturally occurring Saccharomyces microorganism includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, ComDE, and Tpa.
- a non-naturally occurring Bacillus microorganism includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, ComDE, and Tpa.
- Cysteate which is an intermediate in some of the biosynthetic pathways described above (see Figs. 4, 5, 6, 7, and 8) be converted to taurine via aspartate aminotransferase (AspAT) (EC 2.6.1.1), which converts cysteate to sulfopyruvate, sulfopyruvate
- ComDE decarboxylase
- sulfoacetaldehyde to taurine, instead of or in addition to CSAD or GAD. This is shown schematically in Fig. 12.
- Non-naturally occurring microorganisms include the following enzymes or enzyme activities: aspartate aminotransferase (AspAT) (EC 2.6.1.1);
- sulfopyruvate decarboxylase (EC4.1.7.9); and taurine-pyruvate aminotransferase (Tpa) (EC 2.67.1.77), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed, and optionally other enzyme activities for production of cysteate, as shown in Fig. 12, either endogenous to the microorganism or encoded by exogenous polynucleotide(s) with which the microorganism has been transformed.
- ComDE sulfopyruvate decarboxylase
- Tpa taurine-pyruvate aminotransferase
- one or more of AspAT, ComDE, and Tpa enzymes or enzyme activities is encoded by exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non- naturally occurring microorganism is derived, i.e., not expressed from an exogenous polynucleotide.
- the microorganism expresses an endogenous AspAT activity and ComDE and Tpa are encoded by exogenous polynucleotide(s) in the microorganism.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComDE comprising or consisting of the amino acid sequence depicted in SEQ ID NO:25, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:25.
- the polynucleotide that encodes ComDE comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:26 or SEQ ID NO:55 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:26 or SEQ ID NO:55.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:55.
- the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes Tpa comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 27, or a variant or homolog thereof.
- the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:27.
- the polynucleotide that encodes Tpa comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:28 or SEQ ID NO:56 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:28 or SEQ ID NO:56.
- the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:56.
- a non-naturally occurring Methylobacterium microorganism includes one or more exogenous polynucleotide(s) encoding ComDE and Tpa.
- a non-naturally occurring Escherichia microorganism includes one or more exogenous polynucleotide(s) encoding ComDE and Tpa.
- a non-naturally occurring Saccharomyces microorganism includes one or more exogenous polynucleotide(s) encoding ComDE and Tpa.
- a non-naturally occurring Bacillus microorganism includes one or more exogenous polynucleotide(s) encoding ComDE and Tpa. Mutations to enhance accumulation of taurine or an intermediate in taurine biosynthesis
- a non-naturally occurring microorganism that produces taurine, as described above, and that further includes a mutation in a pathway for degradation of taurine and/or in a pathway for degradation of an intermediate of taurine biosynthesis (e.g., a cysteate degradation pathway).
- a pathway for degradation of taurine e.g., a cysteate degradation pathway.
- an intermediate of taurine biosynthesis e.g., a cysteate degradation pathway
- microorganism includes deletion of one or more endogenous gene sequence that encodes an enzyme that degrades taurine or an intermediate in taurine biosynthesis (e.g. , cysteate or sulfoacetaldehyde), thus enhancing accumulation of taurine in the microorganism.
- taurine and cysteate degradation pathways are shown schematically in Fig. 13. Examples of enzymes in taurine degradation pathways include, but are not limited to, taurine
- TDH dehydrogenase
- TDO/TauD taurine dioxygenase
- Tpa taurine-pyruvate aminotransferase
- a non-limiting example of an enzyme in a cysteate degradation pathway is cysteate sulfo-lyase (CuyA).
- a non-limiting example of an enzyme in a sulfoacetaldehyde degradation pathway is sulfoacetaldehyde acetyltransferase (Xsc).
- the non-naturally occurring microorganism includes one or more mutation(s) or deletion of a gene sequence that encodes taurine dehydrogenase (TDH) (EC 1.4.99.2), thus reducing or eliminating activity of TDH in the microorganism in comparison to the host cell from which the microorganism was derived.
- TDH taurine dehydrogenase
- the non-naturally occurring microorganism includes one or more mutation(s) or deletion of a gene sequence that encodes taurine dioxygenase
- TDO TDO/TauD
- EC 1.14.11.17 reducing or eliminating activity of TDO/TauD in the microorganism in comparison the host cell from which the microorganism was derived.
- an Escherichia microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes TDO/TauD, thus reducing or eliminating activity of this enzyme in the microorganism.
- a Saccharomyces microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes TDO/TauD, thus reducing or eliminating activity of this enzyme in the
- a Bacillus microorganism in comparison to the host cell from which the microorganism was derived.
- a Bacillus microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes TDO/TauD, thus reducing or eliminating activity of this enzyme in the microorganism in comparison to the host cell from which the microorganism was derived.
- the non-naturally occurring microorganism includes one or more mutation(s) or deletion of a gene sequence that encodes cysteate sulfo-lyase (CuyA) (EC 4.4.1.25), thus reducing or eliminating activity of CuyA in the microorganism in comparison to the host cell from which the microorganism was derived.
- CuyA cysteate sulfo-lyase
- the non-naturally occurring microorganism includes one or more mutation(s) or deletion of a gene sequence that encodes gamma-glutamyltransferase (EC 2.3.2.2), thus reducing or eliminating activity of gamma-glutamyltransferase in the microorganism in comparison the host cell from which the microorganism was derived.
- aMethylobacterium microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes gamma-glutamyltransferase, thus reducing or eliminating activity of this enzyme in the microorganism.
- an Escherichia microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes gamma-glutamyltransferase, thus reducing or eliminating activity of this enzyme in the microorganism in comparison to the host cell from which the microorganism was derived.
- a Bacillus microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes gamma- glutamyltransferase, thus reducing or eliminating activity of this enzyme in the
- microorganism in comparison to the host cell from which the microorganism was derived.
- the non-naturally occurring microorganism includes one or more mutations(s) or deletion of a gene sequence that encodes a taurine-pyruvate aminotransferase (Tpa) (EC 2.6.1.77), thus reducing or eliminating activity of taurine- pyruvate aminotransferase in the microorganism in comparison the host cell from which the microorganism was derived.
- Tpa taurine-pyruvate aminotransferase
- genetic modifications will take advantage of freely replicating plasmid vectors for cloning.
- These may include small IncP vectors developed for use in Methylobacterium. These vectors may include pCM62, pCM66, or pHC41 for cloning. (Marx, C. J. and M. E. Lidstrom Microbiology (2001) 147: 2065-2075; Chou, H - H. et al. PLoS Genetics (2009) 5: el 000652)
- genetic modifications will take advantage of freely replicating expression plasmids such as pCM80, pCM160, pHC90, or pHC91. (Marx, C. J. and M. E. Lidstrom Microbiology (2001) 147: 2065-2075; Chou, H.-H. et al. PLoS Genetics (2009) 5: el 000652)
- genetic modifications will utilize freely replicating expression plasmids that have the ability to respond to levels of inducing molecules such as cumate or anhydrotetracycline. These include pHC115, pLC 290, pLC291. (Chou, H.-H. et al. PLoS Genetics (2009) 5: el000652; Chubiz, L. M. et al. BMC Research Notes (2013) 6: 183)
- genetic modifications will utilize recyclable antibiotic marker systems such as the cre-lox system.
- This may include use of the pCM157, pCM158, pCM184, pCM351 series of plasmids developed for use in extorquens. (Marx, C. J. and M. E. Lidstrom BioTechniques (2002) 33: 1062-1067)
- genetic modifications will utilize recyclable antibiotic marker systems such as the cre-lox system.
- This may include use of the pCM157, pCM158, pCM184, pCM351 series of plasmids developed for use in M. extorquens. (Marx, C. J. and M. E. Lidstrom BioTechniques (2002) 33: 1062-1067).
- genetic modifications will utilize transposon mutagenesis.
- This may include mini-Tn5 delivery systems such as pCM639 (D'Argenio, D. A. et al. Journal of Bacteriology (2001) 183: 1466-1471) demonstrated in M. extorquens. (Marx, C. J. et al. Journal of Bacteriology (2003) 185: 669-673)
- genetic modifications will utilize expression systems introduced directly into a chromosomal locus. This may include pCM168, pCM172, and pHCOl plasmids developed forM. extorquens. AMI . (Marx, C. J. and M. E. Lidstrom Microbiology (2001) 147: 2065-2075; Lee, M.-C. et al. Evolution (2009) 63: 2813-2830) [228] In certain embodiments, genetic modifications will utilize a sacB-based system for unmarked exchange of alleles due to the sucrose sensitivity provided by sacB expression. This may include the pCM433 vector originally tested with M. extorquens. (Marx, C. J. et al. BMC Research Notes (2008) 1 : 1)
- Methods for producing taurine and/or taurine precursors include culturing a non-naturally occurring microorganism as described herein in a culture medium under conditions suitable for growth of the microorganism and expression of enzymes for taurine biosynthesis as described herein, wherein biomass that includes taurine and/or taurine precursors is produced in the culture.
- the microorganism also produces one or more carotenoid compound(s) (e.g., a microorganism that has been genetically modified or artificially pre-selected to produce elevated levels of one or more carotenoid compound(s)), biomass that includes taurine and/or taurine precursors and the one or more carotenoid compound(s) is produced.
- the culture medium includes carbon source(s), nitrogen source(s), inorganic substances (e.g., inorganic salts), and any other substances required for the growth of the microorganism (e.g. , vitamins, amino acids, etc.).
- inorganic substances e.g., inorganic salts
- any other substances required for the growth of the microorganism e.g. , vitamins, amino acids, etc.
- the carbon source may include sugars, such as glucose, sucrose, lactose, fructose, trehalose, mannose, mannitol, and maltose; organic acids, such as acetic acid, fumaric acid, citric acid, propionic acid, malic acid, pyruvic acid, malonic acid, and ascorbic acid;
- sugars such as glucose, sucrose, lactose, fructose, trehalose, mannose, mannitol, and maltose
- organic acids such as acetic acid, fumaric acid, citric acid, propionic acid, malic acid, pyruvic acid, malonic acid, and ascorbic acid
- alcohols such as ethanol, propanol, butanol, pentanol, hexanol, isobutanol, and glycerol
- oil or fat such as soybean oil, rice bran oil, olive oil, corn oil, sesame oil, linseed oil, and the like.
- the amount of the carbon source added varies according to the kind of the carbon source, for example, about 1 to about 100 g, or about 2 to about 50 g per liter of medium.
- a CI carbon substrate is provided to a microorganism that is capable of converting such a substrate to organic products (e.g. , microorganisms of the genera Methylobacterium, Methylomonas, Methylobacter. Methylococcus, Methylosinus, Methylocyctis, Methylomicrobium).
- the CI carbon substrate is selected from methane, methanol, formaldehyde, formic acid, methylated amines, methylated thiols, and carbon dioxide.
- the CI carbon substrate is selected from methanol, formaldehyde, and methylated amines.
- the CI carbon substrate is methanol.
- the nitrogen source may include potassium nitrate, ammonium nitrate, ammonium chloride, ammonium sulfate, ammonium phosphate, ammonia, urea, and the like, alone or in combination.
- Amount of the nitrogen source added varies according to the kind of the nitrogen source, for example, about 0.1 to about 30 g, or about 1 to about 10 g per liter of medium.
- Inorganic salts may include potassium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate, magnesium sulfate, magnesium chloride, ferric sulfate, ferrous sulfate, ferric chloride, ferrous chloride, manganous sulfate, manganous chloride, zinc sulfate, zinc, chloride, cupric sulfate, calcium chloride, calcium carbonate, sodium carbonate, sodium sulfate, and the like, alone or in combination.
- Amount of inorganic salt varies according to the kind of the inorganic salt, for example, about 0.001 to about 10 g per liter of medium.
- Special required substances for example, vitamins, nucleic acids, yeast extract, peptone, meat extract, malt extract, corn steep liquor, soybean meal, dried yeast etc., may be included alone or in combination.
- Amount of the special required substance used varies according to the kind of the substance, for example, about 0.2 g to about 200 g, or about 3 to about 10 g per liter of medium.
- the pH of the culture medium is adjusted to pH about 2 to about 12, or about 6 to about 9.
- the medium may further include one or more buffer(s) to maintain the culture at the desired pH.
- buffers are known in the art and include phosphate, carbonate, acetate, PIPES, HEPES, and Tris buffers.
- a suitable buffer for a given microorganism can easily be determined by one of ordinary skill in the art.
- Methylobacterium a common medium, described by Lee, et al.
- (2009) Evolution 63:2813- 2830 is a phosphate buffered medium that consists of 1 mL of trace metal solution (to 1 liter of deionized water the following are added in this order: 12.738 g of EDTA disodium salt dihydrate, 4.4 g of ZnSO -7H 2 0, 1 .466 g of CaCI 2 -2H 2 0, 1 .012 g of MnCI 2 -4H 2 0, 0.22 g of ( ⁇ 4)6 ⁇ 7 ⁇ 2 4-4 ⁇ 2 0, 0.314 g of CuSO 4 -5H 2 0, 0.322 g of CoCl 2 -6H 2 0, and 0.998 g of Fe3(SO 4 ) 2 -7H 2 0; pH 5.0 is maintained after every addition), 100 mL of phosphate buffer (25.3 g of K 2 HPO 4 and 22.5 g of NaH 2 PO 4 in 1 liter of deionized water), 100 mL of sulfate solution (5 g of (NH 4 ) 2
- Methylobacterium extorquens takes advantage of an organic buffer and has a citrate-chelated trace metal mix. Culturing is carried out at temperature of 15° to 40°C, and preferably 20° to 35°C, usually for 1 to 20 days, and preferably 1 to 4 days, under aerobic conditions provided by shaking or aeration/agitation. Common practice with Methylobacterium is at 30°C.
- the protocol for making M-PIPES medium is described in Table S I of Delaney et al. (2013) PLoS One (8:e62957).
- Figure 2 in USSN 61/863,701 shows an exemplary recipe for medium optimized for use with extorquens.
- Methanol can be tolerated well at 0.5-1 % v/v (-120-240 mM), and thus this step size of addition can be used repeatedly.
- pH levels drop during culturing on methanol, such that the use of a base such as KOH or NaOH would be important to maintain the pH around 6.5.
- Aeration can be achieved via physical agitation, such as an impeller, via bubbling of filtered air or pure oxygen, or in combination.
- the buffer can be replaced from phosphates or PIPES to a carbonate-buffered medium.
- Microbial cells may be separated from the culture, for example, by a conventional means such as centrifugation or filtration.
- the cells may be isolated whole, or may be lysed to release their contents for extraction or further processing.
- the cells or the medium may be subjected to an extraction with a suitable solvent.
- Intracellular taurine as a molecular chaperone and antioxidant.
- Microbial cells engineered to produce high levels of taurine or hypotaurine have increased levels of an important osmolyte known to promote protein folding and decrease oxidation (Warskulat et al. (2007) Methods Enzymol 428:439-58; Abe et al. (2015) Amino acids 47(5):909-15; Fujii et al. (2007) J Biochem 141(5):697-707); Oliveira et al. (2010) Pharmacological Reports 62: 185-193; Aruoma et al. (1988) Biochem J 256:251-55; Bucolo et al. (2016) Acta Ophthalmologic 95(256); Patel et al.
- intracellular taurine or hypotaurine could aid in increasing protein folding or decreasing protein inactivation through oxidation.
- the use of microorganisms engineered to accumulate intracellular taurine or hypotaurine could be used to increase the yield and/or specific activity of proteins of interest.
- Feed compositions are provided for use in aquaculture, or as animal feed, or as human nutritional supplements containing processed or unprocessed biomass from non- naturally occurring microorganism cells as described herein, as are methods of preparation of the feed compositions.
- the feed compositions or nutritional supplements include taurine and/or one or more taurine precursor(s), e.g., cysteate, sulfoacetaldehyde, and/or hypotaurine, produced by the non-naturally occurring microorganism.
- taurine and/or taurine precursor(s) produced by the microorganism is encapsulated in the microorganism in the feed composition or supplement, e.g. , encapsulated in the lipid bilayer of the cell membrane of the microorganism.
- taurine and/or taurine precursor(s) produced by the microbial biocatalyst is/are excreted into the culture medium and further purified, for example, using chromatographic or other separation and purification procedures.
- taurine and/or taurine precursor(s) is/are chemically extracted from the producing microorganism.
- Taurine and/or taurine precursor(s) can be accumulated and encapsulated by the microorganism or can be exported outside the cell. Conditions required for export may be continuous during microbial growth or can be stimulated by limitation of nutrients, e.g., biotin, or by the presence of an inhibitor of microbial growth, such as an antibiotic or surfactant.
- methods for separating and purifying taurine and/or taurine precursors from a culture containing microbial cells and microbially produced taurine may deploy ion exchange, e.g. , ion exchange resins.
- ion exchange e.g. , ion exchange resins.
- microbial cells may be separated by centrifugation, condensed, or filtered, and taurine and/or taurine precursors concentrated to, for example, at least about 80% purity.
- biomass that is incorporated into a feed or nutritional supplement composition can be in a dry, or substantially dry, form, e.g., containing less than about 20%, 10%, 5%, or 2% of moisture.
- the cultures are isolated by removing substantially all supernatant, such as by filtering, sedimentation, or centrifugation.
- the collection of cultures and further processing of biomass excludes a bacterial lysis step, e.g. , by use of detergents or ultrasound.
- the processed microbial cells maintain substantially whole cell membranes. In some embodiments, a substantial portion (e.g. , more than about 5%, 10%, 20%, 30%, 50%, or 80%) of bacterial cells may maintain viability in the processed biomass.
- the feed composition may contain at least about 1% of the biomass by weight.
- the feed composition is optimized for consumption by fish, seafood, humans, or other animals.
- the feed may include one or more of EPA, DHA, and one or more essential amino acids.
- the method includes: (a) culturing in an appropriate medium at least one non-naturally occurring microorganism as described above; (b) concentrating the medium to provide a biomass; (c) optionally providing additional feed components; and (d) producing the feed composition from the biomass.
- step (b) includes centrifugation.
- step (b) includes allowing the biomass to settle.
- step (b) includes filtration.
- the method further includes a pre-treatment of the biomass after step (a) with a chemical agent (e.g. , a surfactant or solvent) to disrupt the cell membranes of the biomass.
- a chemical agent e.g. , a surfactant or solvent
- the method further includes mechanical disruption of the cell membranes of the biomass after step (a).
- Examples of feedstuffs into which single cell protein enriched with taurine and/or taurine precursors, produced as described herein, may be incorporated include, for example, pet foods, such as cat foods, dog foods and the like, feeds for aquarium fish, cultured fish or crustaceans, etc., feed for farm-raised animals (including livestock and further including fish or crustaceans raised in aquaculture).
- the state of the biomass can be in whole cell, lysed or partially processed.
- the taurine and/or taurine precursors and/or other caloric or nutritional supplements produced in described herein can also be incorporated into food or vitamin supplements for human consumption.
- Food or feed material into which taurine and/or taurine precursors produced as described herein is incorporated is preferably palatable to the organism that is the intended recipient.
- This food or feed material may have any physical properties currently known for a food material (e.g. , solid, liquid, soft).
- feed produced as described herein will undergo a pelletization process, e.g., through a hot or cold extrusion process at an inclusion rate of less than about 1%, 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, or 75%.
- the taurine and/or taurine precursors-enriched protein can be consumed directly at 100% or combined with another substance in the form of liquid, baked goods or other to form, including but not limited to, various types of tablets, capsules, drinkable agents, gargles, etc.
- Methods of producing fish or seafood are also provided, including farming fish or seafood, and providing a diet, which includes a feed composition as described herein, to the fish or seafood.
- Expression plasmids were constructed utilizing standard molecular cloning techniques and codon optimized, synthetically-derived DNA (see Table 1). These plasmids were transformed into Methylobacterium extorquens or Escherichia coli BL21 (DE3).
- M. extorquens strains were grown in a minimal media based on Choi et al(1989) Appl Microbiol Bioeng 17:392-6). This media was amended with 0.5% methanol, lOug/mL trimethylprim, and 50ug/mL Kanamycin.
- a saturated M. extorquens culture was diluted 100 fold into 25mL of fresh media in a 250mL Erlenmeyer flask and shaken at 200rpm at 30°C. At 24 hours and 36 hours, cultures were fed an additional 0.5% methanol and induced with 0.0125-0.05ng/uL anhydrotetracycline (ATC). M. extorquens cultures were harvested between 48 and 52 hours. Following centrifugation, the bacterial pellets were washed once with 1/20X phosphate buffered saline (PBS) and frozen at -20°C.
- PBS 1/20X phosphate buffered saline
- E. coli cultures were grown in LB (lOg Tryptone, lOg NaCl, 5g Yeast extract per liter) amended with lOOug/mL carbenicillin and 125uM isopropyl ⁇ -D-l- thiogalactopyranoside (IPTG). Following a 100-500 fold dilution, E. coli cultures were shaken at 200rpm at 30°C for 12-24 hours. Following centrifugation, the bacterial pellets were washed once with 1/20X PBS and frozen at -20°C.
- LB lOg Tryptone, lOg NaCl, 5g Yeast extract per liter
- IPTG isopropyl ⁇ -D-l- thiogalactopyranoside
- Betaine Bet
- BA Benzyl alcohol
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Sustainable Development (AREA)
- Physiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Birds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Non-naturally occurring microorganisms are provided that produce taurine and/or taurine precursors, e.g., hypotaurine, sulfoacetaldehyde, or cysteate, utilizing exogenously added enzyme activities. Methods of producing taurine and/or taurine precursors in microbial cultures, and feed and nutritional supplement compositions that include taurine and/or taurine precursors produced in the microbial cultures, such as taurine- and/or taurine precursor-containing biomass, are also provided.
Description
HETEROLOGOUS EXPRESSION OF TAURINE IN
MICROORGANISMS
CROSS-REFERENCE TO RELATED APPLICATIONS
[01] This application claims the benefit of U.S. Provisional Application No.
62/252,971, filed November 9, 2015, which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[02] The invention relates to recombinant production of taurine in microbial organisms, and use in feed compositions, in particular for aquaculture, animal feeds and human nutrition.
BACKGROUND
[03] Taurine (2-aminoethanesulfonic acid) is a 2-carbon ( )-amino acid found in a broad swath of organisms, from birds to mammals, fish to plants, fungi and bacteria (McCusker et al. (2014) JNutr Sci 3:e39). While some proteins contain taurine, it does not form peptide bonds due to the lack of a carboxyl group. In fact, taurine is the most abundant free amino acid (FAA) present in animal tissues, constituting 19% of the FAA in the brain, 50% in kidney, and 53% in muscle. (Brosnan et al. (2006) JNutr. 136(6): 16365 -16405)
[04] Taurine is critical in many basic cellular processes, including osmoregulation, membrane stabilization, and anti oxidation. (Honjoh et al. (2010) Amino Acids . 38(4): 1173- 1183; Takeuchi et al. (2000) Biochim Biophys Acta. 1464(2):219-230) In addition, taurine participates in a variety of more complex physiological functions, such as bile conjugation and calcium signaling. (Salze et al. (2015) Aquaculture 437:215-229). Taurine and hypotaurine have also been shown to aid in protein folding (Warskulat et al. (2007) Methods Enzymol 428:439-58; Abe et al. (2015) Amino acids 47(5):909-15; Fujii et al. (2007) J Biochem 141(5):697-707).
[05] While taurine can be detected at high levels in a variety of fish species, some taurine has been suggested as a conditionally essential nutrient for many carnivorous fish species, from trout to snakehead, and its supplementation has been shown to increase their growth rate. (Gibson et al. (2007) Aquaculture 269(l-4):514-524; Wu et al. (2015) Aquae Nutr.
21 (2):214-222) Furthermore, it appears that taurine supplementation can complement the reduction of fishmeal in the feedstock, a critical objective for achieving a more sustainable form of aquaculture.
[06] For cats, dietary taurine is often a necessary addition to feed. Inadequate levels of taurine may cause severe degenerative changes in the retina, visual cortex and brain development. Taurine has also been reported to have anti-epilepsy properties. (Ripps and Shen (2012) Molecular Vision 18:2673-2786)
[07] Chemical synthesis of taurine is undoubtedly the predominant means of production, via a plethora of known synthetic mechanisms. (Salze et al. (2015) Aquaculture 437:215- 229) The biosynthesis of taurine in plant cells has also been described. (US2012/0222148 Al) Contrary to prior belief, a series of recent publications indicate that a large number of bacteria, fungi, and algae contain individual enzymes, or in some cases entire anabolic pathways, which are capable of taurine synthesis. (Tevatia et al. (2015) Algal Res. 9:21-26; Agnello et al. (2013) ACS Chem Biol. 8(10): 2264-2271)
[08] There is a need for a combined protein/taurine feedstock to serve the fields of animal nutrition. The need is especially pressing in aquaculture during the larval stage of fish. Larval feed, which can sit in the water longer than adult feed, can result in significant loss of taurine due to dissipation. Chemically synthesized taurine in crystalline form is particularly susceptible to this process. Enriching rotifers with taurine is an effective solution (Matsunari et al. (2013) Fish Sci. 79(5):815-821), but a potentially uneconomical one, as live feeds tend to be expensive. An alternative strategy is to encapsulate taurine in microparticles, such as lipid-walled capsules (Langdon et al. (2003) Aquaculture 227(1- 4):259-275). Plant-based production systems could achieve this objective by employing the cell membrane as a natural lipid-capsule. This approach is imperfect, however, as direct feeding with plant cells suffers from the anti-nutritional factors found in plant-based feeds. (Francis et al. (2001) Aquaculture 199(3-4): 197-227) Therefore, there exists a need for an aquaculture feed that protects taurine from dissolving in water, while eschewing solutions involving plant-based biosynthesis or live feeds. The invention herein describes just such a solution.
BRIEF SUMMARY OF THE INVENTION
[09] In one aspect, non-naturally occurring microorganisms are provided that express one or more polynucleotide(s) expressing exogenous enzyme(s) for production of taurine. For example, a non-naturally occurring microorganism expresses the following enzyme activities: (a) cysteamine (2-aminoethanethiol) di oxygenase (ADO); (b) cysteine dioxygenase (CDO), and cysteine sulfinic acid decarboxylase (CSAD) or glutamate decarboxylase (GAD); (c) 3-mercaptopropionate dioxygenase (p3MDO), and CSAD or GAD; (d) L-serine dehydratase; sulfate adenyltransferase and adenylyl-sulfate kinase (APSK), and/or 3'-phosphoadenosine 5'-phosphosulfate synthase (PAPSS 1)); 3'- phosphoadenylyl sulfate:2-aminoacrylate C-sulfotransferase (PAPS-AS), and CSAD or GAD; (e) cysteate synthase, optionally L-serine dehydratase, and CSAD or GAD; (f) L- cysteine desulfydrase (CD) activity; optionally cystathionine gamma-lyase (CGL) activity; sulfate adenyltransferase and APSK, and/or PAPSS 1); PAPS-AS, and CSAD or GAD; (g) CD) activity; optionally CGL activity; cysteate synthase, and CSAD or GAD; (h) cysteate sulfo-lyase (CuyA), and CSAD or GAD; (i) phosphosulfolactate synthase (ComA), 2- phospho-3-sulfolactate phosphohydrolase (ComB), sulfolactate dehydrogenase (ComC), aspartate aminotransferase (AspAT), and CSAD or GAD; (j) sulfoacetaldehyde acetyltransferase (Xsc) and taurine-pyruvate aminotransferase (Tpa); (k) ComA, ComB, ComC, sulfopyruvate decarboxylase (ComDE), and Tpa; or (1) AspAT, ComDE and Tpa, wherein at least one of said enzyme activities is encoded by an exogenous polynucleotide that is expressed in the microorganism.
[10] In some embodiments, the non-naturally occurring microorganism is derived from a host cell from genera selected from Methylobacterium, Methylomonas , Methylobacter . Methylococcus , Methylosinus , Methylocyctis , Methylomicrobium, Methylomonas,
Methylpophilus , Methylobacillus , Methylobacterium, Hyphomicrobium, Xanthobacter , Bacillus, Paracoccus, Nocardia, Arthrobacter, Rhodopseudomonas , Pseudomonas, Candida, Hansenula, Pichia, Torulopsis, Rhodotorula, Escherichia, and Saccharomyces . For example, the microorganism may be selected from Methylobacterium, Escherichia, Saccharomyces, and Bacillus. In some embodiments, the non-naturally occurring microorganism is a methylotrophic bacterium. For example, the non-naturally occurring
microorganism may be aMethylobacterium species, such as but not limited to,
Methylobacterium extorquens.
[11] In some embodiments, the one or more exogenous polynucleotide(s) is/are codon optimized for expression in the microorganism. In some embodiments, the one or more exogenous polynucleotide(s) is/are operably linked to promoter(s) for expression in the microorganism.
[12] In some embodiments, the non-naturally occurring microorganism includes deletion of one or more genes that encode enzyme(s) that degrade taurine or the taurine precursor cysteate or sulfoacetaldehyde or modification of one or more genes that encode enzyme(s) that degrade taurine, cysteate, or sulfoacetaldehyde such that activity of the one or more enzyme(s) that degrade taurine, cysteate, or sulfoacetaldehyde is lower than in the microorganism parent strain from which the non-naturally microorganism is derived. In some embodiments, the one or more enzyme(s) that degrade taurine, cysteate, or sulfoacetaldehyde includes taurine dehydrogenase, taurine dioxygenase, Xsc, CuyA, Tpa, and/or gamma-glutamyltransferase.
[13] In some embodiments, the non-naturally occurring microorganism is genetically modified or artificially pre-selected to produce elevated levels of a carotenoid compound relative to the corresponding unmodified or unselected microorganism. For example, the microorganism may produce elevated levels of one or more carotenoid compound(s) selected from β-carotene, lycopene, rhodopsin, zeaxanthin, lutein, canthaxanthin, astaxanthin, and sprilloxanthin, in comparison to the host cell from which the carotenoid producing microorganism is derived.
[14] In some embodiments, the non-naturally occurring microorganism accumulates intracellular taurine and/or hypotaurine, wherein the taurine and/or hypotaurine aids in the folding of one or more native and/or heterologous protein(s), e.g., for the purpose of increased enzymatic activity and/or protein yield in comparison to the parent
microorganism from which the non-naturally occurring microorganism is derived, e.g., a parent microorganism that does not include the one or more exogenous polynucleotide(s).
[15] In another aspect, methods are provided for producing biomass that includes taurine and/or taurine precursors such as cysteate, sulfoacetaldehyde, and/or hypotaurine. The methods include culturing a non-naturally occurring microorganism as described herein in a
culture medium under conditions suitable for growth of the microorganism and expression of exogenous enzyme(s) for production of taurine and/or taurine precursors, wherein biomass comprising taurine and/or taurine precursors is produced in the culture.
[16] In another aspect, a feed or nutritional supplement is provided that includes taurine- and/or taurine precursor-containing biomass produced as described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[17] Figure 1 depicts an embodiment of a biosynthetic pathway for production of taurine from cysteamine.
[18] Figure 2 depicts an embodiment of a biosynthetic pathway for production of taurine from L-cysteine.
[19] Figure 3 depicts an embodiment of a biosynthetic pathway for production of taurine from L-cysteine.
[20] Figure 4 depicts an embodiment of a biosynthetic pathway for production of taurine from L-serine.
[21] Figure 5 depicts an embodiment of a biosynthetic pathway for production of taurine from L-phosphoserine or L-serine.
[22] Figure 6 depicts an embodiment of a biosynthetic pathway for production of taurine from L-cysteine.
[23] Figure 7 depicts an embodiment of a biosynthetic pathway for production of taurine from L-cysteine.
[24] Figure 8 depicts an embodiment of a biosynthetic pathway for production of taurine from pyruvate.
[25] Figure 9 depicts an embodiment of a biosynthetic pathway for production of taurine from phosphoenolpyruvate.
[26] Figure 10 depicts an embodiment of a biosynthetic pathway for production of taurine from acetyl phosphate.
[27] Figure 11 depicts an embodiment of a biosynthetic pathway for production of taurine from phosphoenolpyruvate.
[28] Figure 12 depicts an embodiment of a biosynthetic pathway for production of taurine through taurine-pyruvate aminotransferase.
[29] Figure 13 depicts taurine and cysteate degradation pathways.
DETAILED DESCRIPTION
[30] The invention described herein addresses the dual challenge of producing taurine from an inexpensive feedstock, and encapsulating it to prevent dissolution in water for aquaculture. Microbial systems for taurine production are described as well as feed products in which the taurine is encapsulated in a natural lipid bilayer (microbial cells).
[31] Provided herein are non-naturally occurring microorganisms, e.g., bacteria, yeast, Archaea, that are capable of producing taurine and/or the taurine precursor(s), e.g., hypotaurine or cysteate. Also provided are methods of engineering and culturing such microorganisms, methods of using such microorganisms to produce taurine, and methods of producing taurine-containing compositions, such as feed compositions that contain the microorganisms or compositions that contain taurine recovered from such organisms.
[32] One aspect pertains to the field of aquaculture. Another aspect is the field of pet foods, for example, for cats and dogs. A further aspect is in the field of human nutrition and supplements. More specifically, aquaculture feeds, pet food, and nutritional supplement compositions are provided that include taurine-containing microbial biomass and a complete protein nutrition, that is, containing most or all amino acids necessary for healthy growth of the animal to which it is administered. In some embodiments, the aquaculture feed compositions herein contain one or more carotenoid(s) produced by the microorganism that produces taurine and/or taurine precursor(s), e.g. , hypotaurine or cysteate. The microbial biomass can be blended with other ingredients to form a portion or whole of a feed, or may be consumed directly as a protein-rich powder.
[33] Another aspect pertains to the field of industrial protein production. Osmolytes such as betaine, glycine, trimethylamine N-Oxide (TMAO), and taurine can aid in protein folding (Warskulat et al. (2007) Methods Enzymol 428:439-58; Abe et al. (2015) Amino acids 47(5):909-15; Fujii et al. (2007) J Biochem 141(5):697-707). Microorganisms engineered to accumulate intracellular taurine as a chemical chaperone could produce higher yields or more active proteins of interest. As antioxidants, taurine, hypotaurine, and their precursors also promote protein activity by limiting protein inactivation through oxidation (Oliveira et al. (2010) Pharmacological Reports 62: 185-193; Aruoma et al. (1988) Biochem J 256:251-55; Bucolo et al. (2016) Acta Ophthalmologic 95(256); Patel et al. (2016) Exp Toxic Pathol 68(2-3): 103-12; Fontana et al. (2004) Neurochemical Research 29(1): 111-116).
Definitions
[34] Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton, et al. Dictionary of Microbiology and Molecular Biology, second ed., John Wiley and Sons, New York (1994), and Hale & Markham. The Harper Collins Dictionary of Biology. Harper Perennial, NY (1991) provide one of skill with a general dictionary of many of the terms used in this invention. Any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention.
[35] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, for example, Molecular Cloning: A
Laboratory Manual, second edition (Sambrook et al, 1989); Oligonucleotide Synthesis (M. J. Gait, ed., 1984; Current Protocols in Molecular Biology (F. M. Ausubel et al, eds., 1994); PCR: The Polymerase Chain Reaction (Mullis et al, eds., 1994); and Gene Transfer and Expression: A Laboratory Manual (Kriegler, 1990).
[36] Numeric ranges provided herein are inclusive of the numbers defining the range.
[37] Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.
[38] "A," "an" and "the" include plural references unless the context clearly dictates otherwise.
[39] As used herein, the term "polynucleotide" refers to a polymeric form of nucleotides of any length and any three-dimensional structure and single- or multi-stranded (e.g., single-stranded, double-stranded, triple-helical, etc.), which contain
deoxyribonucleotides, ribonucleotides, and/or analogs or modified forms of
deoxyribonucleotides or ribonucleotides, including modified nucleotides or bases or their analogs. Because the genetic code is degenerate, more than one codon may be used to encode a particular amino acid, and the present invention encompasses polynucleotides which encode a particular amino acid sequence. Any type of modified nucleotide or nucleotide analog may be used, so long as the polynucleotide retains the desired
functionality under conditions of use, including modifications that increase nuclease resistance (e.g., deoxy, 2'-0-Me, phosphorothioates, etc.). Labels may also be incorporated for purposes of detection or capture, for example, radioactive or nonradioactive labels or anchors, e.g., biotin. The term polynucleotide also includes peptide nucleic acids (PNA). Polynucleotides may be naturally occurring or non-naturally occurring. The terms
"polynucleotide," "nucleic acid," and "oligonucleotide" are used herein interchangeably. Polynucleotides may contain RNA, DNA, or both, and/or modified forms and/or analogs thereof. A sequence of nucleotides may be interrupted by non-nucleotide components. One or more phosphodiester linkages may be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(0)S ("thioate"), P(S)S ("dithioate"), (0)NR.sub.2 ("amidate"), P(0)R, P(0)OR', CO or CH.sub.2 ("formacetal"), in which each R or R is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (— 0~) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. Polynucleotides may be linear or circular or comprise a combination of linear and circular portions.
[40] As used herein, "polypeptide" refers to a composition comprised of amino acids and recognized as a protein by those of skill in the art. The conventional one-letter or three- letter code for amino acid residues is used herein. The terms "polypeptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art.
[41] As used herein, a "vector" refers to a polynucleotide sequence designed to introduce nucleic acids into one or more cell types. Vectors include cloning vectors, expression vectors, shuttle vectors, plasmids, phage particles, cassettes and the like.
[42] As used herein, the term "expression" refers to the process by which a polypeptide is produced based on the nucleic acid sequence of a gene. The process includes both transcription and translation.
[43] As used herein, "expression vector" refers to a DNA construct containing a DNA coding sequence (e.g., gene sequence) that is operably linked to one or more suitable control sequence(s) capable of effecting expression of the coding sequence in a host. Such control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control termination of transcription and translation. The vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself. The plasmid is the most commonly used form of expression vector. However, the invention is intended to include such other forms of expression vectors that serve equivalent functions and which are, or become, known in the art.
[44] A "promoter" refers to a regulatory sequence that is involved in binding RNA polymerase to initiate transcription of a gene. A promoter may be an inducible promoter or a constitutive promoter. An "inducible promoter" is a promoter that is active under environmental or developmental regulatory conditions.
[45] The term "operably linked" refers to a juxtaposition or arrangement of specified elements that allows them to perform in concert to bring about an effect. For example, a promoter is operably linked to a coding sequence if it controls the transcription of the coding sequence.
[46] "Under transcriptional control" is a term well understood in the art that indicates that transcription of a polynucleotide sequence depends on its being operably linked to an element which contributes to the initiation of, or promotes transcription.
[47] "Under translational control" is a term well understood in the art that indicates a regulatory process which occurs after mRNA has been formed.
[48] A "gene" refers to a DNA segment that is involved in producing a polypeptide and includes regions preceding and following the coding regions as well as intervening sequences (introns) between individual coding segments (exons).
[49] As used herein, the term "host cell" refers to a cell or cell line into which a recombinant expression vector for production of a polypeptide may be transfected for expression of the polypeptide. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. A host cell includes cells transfected or transformed in vivo with an expression vector.
[50] The term "recombinant," refers to genetic material (i.e., nucleic acids, the polypeptides they encode, and vectors and cells comprising such polynucleotides) that has been modified to alter its sequence or expression characteristics, such as by mutating the coding sequence to produce an altered polypeptide, fusing the coding sequence to that of another gene, placing a gene under the control of a different promoter, expressing a gene in a heterologous organism, expressing a gene at a decreased or elevated levels, expressing a gene conditionally or constitutively in manner different from its natural expression profile, and the like. Generally recombinant nucleic acids, polypeptides, and cells based thereon, have been manipulated by man such that they are not identical to related nucleic acids, polypeptides, and cells found in nature.
[51] A "signal sequence" refers to a sequence of amino acids bound to the N-terminal portion of a protein which facilitates the secretion of the mature form of the protein from the cell. The mature form of the extracellular protein lacks the signal sequence which is cleaved off during the secretion process.
[52] The term "selective marker" or "selectable marker" refers to a gene capable of expression in a host cell that allows for ease of selection of those hosts containing an introduced nucleic acid or vector. Examples of selectable markers include but are not limited to antimicrobial substances (e.g. , hygromycin, bleomycin, or chloramphenicol) and/or genes that confer a metabolic advantage, such as a nutritional advantage, on the host cell.
[53] The term "derived from" encompasses the terms "originated from," "obtained from," "obtainable from," "isolated from," and "created from," and generally indicates that one specified material finds its origin in another specified material or has features that can be described with reference to the another specified material.
[54] The term "culturing" refers to growing a population of cells, e.g., microbial cells, under suitable conditions for growth, in a liquid or solid medium.
[55] The term "heterologous" or "exogenous," with reference to a polynucleotide or protein, refers to a polynucleotide or protein that does not naturally occur in a specified cell, e.g., a host cell. It is intended that the term encompass proteins that are encoded by naturally occurring genes, mutated genes, and/or synthetic genes. In contrast, the term "homologous," with reference to a polynucleotide or protein, refers to a polynucleotide or protein that occurs naturally in the cell.
[56] The term "introduced," in the context of inserting a nucleic acid sequence into a cell, includes "transfection," "transformation," or "transduction" and refers to the incorporation of a nucleic acid sequence into a eukaryotic or prokaryotic cell wherein the nucleic acid sequence may be incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed.
[57] "Transfection" or "transformation" refers to the insertion of an exogenous polynucleotide into a host cell. The exogenous polynucleotide may be maintained as a non- integrated vector, for example, a plasmid, or alternatively, may be integrated into the host cell genome. The term "transfecting" or "transfection" is intended to encompass all conventional techniques for introducing nucleic acid into host cells. Examples of transfection techniques include, but are not limited to, calcium phosphate precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, and microinjection.
[58] As used herein, the terms "transformed," "stably transformed," and "transgenic" refer to a cell that has a non-native (e.g. , heterologous) nucleic acid sequence integrated into its genome or as an episomal plasmid that is maintained through multiple generations.
[59] The terms "recovered," "isolated," "purified," and "separated" as used herein refer to a material (e.g., a protein, nucleic acid, or cell) that is removed from at least one component with which it is naturally associated. For example, these terms may refer to a material which is substantially or essentially free from components which normally accompany it as found in its native state, such as, for example, an intact biological system.
[60] A "signal sequence" (also termed "presequence," "signal peptide," "leader sequence," or "leader peptide") refers to a sequence of amino acids at the amino terminus of a nascent polypeptide that targets the polypeptide to the secretory pathway and is cleaved
from the nascent polypeptide once it is translocated in the endoplasmic reticulum membrane.
[61] Related (and derivative) proteins encompass "variant" proteins. Variant proteins differ from a parent protein and/or from one another by a small number of amino acid residues. In some embodiments, the number of different amino acid residues is any of about 1, 2, 3, 4, 5, 10, 20, 25, 30, 35, 40, 45, or 50. In some embodiments, variants differ by about 1 to about 10 amino acids. Alternatively or additionally, variants may have a specified degree of sequence identity with a reference protein or nucleic acid, e.g., as determined using a sequence alignment tool, such as BLAST, ALIGN, and CLUSTAL (see, infra). For example, variant proteins or nucleic acid may have at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or even 99.5% amino acid sequence identity with a reference sequence.
[62] As used herein, the term "analogous sequence" refers to a polypeptide sequence within a protein that provides a similar function, tertiary structure, and/or conserved residues with respect to a reference protein. For example, in epitope regions that contain an alpha helix or a beta sheet structure, replacement amino acid(s) in an analogous sequence maintain the same structural element. In some embodiments, analogous sequences are provided that result in a variant enzyme exhibiting a similar or improved function with respect to the parent protein from which the variant is derived.
[63] As used herein, "homologous protein" refers to a protein that has similar function and/or structure as a reference protein. Homologs may be from evolutionarily related or unrelated species. In some embodiments, a homolog has a quaternary, tertiary and/or primary structure similar to that of a reference protein, thereby potentially allowing for replacement of a segment or fragment in the reference protein with an analogous segment or fragment from the homolog, with reduced disruptiveness of structure and/or function of the reference protein in comparison with replacement of the segment or fragment with a sequence from a non-homologous protein.
[64] As used herein, "wild-type," "native," and "naturally-occurring" proteins are those found in nature. The terms "wild-type sequence" refers to an amino acid or nucleic acid sequence that is found in nature or naturally occurring. In some embodiments, a wild-type
sequence is the starting point of a protein engineering project, for example, production of variant proteins.
[65] The phrases "substantially similar" and "substantially identical" in the context of at least two nucleic acids or polypeptides typically means that a polynucleotide, polypeptide, or region or domain of a polypeptide that comprises a sequence that has at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or even 99.5% sequence identity, in comparison with a reference (e.g., wild-type) polynucleotide, polypeptide, or region or domain of a polypeptide. A region or domain of a polypeptide may contain, for example, at least about 20, 50, 100, or 200 amino acids within a longer polypeptide sequence. Sequence identity may be determined using known programs such as BLAST, ALIGN, and CLUSTAL using standard parameters. (See, e.g., Altshul et al. (1990) J. Mol. Biol. 215:403-410; Henikoff et al. (1989) Proc. Natl. Acad. Sci. 89: 10915; Karin et al. (1993) Proc. Natl. Acad. Sci. 90:5873; and Higgins et al. (1988) Gene 73:237). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. Also, databases may be searched using FASTA (Person et al. (1988) Proc. Natl. Acad. Sci. 85:2444-2448.) In some embodiments, substantially identical polypeptides differ only by one or more conservative amino acid substitutions. In some embodiments, substantially identical polypeptides are immunologically cross- reactive. In some embodiments, substantially identical nucleic acid molecules hybridize to each other under stringent conditions (e.g., within a range of medium to high stringency).
[66] The term "carotenoid" is understood in the art to refer to a structurally diverse class of pigments derived from isoprenoid pathway intermediates. The commitment step in carotenoid biosynthesis is the formation of phytoene from geranylgeranyl pyrophosphate. Carotenoids can be acyclic or cyclic, and may or may not contain oxygen, so that the term carotenoids include both carotenes and xanthophylls. In general, carotenoids are hydrocarbon compounds having a conjugated polyene carbon skeleton formally derived from the five-carbon compound IPP, including triterpenes (C30 diapocarotenoids) and tetraterpenes (C40 carotenoids) as well as their oxygenated derivatives and other compounds that are, for example, C35, C50, C60, C70, Cso in length or other lengths. Many carotenoids have strong light absorbing properties and may range in length in excess of C200- C30 diapocarotenoids typically consist of six isoprenoid units joined in such a manner that the
arrangement of isoprenoid units is reversed at the center of the molecule so that the two central methyl groups are in a 1 ,6-positional relationship and the remaining non-terminal methyl groups are in a 1 ,5-positional relationship. Such C30 carotenoids may be formally derived from the acyclic C30H42 structure, having a long central chain of conjugated double bonds, by: (i) hydrogenation (ii) dehydrogenation, (iii) cyclization, (iv) oxidation, (v) esterification/glycosylation, or any combination of these processes. C40 carotenoids typically consist of eight isoprenoid units joined in such a manner that the arrangement of isoprenoid units is reversed at the center of the molecule so that the two central methyl groups are in a 1 ,6-positional relationship and the remaining non-terminal methyl groups are in a 1 ,5-positional relationship. Such C40 carotenoids may be formally derived from the acyclic C40H56 structure, having a long central chain of conjugated double bonds, by (i) hydrogenation, (ii) dehydrogenation, (iii) cyclization, (iv) oxidation, (v)
esterification/glycosylation, or any combination of these processes. The class of C40 carotenoids also includes certain compounds that arise from rearrangements of the carbon skeleton, or by the (formal) removal of part of this structure. More than 600 different carotenoids have been identified in nature. Carotenoids include but are not limited to:
antheraxanthin, adonirubin, adonixanthin, astaxanthin, canthaxanthin, capsorubrin, β- cryptoxanthin, a-carotene, β-carotene, β,ψ-carotene, δ-carotene, ε-carotene, echinenone, 3- hydroxyechinenone, 3 '-hydroxy echinenone, γ-carotene, ψ-carotene, 4-keto-Y-carotene, ζ- carotene, a-cryptoxanthin, deoxyflexixanthin, diatoxanthin, 7,8-didehydroastaxanthin, didehydrolycopene, fucoxanthin, fucoxanthinol, isorenieratene, β-isorenieratene, lactucaxanthin, lutein, lycopene, myxobactone, neoxanthin, neurosporene,
hydroxyneurosporene, peridinin, phytoene, rhodopin, rhodopin glucoside, 4-keto- rubixanthin,siphonaxanthin, spheroidene, spheroidenone, spirilloxanthin, torulene, 4-keto- torulene, 3-hydroxy-4-keto-torulene, uriolide, uriolide acetate, violaxanthin, zeaxanthin-β- diglucoside, zeaxanthin, and C30 carotenoids. Additionally, carotenoid compounds include derivatives of these molecules, which may include hydroxy-, methoxy-, 0x0-, epoxy-, carboxy-, or aldehydic functional groups. Further, included carotenoid compounds include ester (e.g., glycoside ester, fatty acid ester) and sulfate derivatives (e.g., esterified xanthophylls).
[67] The "isoprenoid pathway" is understood in the art to refer to a metabolic pathway that either produces or utilizes the five-carbon metabolite isopentyl pyrophosphate (IPP). As
discussed herein, two different pathways can produce the common isoprenoid precursor IPP— the "mevalonate pathway" and the "non-mevalonate pathway." The term "isoprenoid pathway" is sufficiently general to encompass both of these types of pathway. Biosynthesis of isoprenoids from IPP occurs by polymerization of several five-carbon isoprene subunits. Isoprenoid metabolites derived from IPP vary greatly in chemical structure, including both cyclic and acyclic molecules. Isoprenoid metabolites include, but are not limited to, monoterpenes, sesquiterpenes, diterpenes, sterols, and polyprenols such as carotenoids.
[68] The term "isoprenoid compound" refers to any compound which is derived via the pathway beginning with isopentenyl pyrophosphate (IPP) and formed by the head-to-tail condensation of isoprene units which may be of 5, 10, 15, 20, 30 or 40 carbons in length. There term "isoprenoid pigment" refers to a class of isoprenoid compounds which typically have strong light absorbing properties.
[69] The term "feed premix" refers to the crude mixture of aquaculture feed or animal/pet food components prior to processing, optionally at high temperature, into an aquaculture feed or animal or pet food composition that is in the form of pellets or flakes.
[70] An aquaculture feed composition is used in the production of an "aquaculture product," wherein the product is a harvestable aquacultured species (e.g., finfish, crustaceans), which is often sold for human consumption. For example, salmon are intensively produced in aquaculture and thus are aquaculture products. Aquaculture compositions may also be used as feed for aquaculture feed organisms such as small fish like krill, rotifers, and the like, that are food sources for larger aquaculture organisms such as carnivorous fish. In addition, aquaculture compositions described herein can be used as feed for ornamental fish, shrimp, hobbyist aquaculture, and the like, that are not intended as food for other organisms.
[71] The term "aquaculture meat product" refers to food products intended for human consumption comprising at least a portion of meat from an aquaculture product as defined above. An aquaculture meat product may be, for example, a whole fish or a filet cut from a fish, each of which may be consumed as food. In some embodiments, such a product can be referred to as a fish or seafood product.
[72] The term "biomass" refers to microbial cellular material. Biomass may be produced naturally, or may be produced from the fermentation of a native host or a recombinant production host. The biomass may be in the form of whole cells, whole cell lysates,
homogenized cells, partially hydrolyzed cellular material, and/or partially purified cellular material (e.g., microbially produced oil).
[73] The term "processed biomass" refers to biomass that has been subjected to additional processing such as drying, pasteurization, disruption, etc., each of which is discussed in greater detail below.
[74] The term "C-l carbon substrate" refers to any carbon-containing molecule that lacks a carbon-carbon bond. Examples are methane, methanol, formaldehyde, formic acid, formate, methylated amines (e.g., mono-, di-, and tri- methyl amine), methylated thiols, and carbon dioxide.
[75] The term "CI metabolizer" refers to a microorganism that has the ability to use a single carbon substrate as a sole source of energy and biomass. CI metabolizers will typically be methylotrophs and/or methanotrophs capable of growth.
[76] The term "methylotroph" means an organism capable of oxidizing organic compounds which do not contain carbon-carbon bonds. Where the methylotroph is able to oxidize CH4, the methylotroph is also a methanotroph.
[77] The term "methanotroph" means a prokaryote capable of utilizing methane as a substrate. Complete oxidation of methane to carbon dioxide occurs by aerobic degradation pathways. Typical examples of methanotrophs useful in the present invention include but are not limited to the genera Methylomonas, Methylobacter , Methylococcus , and
Methylosinus .
[78] The term "high growth methanotrophic bacterial strain" refers to a bacterium capable of growth using methane as its sole carbon and energy source.
Microorganisms
[79] Non-naturally occurring microorganisms are provided for production of taurine or the taurine precursors hypotaurine, cysteate, or sulfoacetaldehyde. Non-naturally occurring, e.g., recombinant, microorganisms herein include, e.g., bacteria, yeast, Archaea, that have been engineered to express at least one (i.e. , one or more) enzyme(s) for biosynthesis of taurine or taurine precursors and that produce taurine or taurine precursors when cultured under conditions suitable for microbial growth and taurine production.
[80] Non-naturally occurring microorganisms as described herein include one or more exogenous polynucleotide(s) that encode and express one or more enzyme or enzyme activity for biosynthesis of taurine or the taurine precursors cysteate, sulfoacetaldehyde, or
hypotaurine. The exogenous polynucleotide(s) may include one or more coding sequence for one or more enzyme or enzyme activity for biosynthesis of taurine or taurine precursors, operably linked to one or more promoter for expression in the non-naturally occurring microorganism. Such promoters may include, but are not limited to, P R (e.g., SEQ ID NO:42), P Lac (e.g., SEQ ID NO:41), P tac (e.g. , SEQ ID NO:39), P tacA (e.g. , SEQ ID NO:40), PmxaF (e.g. , SEQ ID NO:43), P rrnB, and P T7. In some embodiments, the polynucleotide(s) are codon optimized for expression in the microorganism.
[81] In some embodiments, the non-naturally occurring microorganism includes one or more exogenous and/or endogenous polynucleotide(s) that encodes one or more enzymes or enzyme activities for taurine biosynthesis, as described herein, that has been modified for improved stability and/or activity relative to the stability and/or activity of the enzyme or enzyme activity in the host cell from which it is derived or relative to the wild-type stability and/or activity of the enzyme or enzyme activity. For example, the non-naturally occurring microorganism may express a variant of an enzyme of taurine biosynthesis that has greater stability and/or activity than the wild-type enzyme from which it is derived.
[82] In some embodiments, the host cell from which a non-naturally occurring microorganism as described herein is derived has one or more endogenous taurine, cysteate, or sulfoacetaldehyde degrading activity, for example, but not limited to, taurine
dehydrogenase, Tpa, CuyA, gamma-glutamyltransferase, Xsc, and/or taurine dioxygenase. In some embodiments, the non-naturally occurring microorganism includes deletion of one or more genes that encode taurine, cysteate, or sulfoacetaldehyde degrading enzyme(s). In some embodiments, the host cell from which a non-naturally occurring microorganism includes modification of one or more genes that encode taurine, cysteate, or
sulfoacetaldehyde degrading enzyme(s), such that the taurine, cysteate, or
sulfoacetaldehyde degrading activity of the enzyme(s) is lower in the non-naturally occurring microorganism than in the host cell from which it is derived. In some embodiments, the host cell is Methylobacterium extorquens and the non-naturally occurring microorganism derived from the host cell includes deletion or modification of the gene that encodes gamma-glutamyltransferase in the host cell.
[83] In certain embodiments, the host cell comprises one or more of endogenous genes in the described pathway. In certain embodiments, the host cell is modified so that one or more genes producing enzymes that divert compounds and taurine precursors away from a
taurine biosynthetic pathway are blocked or deleted. In certain embodiments, the one or more blocked or deleted genes are selected from genes involved in the degradation of taurine, cysteate, or sulfoacetaldehyde. In certain embodiments, the host cell is a spontaneous mutant whose rate of growth is increased relative to a corresponding non- mutant. In certain embodiments, the host cell is cultured under stress conditions selected from light depletion, nutrient depletion, nitrogen depletion, high salt, or a chemical that inhibits growth of the host cell, wherein the stress conditions induce changes in gene expression leading to increased taurine or taurine precursor production.
[84] In some embodiments, the non-naturally occurring microorganism or the host cell from which the non-naturally occurring microorganism is derived is genetically modified or artificially pre-selected to produce elevated levels of one or more carotenoid compound(s) relative to the corresponding unmodified or unselected microorganism. The one or more carotenoid compound(s) may include, but are not limited to, β-carotene, lycopene, zeaxanthin, lutein, canthaxanthin, rhodopin, astaxanthin, and/or sprilloxanthin. Non- limiting examples of host cells that produce elevated levels of one or more carotenoid compound(s) and methods for producing such microorganisms are provided in
WO2015/021352 A2.
[85] Non-limiting examples of genera from which the non-naturally occurring microorganism may be derived include Methylobacterium, Methylomonas , Methylobacter . Methylococcus , Methylosinus , Methylocyctis , Methylomicrobium, Methylomonas,
Methylpophilus , Methylobacillus , Methylobacterium, Hyphomicrobium, Xanthobacter , Bacillus, Paracoccus, Nocardia, Arthrobacter , Rhodopseudomonas , Pseudomonas, Candida, Hansenula, Pichia, Torulopsis, Rhodotorula, Escherichia, and Saccharomyces . Non-limiting examples of microbial species from which the non-naturally occurring microorganism may be derived include Methylobacterium extorquens {e.g. , strains AMI, DM4, CM4, PA1, or BJ001 (formerly Methylobacterium populi)), Methylobacterium radiotolerans, Methylobacterium nodulans, Methylobacterium spp. 4-46, and Escherichia coli.
[86] In some embodiments, the non-naturally occurring microorganism is a methylotrophic bacterium.
Conversion of cvsteamine to taurine
[87] In some embodiments, a non-naturally occurring microorganism is provided that expresses an exogenous enzyme activity of 2-aminoethanol (cysteamine) dioxygenase (ADO) (EC 1.13.11.19), which converts cysteamine to hypotaurine, for biosynthesis of taurine, as shown in Fig. 1.
[88] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ADO comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 44, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:44. In some embodiments, the polynucleotide that encodes ADO comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:45 or SEQ ID NO:57 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:45 or SEQ ID NO:57. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:57.
[89] In some embodiments, the non-naturally occurring microorganism is a
Methylobacterium, Escherichia, Saccharomyces , or Bacillus microorganism that includes an exogenous polynucleotide that encodes ADO.
Conversion of cysteine to taurine via CDO
[90] In some embodiments, a non-naturally occurring microorganism is provided that expresses one or more exogenous enzyme activity/ies for the conversion of cysteine to taurine via the enzyme cysteine dioxygenase (CDO), for example, exogenous enzyme(s) of the CDO/CSAD or GAD pathway for biosynthesis of taurine. The CDO/CSAD or GAD pathway for taurine biosynthesis is shown schematically in Fig. 2.
[91] In some embodiments, the non-naturally occurring microorganism that expresses exogenous enzyme activities of the CDO/CSAD or GAD pathway is not of genera
Escherichia or species Escherichia coli. In some embodiments, the non-naturally occurring microorganism is not of genera Saccharomyces or species Saccharomyces cerevisiae.
[92] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: cysteine dioxygenase (CDO) (EC 1.13.11.20); and cysteine sulfinic acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or
enzyme activities is encoded by an exogenous polynucleotide with which the
microorganism has been transformed. In some embodiments, CDO and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one or two exogenous polynucleotide(s)) in the microorganism. In some embodiments, one of CDO and CSAD enzymes or enzyme activities is encoded an exogenous polynucleotide in the microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from an exogenous polynucleotide. In one embodiment, the microorganism expresses an endogenous CSAD activity and CDO is encoded by an exogenous polynucleotide in the microorganism. In one embodiment, the microorganism expresses an endogenous CDO activity and CSAD is encoded by an exogenous polynucleotide in the microorganism.
[93] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: cysteine dioxygenase (CDO) (EC 1.13.11.20); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some embodiments, CDO and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one or two exogenous polynucleotide(s)) in the microorganism. In some embodiments, one of CDO and GAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the
microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from an exogenous polynucleotide. In one embodiment, the microorganism expresses an
endogenous GAD activity and CDO is encoded by an exogenous polynucleotide in the microorganism. In one embodiment, the microorganism expresses an endogenous CDO activity and GAD is encoded by an exogenous polynucleotide in the microorganism.
[94] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CDO comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 15, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 15. In some embodiments, the polynucleotide that encodes CDO comprises or consists of the polynucleotide sequence
depicted in SEQ ID NO: 16, SEQ ID NO:50, or SEQ ID NO:58 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 16, SEQ ID NO:50, or SEQ ID NO:58. In some embodiments, the
polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:58.
[95] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CDO comprising or consisting of the amino acid sequence depicted in SEQ ID NO:35, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:35. In some embodiments, the polynucleotide that encodes CDO comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 36, SEQ ID NO: 51, or SEQ ID NO: 59 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:36, SEQ ID NO:51, or SEQ ID NO:59. In some embodiments, the
polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ. NO:51 or SEQ ID NO: 59.
[96] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11. In some embodiments, the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40,45,50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54. In some embodiments, the
polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
[97] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13. In some embodiments, the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14. In some
embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism.
[98] In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CDO and CSAD. In another embodiment, a non-naturally occurring Methylobacterium
microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CDO and GAD.
[99] In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes an exogenous polynucleotide encoding CDO. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CDO and CSAD.
[100] In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes an exogenous polynucleotide encoding CDO. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CDO and CSAD.
[101] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes an exogenous polynucleotide encoding CSAD.
Conversion of cysteine to taurine via p3MDO
[102] In some embodiments, a non-naturally occurring microorganism is provided that expresses one or more exogenous enzyme activity/ies for the conversion of cysteine to taurine via the enzyme 3-mercaptopropionate dioxygenase (p3MDO), for example, exogenous enzyme(s) of the p3MDO/CSAD or GAD pathway for biosynthesis of taurine. The p3MDO/CSAD or GAD pathway for taurine biosynthesis is shown schematically in Fig. 3
[103] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: 3-mercaptopropionate dioxygenase (MDO; p3MDO) (EC
1.13.11.-); and cysteine sulfinic acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some embodiments, p3MDO and CSAD enzymes or enzyme activities are encoded by one or more exogenous
polynucleotide(s) (e.g., one or two, exogenous polynucleotide(s)) in the microorganism. In some embodiments, one of p3MDO and CSAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring
microorganism is derived, i.e. , not expressed from an exogenous polynucleotide. In one embodiment, the microorganism expresses an endogenous CSAD activity and p3MDO is encoded by an exogenous polynucleotide in the microorganism. In one embodiment, the microorganism expresses an endogenous p3MDO activity and CSAD is encoded by an exogenous polynucleotide in the microorganism.
[104] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: 3-mercaptopropionate dioxygenase (MDO; p3MDO) (EC 1.13.11.-); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some embodiments, p3MDO and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one or two, exogenous polynucleotide(s)) in the microorganism. In some embodiments, one of p3MDO and GAD enzymes or enzyme activities is encoded an exogenous polynucleotide in the microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from an exogenous polynucleotide. In one embodiment, the microorganism expresses an endogenous GAD activity and p3MDO is encoded by an exogenous polynucleotide in the microorganism. In one embodiment, the microorganism expresses an endogenous p3MDO activity and GAD is encoded by an exogenous polynucleotide in the microorganism.
[105] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes p3MDO comprising or consisting of the amino acid sequence depicted in SEQ ID NO:33, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70,
75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:33. In some embodiments, the polynucleotide that encodes p3MDO comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:34 or SEQ ID NO:60 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:34 or SEQ ID NO:60. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:60.
[106] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11. In some embodiments, the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54. In some embodiments, the
polynucleotide sequence is codon optimized for expression in the microorganism, e.g. SEQ ID NO: 53 or SEQ ID NO:54.
[107] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13. In some embodiments, the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14. In some
embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism.
[108] In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding p3MDO and CSAD. In another embodiment, a non-naturally occurring Methylobacterium
microorganism is provided that includes one or more exogenous polynucleotide(s) encoding p3MDO and GAD.
[109] In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes an exogenous polynucleotide encoding p3MDO. In one
embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding p3MDO and CSAD.
[110] In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes an exogenous polynucleotide encoding p3MDO. In one
embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding p3MDO and CSAD.
[Ill] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes an exogenous polynucleotide encoding p3MDO. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding p3MDO and CSAD.
Conversion of serine to taurine
[112] In some embodiments, a non-naturally occurring microorganism is provided that expresses one or more exogenous enzyme activity/ies of the serine/sulfate pathway for biosynthesis of taurine. The serine/sulfate pathway for taurine biosynthesis is shown schematically in Fig. 4.
[113] In some embodiments, the non-naturally occurring microorganism includes one or more mutations that cause accumulation of serine in the microorganism. For example, a methylotrophic strain that uses ribulose monophosphate (RuMP) for carbon assimilation from methanol may include a deletion or mutation in HprA (hydroxypyruvate reductase), which blocks the serine cycle from being completed, resulting in serine accumulation.
[114] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: L-serine dehydratase (EC 4.3.1.17); sulfate adenyltransferase (EC 2.7.7.4) and adenylyl-sulfate kinase (APS kinase) (EC 2.7.1.25), and/or 3'- phosphoadenosine 5'-phosphosulfate synthase (PAPSS1) (EC 2.7.7.4/EC 2.7.1.25); 3'- phosphoadenylyl sulfate: 2-aminoacrylate C-sulfotransferase (PAPS-AS) (EC 2.8.2.-); and cysteine sulfinic acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some embodiments, L-serine dehydratase; sulfate
adenyltransferase and APS kinase, and/or PAPSS 1; PAPS-AS; and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, five, six, or seven exogenous polynucleotide(s)) in the microorganism. In some embodiments, one, two, three, four, five, or six of L-serine dehydratase, sulfate
adenyltrasnferase, APS kinase, PAPSS1, PAPS-AS, and CSAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses an endogenous L- serine dehydratase activity, and sulfate adenyltransferase and APS kinase, and/or PAPSS 1, PAPS-AS, and CSAD are expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses endogenous L-serine dehydratase, sulfate adenyltransferase, and APS kinase activity, and PAPS-AS and CSAD are expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses endogenous L-serine dehydratase, sulfate adenyltransferase, APS kinase, and CSAD activities, and PAPS-AS is expressed from an exogenous polynucleotide.
[115] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: L-serine dehydratase (EC 4.3.1.17); sulfate adenyltransferase (EC 2.7.7.4) and adenylyl-sulfate kinase (APS kinase) (EC 2.7.1.25), and/or 3'- phosphoadenosine 5'-phosphosulfate synthase (PAPSS1) (EC 2.7.7.4/EC 2.7.1.25); 3'- phosphoadenylyl sulfate: 2-aminoacrylate C-sulfotransferase (PAPS-AS) (EC 2.8.2.-); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the
microorganism has been transformed. In some embodiments, L-serine dehydratase; sulfate adenyltrasnferase and APS kinase, and/or PAPSS1 ; PAPS-AS; and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, five, six, or seven exogenous polynucleotide(s)) in the microorganism. In some embodiments, one, two, three, four, five, or six of L-serine dehydratase, sulfate
adenyltransferase, APS kinase, PAPSS1, PAPS-AS, and GAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous
polynucleotide(s). In one embodiment, the microorganism expresses an endogenous L- serine dehydratase activity, and sulfate adenyltransferase and APS kinase, and/or PAPSS 1, PAPS-AS, and GAD are expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses endogenous L-serine dehydratase, sulfate adenyltransferase, APS kinase activity, and PAPS-AS and GAD are expressed from exogenous
polynucleotide(s). In one embodiment, the microorganism expresses endogenous L-serine dehydratase, sulfate adenyltransferase, APS kinase, and GAD activities, and PAPS-AS is expressed from an exogenous polynucleotide.
[116] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes L-serine dehydratase comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 1, or a variant or homolog thereof. In some embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: l. In some embodiments, the polynucleotide that encodes L-serine dehydratase comprises or consists of the
polynucleotide sequence depicted in SEQ ID NO: 2 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:2. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism.
[117] In some embodiments, the non-naturally occurring microorganism includes exogenous polynucleotides that encode sulfate adenyltransferase comprising or consisting of the amino acid sequences depicted in SEQ ID NO:3 and SEQ ID NO:5, or a variant or homolog thereof. In some embodiments, the exogenous polynucleotides encode polypeptides comprising or consisting of amino acid sequences having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:3 or SEQ ID NO: 5. In some embodiments, the polynucleotides that encode sulfate adenyltransferase comprise or consists of the polynucleotide sequences depicted in SEQ ID NO:4 and SEQ ID NO:6 or polynucleotides having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:4 or SEQ ID NO:6. In some embodiments, the polynucleotide sequences are codon optimized for expression in the microorganism.
[118] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes APS kinase comprising or consisting of the amino
acid sequence depicted in SEQ ID N0:7, or a variant or homolog thereof. In some embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:7. In some embodiments, the polynucleotide that encodes APS kinase comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:8 or SEQ ID NO:62 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:8 or SEQ ID NO:62. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. SEQ ID NO:62.
[119] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes PAPSS1 comprising or consisting of the amino acid sequence depicted in SEQ ID NO:31, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:31. In some embodiments, the polynucleotide that encodes PAPSS1 comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:32 or SEQ ID NO:63 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:32 or SEQ ID NO:63. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:63.
[120] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes PAPS-AS comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 9, or a variant or homolog thereof. In some embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:9. In some embodiments, the polynucleotide that encodes PAPS-AS comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 10 or SEQ ID NO:61 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 10 or SEQ ID NO:61. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:61.
[121] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11. In some embodiments, the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54. In some embodiments, the
polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
[122] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13. In some embodiments, the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14. In some
embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism.
[123] In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding: sulfate adenyltransferase and APS kinase, and/or PAPSS1 ; PAPS-AS; and CSAD. In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPS-AS and CSAD. In another embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding: sulfate adenyltransferase and APS kinase, and/or PAPSS1 ; PAPS-AS; and GAD. In one
embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPS-AS and GAD.
[124] In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1 and PAPS-AS. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
[125] In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1 and PAPS-AS. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
[126] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS 1 and PAPS-AS. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
Conversion of phosphoserine or serine to taurine
[127] In some embodiments, a non-naturally occurring microorganism is provided that expresses one or more exogenous enzyme activity/ies for the conversion of phosphoserine to taurine via the enzyme cysteate synthase, for example, enzyme(s) of the cysteate synthase (e.g., MA_3297)/CSAD or GAD pathway for biosynthesis of taurine, and/or expresses one or more exogenous enzyme activity/ies for the conversion of serine to taurine via the enzymes L-serine dehydratase, cysteate synthase (e.g. , MA_3297), and CS AD/GAD. The cysteate synthase (e.g., MA_3297)/CSAD or GAD, and L-serine dehydratase cysteate synthase (e.g., MA_3297)/CSAD or GAD pathways for taurine biosynthesis are shown schematically in Fig. 5.
[128] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: cysteate synthase, e.g. , MA_3297 (EC 2.5.1.76); optionally L-serine dehydratase (EC 4.3.1.17); and cysteine sulfinic acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some embodiments, cysteate synthase, optionally L-serine dehydratase, and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, or three, exogenous polynucleotide(s)) in the microorganism. In some embodiments, one of cysteate synthase, L-serine dehydratase, or CSAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses endogenous CSAD and optionally L-serine dehydratase activity, and cysteate synthase (e.g., MA_3297) is encoded by an exogenous polynucleotide in the microorganism. In one embodiment, the microorganism expresses an endogenous cysteate synthase and CSAD is encoded by an exogenous polynucleotide in the microorganism.
[129] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: cysteate synthase, e.g. , MA_3297 (EC 2.5.1.76); optionally L-serine dehydratase (EC 4.3.1.17); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some
embodiments, cysteate synthase, optionally L-serine dehydratase, and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, or three, exogenous polynucleotide(s)) in the microorganism. In some embodiments, one of cysteate synthase, L-serine dehydratase, or GAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses endogenous GAD and optionally L-serine dehydratase activity and cysteate synthase (e.g., MA_3297) is encoded by an exogenous polynucleotide in the microorganism. In one embodiment, the microorganism expresses an
endogenous cysteate synthase and GAD is encoded by an exogenous polynucleotide in the microorganism.
[130] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes cysteate synthase comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 17, or a variant or homolog thereof. In some embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 17. In some embodiments, the polynucleotide that encodes cysteate synthase comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 18, SEQ ID NO:52, or SEQ ID NO:64 or a
polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 18, SEQ ID NO:52, or SEQ ID NO:64. In some
embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:52 or SEQ ID NO:64.
[131] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes L-serine dehydratase comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 1, or a variant or homolog thereof. In some embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: l. In some embodiments, the polynucleotide that encodes L-serine dehydratase comprises or consists of the
polynucleotide sequence depicted in SEQ ID NO: 2 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:2. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism.
[132] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11. In some embodiments, the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence
depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54. In some embodiments, the
polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
[133] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13. In some embodiments, the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14. In some
embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism.
[134] In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g. , MA_3297) and CSAD. In another embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g. , MA_3297) and GAD.
[135] In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g., MA_3297) and optionally L-serine dehydratase. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g. , MA_3297), optionally L-serine dehydratase, and CSAD.
[136] In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g., MA_3297) and optionally L-serine dehydratase. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous
polynucleotide(s) encoding cysteate synthase (e.g. , MA_3297), optionally L-serine dehydratase, and CSAD.
[137] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g. , MA 3297) and optionally L-serine dehydratase. In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g. , MA_3297), optionally L-serine dehydratase, and CSAD.
Conversion of cysteine to taurine, via CGL/CD; PAPS-AS. and CSAD or GAD
[138] In some embodiments, a non-naturally occurring microorganism is provided that expresses one or more exogenous enzyme activity/ies for the conversion of cysteine to taurine via the enzymes cystathionine gamma-lyase (CGL)/ L-cysteine desulfhydrase (CD), 3'phosphoadenylyl sulfate: 2-aminoacry late C-sulfotransferase (PAPS-AS), and cysteine sulfinic acid decarboxylase (CSAD) or glutamate decarboxylase (GAD). This pathway for taurine biosynthesis is shown schematically in Fig. 6. Several proteins have been found to have L-cysteine desulfhydrase (CD) activity (EC 4.4.1.1) including cystathionine gamma- lyase (CGL), tryptophanase, cysteine synthases, and MalY (Awano et al. (2005) Appl Environ Microbiol 71(7):4149-52.). In some embodiments, a single enzyme includes both CGL and CD activities. In other embodiments, CGL and CD activities are provided by two separate enzymes. In some embodiments, CD activity is provided by an enzyme and CGL activity is absent. When CGL activity is present, it may provide greater flux via production of L-cysteine, which serves as a substrate for CD activity. In some embodiments, a first enzyme that includes both CGL and CD activities and a second enzyme that includes only CD activity are provided.
[139] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: cystathionine gamma-lyase (CGL)/L-cysteine desulfhydrase (CD) (EC 4.4.1.1); sulfate adenyltransferase (EC 2.7.7.4) and adenylyl-sulfate kinase (APS kinase) (EC 2.7.1.25), and/or 3'-phosphoadenosine 5'-phosphosulfate synthase (PAPSS1) (EC 2.7.7.4/EC 2.7.1.25); 3'- phosphoadenylyl sulfate: 2-aminoacrylate C-sulfotransferase (PAPS-AS) (EC 2.8.2.-); and cysteine sulfinic acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some
embodiments, CGL/CD; sulfate adenyltransferase and APS kinase, and/or PAPSS l; PAPS- AS; and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, five, six, or seven exogenous
polynucleotide(s)) in the microorganism. In some embodiments, one, two, three, four, five, or six of CGL/CD, sulfate adenyltransferase, APS kinase, PAPSSl, PAPS-AS, and CSAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses an endogenous activity, and sulfate adenyltransferase and APS kinase and/or PAPSSl, PAPS- AS, and CSAD are expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses endogenous CGL/CD and sulfate adenyltransferase, APS kinase activities, and PAPS-AS and CSAD activities are expressed from exogenous
polynucleotide(s). In one embodiment, the microorganism expresses endogenous CGL/CD, sulfate adenyltransferase, APS kinase, and CSAD activities, and PAPS-AS is expressed from an exogenous polynucleotide.
[140] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: cystathionine gamma-lyase (CGL)/ L-cysteine desulfhydrase (CD) (EC 4.4.1.1); sulfate adenyltransferase (EC 2.7.7.4) and adenylyl-sulfate kinase (APS kinase) (EC 2.7.1.25), and/or 3'-phosphoadenosine 5'-phosphosulfate synthase (PAPSSl) (EC 2.7.7.4/EC 2.7.1.25); 3'- phosphoadenylyl sulfate: 2-aminoacrylate C-sulfotransferase (PAPS-AS) (EC 2.8.2.-); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some embodiments, CGL/CD, sulfate adenyltransferase and APS kinase, and/or PAPSS l, PAPS-AS, and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, five, six, or seven exogenous polynucleotide(s)) in the microorganism. In some embodiments, one, two, three, four, five, or six of CGL/CD, sulfate adenyltransferase, APS kinase, PAPSSl, PAPS-AS, and GAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from exogenous polynucleotide(s). In one
embodiment, the microorganism expresses an endogenous activity, and sulfate
adenyltransferase and APS kinase, and/or PAPSS1, PAPS-AS, and GAD are expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses endogenous CGL/CD, sulfate adenyltransferase, and APS kinase activities, and PAPS-AS and GAD activities are expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses endogenous CGL/CD, sulfate adenyltransferase, APS kinase, and GAD activities, and PAPS-AS is expressed from an exogenous polynucleotide.
[141] In some embodiments, the non-naturally occurring microorganism includes one or more exogenous polynucleotide(s) that encode(s) CGL/CD comprising or consisting of the amino acid sequence(s) depicted in SEQ ID NO:46, SEQ ID NO:70, and/or SEQ ID NO:72 or variant(s) or homolog(s) thereof. In some embodiments, the exogenous polynucleotide(s) encode(s) polypeptide(s) comprising or consisting of amino acid sequence(s) having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:46, SEQ ID NO:70, and/or SEQ ID NO:72. In some embodiments, the
polynucleotide(s) that encode(s) CGL/CD comprise or consist of the polynucleotide sequence(s) depicted in SEQ ID NO:47, SEQ ID NO:65, SEQ ID NO:71 and/or SEQ ID NO:73, or polynucleotide(s) having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:47, SEQ ID NO:65, SEQ ID NO:71, and/or SEQ ID NO:73. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:65.
[142] In some embodiments, the non-naturally occurring microorganism includes exogenous polynucleotides that encode sulfate adenyltransferase comprising or consisting of the amino acid sequences depicted in SEQ ID NO:3 and SEQ ID NO:5, or a variant or homolog thereof. In some embodiments, the exogenous polynucleotides encode polypeptides comprising or consisting of an amino acid sequences having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:3 or SEQ ID NO:5. In some embodiments, the polynucleotides that encode sulfate
adenyltransferase comprises or consists of the polynucleotide sequences depicted in SEQ ID NO:4 or SEQ ID NO:6 or polynucleotides having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:4 or SEQ ID NO:6. In some embodiments, the polynucleotide sequences are codon optimized for expression in the microorganism.
[143] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes APS kinase comprising or consisting of the amino acid sequence depicted in SEQ ID NO:7, or a variant or homolog thereof. In some embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:7. In some embodiments, the polynucleotide that encodes APS kinase comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:8 or SEQ ID NO:62 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:8 or SEQ ID NO:62. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:62.
[144] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes PAPSS1 comprising or consisting of the amino acid sequence depicted in SEQ ID NO:31, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:31. In some embodiments, the polynucleotide that encodes PAPSS1 comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:32 or SEQ ID NO:63 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:32 or SEQ ID NO:63. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:63.
[145] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes PAPS-AS comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 9, or a variant or homolog thereof. In some embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:9. In some embodiments, the polynucleotide that encodes PAPS-AS comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 10 or SEQ ID NO:61 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 10 or
SEQ ID NO:61. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:61.
[146] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11. In some embodiments, the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54. In some embodiments, the
polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
[147] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13. In some embodiments, the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14. In some
embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism.
[148] In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding: CGL/CD, sulfate adenyltransferase and APS kinase, and/or PAPSS1 ; PAPS-AS, and CSAD. In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CGL/CD, PAPS-AS and CSAD. In another embodiment, a non-naturally occurring Methylobacterium
microorganism is provided that includes one or more exogenous polynucleotide(s)
encoding: CGL/CD; sulfate adenyltransferase and APS kinase, and/or PAPSS 1, PAPS-AS, and GAD. In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CGL/CD, PAPS-AS and GAD.
[149] In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1 and PAPS-AS. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
[150] In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1 and PAPS-AS. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
[151] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes an exogenous polynucleotide encoding PAPS-AS. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS 1 and PAPS-AS. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding PAPSS1, PAPS-AS, and CSAD.
Conversion of cysteine to taurine via CGL/CD and cvsteate synthase
[152] In some embodiments, a non-naturally occurring microorganism is provided that expresses one or more exogenous enzyme activity/ies for the conversion of cysteine to taurine via the enzymes cystathionine gamma-lyase/ L-cysteine desulfhydrase, cysteate synthase (e.g. , MA_3297), and cysteine sulfinic acid decarboxylase (CSAD) or glutamate decarboxylase (GAD). The CGL/CD, cysteate synthase (e.g., MA_3297), CSAD or GAD pathway for taurine biosynthesis is shown schematically in Fig. 7. Several proteins have been found to have L-cysteine desulfhydrase (CD) activity (EC 4.4.1.1) including
cystathionine gamma-lyase (CGL), tryptophanase, cysteine synthases, and MalY (Awano et al. (2005) Appl Environ Microbiol 71(7):4149-52.). In some embodiments, a single enzyme includes both CGL and CD activities. In other embodiments, CGL and CD activities are provided by two separate enzymes. In some embodiments, CD activity is provided by an enzyme and CGL activity is absent. When CGL activity is present, it may provide greater flux via production of L-cysteine, which serves as a substrate for CD activity. In some embodiments, a first enzyme that includes both CGL and CD activities and a second enzyme that includes only CD activity are provided.
[153] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: cystathionine gamma-lyase (CGL)/ L-cysteine desulfhydrase (CD) (EC4.4.4.1), cysteate synthase, e.g. , MA_3297 (EC 2.5.1.76); and cysteine sulfuric acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the
microorganism has been transformed. In some embodiments, CGL/CD, cysteate synthase, and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, or four exogenous polynucleotide(s)) in the microorganism. In some embodiments, one or more of CGL/CD, cysteate synthase, and CSAD enzymes or enzyme activities is encoded by one or more exogenous
polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s). In one embodiment, the
microorganism expresses an endogenous CSAD activity and CGL/CD and cysteate synthase (e.g., MA_3297) are encoded by exogenous polynucleotide(s) in the
microorganism. In one embodiment, the microorganism expresses endogenous CGL/CD and CSAD activities and cysteate synthase (e.g., MA_3297) is encoded by an exogenous polynucleotide in the microorganism.
[154] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: cystathionine gamma-lyase (CGL)/ L-cysteine desulfhydrase (CD) (EC4.4.4.1), cysteate synthase, e.g. , MA_3297 (EC 2.5.1.76); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some embodiments, CGL/CD, cysteate synthase, and GAD enzymes
or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, or four exogenous polynucleotide(s)) in the microorganism. In some embodiments, one or more of CGL/CD, cysteate synthase, and GAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses an endogenous GAD activity and CGL/CD and cysteate synthase (e.g., MA_3297) are encoded by exogenous polynucleotide(s) in the microorganism. In one embodiment, the microorganism expresses endogenous CGL/CD and GAD activities and cysteate synthase (e.g., MA_3297) is encoded by an exogenous polynucleotide in the microorganism.
[155] In some embodiments, the non-naturally occurring microorganism includes one or more exogenous polynucleotide(s) that encode(s) CGL/CD comprising or consisting of the amino acid sequence(s) depicted in SEQ ID NO:46, SEQ ID NO:70, and/or SEQ ID NO:72 or variant(s) or homolog(s) thereof. In some embodiments, the exogenous
polynucleotide(s) encode(s) polypeptide(s) comprising or consisting of amino acid sequence(s) having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:46, SEQ ID NO:70, and/or SEQ ID NO:72. In some embodiments, the polynucleotide(s) that encode(s) CGL/CD comprise or consist of the polynucleotide sequence(s) depicted in SEQ ID NO:47, SEQ ID NO:65, SEQ ID NO:71, and/or SEQ ID NO:73 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:47, SEQ ID NO:65, SEQ ID NO:71, and/or SEQ ID NO:73. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO: 65.
[156] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes cysteate synthase comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 17, or a variant or homolog thereof. In some embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 17. In some embodiments, the polynucleotide that encodes cysteate synthase comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 18, SEQ ID NO:52, or SEQ ID NO:64 or a
polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 18, SEQ ID NO:52, or SEQ ID NO:64. In some
embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:52 or SEQ ID NO:64.
[157] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11. In some embodiments, the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54. In some embodiments, the
polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
[158] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13. In some embodiments, the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14. In some
embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism.
[159] In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CGL/CD, cysteate synthase (e.g., MA_3297), and CSAD. In another embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more
exogenous polynucleotide(s) encoding CGL/CD, cysteate synthase (e.g., MA_3297), and GAD.
[160] In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CGL/CD and cysteate synthase (e.g., MA_3297). In one embodiment, a non-naturally occurring
Escherichia microorganism is provided that includes one or more exogenous
polynucleotide(s) encoding CGL/CD, cysteate synthase, and CSAD.
[161] In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CGL/CD and cysteate synthase (e.g., MA_3297). In one embodiment, a non-naturally occurring
Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding CGL/CD, cysteate synthase, and CSAD.
[162] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cysteate synthase (e.g., MA_3297) and CSAD.
Conversion of pyruvate to taurine
[163] In some embodiments, a non-naturally occurring microorganism is provided that expresses exogenous enzyme activity/ies for the conversion of pyruvate to taurine via the enzyme L-cysteate sulfo-lyase (cuyA), for example, exogenous enzyme(s) of the L-cysteate sulfo-lyase (cuyA)/CSAD or GAD pathway for biosynthesis of taurine. The cuyA/CSAD or GAD pathway for taurine biosynthesis is shown schematically in Fig. 8.
[164] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: L-cysteate sulfo-lyase (cuyA) (EC 4.4.1.25); and cysteine sulfinic acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the
microorganism has been transformed. In some embodiments, cuyA and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one or two exogenous polynucleotide(s)) in the microorganism. In some embodiments, one of cuyA and CSAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from an exogenous polynucleotide. In one embodiment, the microorganism expresses an
endogenous CSAD activity and cuyA is encoded by an exogenous polynucleotide in the microorganism. In one embodiment, the microorganism expresses an endogenous cuyA activity and CSAD is encoded by an exogenous polynucleotide in the microorganism.
[165] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: L-cysteate sulfo-lyase (cuyA) (EC 4.4.1.25); and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some embodiments, cuyA and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one or two exogenous polynucleotide(s)) in the microorganism. In some embodiments, one of cuyA and GAD enzymes or enzyme activities is encoded by an exogenous polynucleotide in the
microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from an exogenous polynucleotide. In one embodiment, the microorganism expresses an endogenous GAD activity and cuyA is encoded by an exogenous polynucleotide in the microorganism. In one embodiment, the microorganism expresses an endogenous cuyA activity and GAD is encoded by an exogenous polynucleotide in the microorganism.
[166] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes cuyA comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 37, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:37. In some embodiments, the polynucleotide that encodes cuyA comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:38 or SEQ ID NO:66 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:38 or SEQ ID NO:66. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:66.
[167] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or
consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11. In some embodiments, the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54. In some embodiments, the
polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
[168] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13. In some embodiments, the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14. In some
embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism.
[169] In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cuyA and CSAD. In another embodiment, a non-naturally occurring Methylobacterium
microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cuyA and GAD.
[170] In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes an exogenous polynucleotide encoding cuyA. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cuyA and CSAD.
[171] In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes an exogenous polynucleotide encoding cuyA. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cuyA and CSAD.
[172] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes an exogenous polynucleotide encoding cuyA. In one embodiment, a non- naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding cuyA and CSAD.
Conversion of phosphoenolpyruvate to taurine via CSAD or GAD
[173] In some embodiments, a non-naturally occurring microorganism is provided that expresses one or more exogenous enzyme activity/ies for the conversion of
phosphoenolpyruvate to taurine via the enzymes phosphosulfolactate synthase (ComA), 2- phsopho-e-sulfolactate dehydrogenase (ComB), sulfolactate dehydrogenase (ComC), and aspartate aminotransferase (AspAT), for example, one or more exogenous enzyme(s) of the ComA/ComB/ComC/AspAT/CSAD or GAD pathway for biosynthesis of taurine. The ComA/ComB/ComC/AspAT/CSAD or GAD pathway for taurine biosynthesis is shown schematically in Fig. 9.
[174] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: phosphosulfolactate synthase (ComA) (EC 4.4.1.19), 2- phospho-3 -sulfolactate phosphohydrolase (ComB) (EC 3.1.3.71), sulfolactate
dehydrogenase (ComC) (EC 1.1.1.337), aspartate aminotransferase (AspAT) (EC 2.6.1.1), and cysteine sulfinic acid decarboxylase (CSAD) (EC 4.1.1.29), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some embodiments, ComA, ComB, ComC, AspAT, and CSAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, or five exogenous polynucleotide(s)) in the microorganism. In some embodiments, one or more of ComA, ComB, ComC, AspAT, and CSAD enzymes or enzyme activities is encoded by one or more exogenous
polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s). In one embodiment, the
microorganism expresses endogenous CSAD and AspAT activities, and ComA, ComB, and ComC are encoded by exogenous polynucleotide(s) in the microorganism. In one embodiment, the microorganism expresses endogenous AspAT activity, and ComA, ComB, ComC, and CSAD are encoded by exogenous polynucleotide(s) in the microorganism.
[175] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: phosphosulfolactate synthase (ComA) (EC 4.4.1.19), 2- phospho-3-sulfolactate phosphohydrolase (ComB) (EC 3.1.3.71), sulfolactate
dehydrogenase (ComC) (EC 1.1.1.337), aspartate aminotransferase (AspAT) (EC 2.6.1.1), and glutamate decarboxylase (GAD) (EC 4.1.1.15), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the
microorganism has been transformed. In some embodiments, ComA, ComB, ComC, AspAT, and GAD enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, or five exogenous polynucleotide(s)) in the microorganism. In some embodiments, one or more of ComA, ComB, ComC, AspAT, and GAD enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from exogenous polynucleotide(s). In one embodiment, the microorganism expresses endogenous GAD and AsPAT activities, and ComA, ComB, and ComC are encoded by exogenous polynucleotide(s) in the microorganism. In one embodiment, the microorganism expresses endogenous AsPAT activity, and ComA, ComB, ComC, and GAD are encoded by exogenous polynucleotide(s) in the microorganism.
[176] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComA comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 19, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 19. In some embodiments, the polynucleotide that encodes ComA comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:20 or SEQ ID NO:67 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:20 or SEQ ID NO:67. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:67.
[177] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComB comprising or consisting of the amino acid sequence depicted in SEQ ID NO:21, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:21. In some embodiments, the polynucleotide that encodes ComB comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:22 or SEQ ID NO:68 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:22 or SEQ ID NO:68. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:68.
[178] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComC comprising or consisting of the amino acid sequence depicted in SEQ ID NO:23, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:23. In some embodiments, the polynucleotide that encodes ComC comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:24 or SEQ ID NO:69 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:24 or SEQ ID NO:69. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. SEQ ID NO:69.
[179] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes CSAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 11, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 11. In some embodiments, the polynucleotide that encodes CSAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 12, SEQ ID NO:53, or SEQ ID NO:54. In some embodiments, the
polynucleotide sequence is codon optimized for expression in the microorganism, e.g., SEQ ID NO:53 or SEQ ID NO:54.
[180] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes GAD comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 13, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 13. In some embodiments, the polynucleotide that encodes GAD comprises or consists of the polynucleotide sequence depicted in SEQ ID NO: 14 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 14. In some
embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism.
[181] In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and CSAD. In another embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and GAD.
[182] In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, and ComC. In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and CSAD.
[183] In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, and ComC. In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and CSAD.
[184] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, and ComC. In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and CSAD.
Conversion of acetyl phosphate to taurine
[185] In some embodiments, a non-naturally occurring microorganism is provided that expresses one or more exogenous enzyme activity/ies for the conversion of acetyl phosphate to taurine, for example, enzymes of the Xsc/Tpa pathway for biosynthesis of taurine. The Xsc/Tpa pathway of taurine biosynthesis is shown schematically in Fig. 10.
[186] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: sulfoacetaldehyde acetyltransferase (Xsc) (EC 2.3.3.15); and taurine-pyruvate aminotransferase (Tpa) (EC 2.6.1.77), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some embodiments, Xsc and Tpa enzymes or enzyme activities are encoded by one or more exogenous polynucleotides in the
microorganism (e.g., one or two exogenous polynucleotide(s). In some embodiments, one of Xsc and Tpa enzymes or enzyme activities is encoded an exogenous polynucleotide in the microorganism and the remaining activity is endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e. , not expressed from an exogenous polynucleotide.
[187] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes Xsc comprising or consisting of the amino acid sequence depicted in SEQ ID NO:48, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:48. In some embodiments, the polynucleotide that encodes Xsc comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:49 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:49. In some
embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism.
[188] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes Tpa comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 27, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70,
75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:27. In some embodiments, the polynucleotide that encodes Tpa comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:28 or SEQ ID NO:56 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:28 or SEQ ID NO:56. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:56.
[189] In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding Xsc and Tpa.
[190] In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes an exogenous polynucleotide encoding Xsc and Tpa.
[191] In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes an exogenous polynucleotide encoding Xsc and Tpa.
[192] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes an exogenous polynucleotide encoding Xsc and Tpa.
Conversion of phosphoenolpyruvate to taurine via Tpa
[193] In some embodiments, a non-naturally occurring microorganism is provided that expresses one or more exogenous enzyme activity/ies for the conversion of
phosphoenolpyruvate to taurine via the enzymes phosphosulfolactate synthase (ComA), 2- phsopho-e-sulfolactate dehydrogenase (ComB), sulfolactate dehydrogenase (ComC), sulfopyruvate decarboxylase (ComDE), and taurine-pyruvate aminotransferase (Tpa), for example, one or more exogenous enzyme(s) of the ComA/ComB/ComC, ComDE/Tpa pathway for biosynthesis of taurine. This pathway for taurine biosynthesis is shown schematically in Fig. 11.
[194] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: phosphosulfolactate synthase (ComA) (EC 4.4.1.19), 2- phospho-3 -sulfolactate phosphohydrolase (ComB) (EC 3.1.3.71), sulfolactate
dehydrogenase (ComC) (EC 1.1.1.337), sulfopyruvate decarboxylase (ComDE) (EC 4.1.7.9), and taurine-pyruvate aminotransferase (Tpa) (EC 2.6.1.77), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed. In some embodiments, ComA, ComB, ComC, ComDE, and Tpa enzymes or enzyme activities are encoded by one or more exogenous polynucleotide(s) (e.g., one, two, three, four, or five exogenous polynucleotide(s)) in the
microorganism. In some embodiments, one or more of ComA, ComB, ComC, ComDE, and Tpa enzymes or enzyme activities is encoded by one or more exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non-naturally occurring microorganism is derived, i.e., not expressed from exogenous polynucleotide(s).
[195] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComA comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 19, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO: 19. In some embodiments, the polynucleotide that encodes ComA comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:20 or SEQ ID NO:67 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:20 or SEQ ID NO:67. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:67.
[196] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComB comprising or consisting of the amino acid sequence depicted in SEQ ID NO:21, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:21. In some embodiments, the polynucleotide that encodes ComB comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:22 or SEQ ID NO:68 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:22 or SEQ ID NO:68. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:68.
[197] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComC comprising or consisting of the amino acid sequence depicted in SEQ ID NO:23, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70,
75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:23. In some embodiments, the polynucleotide that encodes ComC comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:24 or SEQ ID NO:69 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:24 or SEQ ID NO:69. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:69.
[198] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComDE comprising or consisting of the amino acid sequence depicted in SEQ ID NO:25, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:25. In some embodiments, the polynucleotide that encodes ComDE comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:26 or SEQ ID NO:55 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:26 or SEQ ID NO:55. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:55.
[199] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes Tpa comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 27, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:27. In some embodiments, the polynucleotide that encodes Tpa comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:28 or SEQ ID NO:56 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:28 or SEQ ID NO:56. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:56.
[200] In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, and ComDE, and Tpa.
[201] In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, ComDE, and Tpa.
[202] In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, ComDE, and Tpa.
[203] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComA, ComB, ComC, ComDE, and Tpa.
Conversion of cvsteate to taurine via AspAT. ComDE. and Tpa
[204] Cysteate, which is an intermediate in some of the biosynthetic pathways described above (see Figs. 4, 5, 6, 7, and 8) be converted to taurine via aspartate aminotransferase (AspAT) (EC 2.6.1.1), which converts cysteate to sulfopyruvate, sulfopyruvate
decarboxylase (ComDE) (EC4.1.7.9), which converts sulfopyruvate to sulfoacetaldehyde, and taurine-pyruvate aminotransferase (Tpa) (EC 2.67.1.77), which converts
sulfoacetaldehyde to taurine, instead of or in addition to CSAD or GAD. This is shown schematically in Fig. 12.
[205] Non-naturally occurring microorganisms are provided that include the following enzymes or enzyme activities: aspartate aminotransferase (AspAT) (EC 2.6.1.1);
sulfopyruvate decarboxylase (ComDE) (EC4.1.7.9); and taurine-pyruvate aminotransferase (Tpa) (EC 2.67.1.77), wherein at least one of these enzymes or enzyme activities is encoded by an exogenous polynucleotide with which the microorganism has been transformed, and optionally other enzyme activities for production of cysteate, as shown in Fig. 12, either endogenous to the microorganism or encoded by exogenous polynucleotide(s) with which the microorganism has been transformed.
[206] In some embodiments, one or more of AspAT, ComDE, and Tpa enzymes or enzyme activities is encoded by exogenous polynucleotide(s) in the microorganism and the remaining activity/ies is/are endogenously expressed in the host cell from which the non- naturally occurring microorganism is derived, i.e., not expressed from an exogenous polynucleotide. In one embodiment, the microorganism expresses an endogenous AspAT activity and ComDE and Tpa are encoded by exogenous polynucleotide(s) in the microorganism.
[207] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes ComDE comprising or consisting of the amino acid sequence depicted in SEQ ID NO:25, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:25. In some embodiments, the polynucleotide that encodes ComDE comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:26 or SEQ ID NO:55 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:26 or SEQ ID NO:55. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:55.
[208] In some embodiments, the non-naturally occurring microorganism includes an exogenous polynucleotide that encodes Tpa comprising or consisting of the amino acid sequence depicted in SEQ ID NO: 27, or a variant or homolog thereof. In some
embodiments, the exogenous polynucleotide encodes a polypeptide comprising or consisting of an amino acid sequence having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:27. In some embodiments, the polynucleotide that encodes Tpa comprises or consists of the polynucleotide sequence depicted in SEQ ID NO:28 or SEQ ID NO:56 or a polynucleotide having at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99% identity to SEQ ID NO:28 or SEQ ID NO:56. In some embodiments, the polynucleotide sequence is codon optimized for expression in the microorganism, e.g. , SEQ ID NO:56.
[209] In one embodiment, a non-naturally occurring Methylobacterium microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComDE and Tpa.
[210] In one embodiment, a non-naturally occurring Escherichia microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComDE and Tpa.
[211] In one embodiment, a non-naturally occurring Saccharomyces microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComDE and Tpa.
[212] In one embodiment, a non-naturally occurring Bacillus microorganism is provided that includes one or more exogenous polynucleotide(s) encoding ComDE and Tpa.
Mutations to enhance accumulation of taurine or an intermediate in taurine biosynthesis
[213] In some embodiments, a non-naturally occurring microorganism is provided that produces taurine, as described above, and that further includes a mutation in a pathway for degradation of taurine and/or in a pathway for degradation of an intermediate of taurine biosynthesis (e.g., a cysteate degradation pathway). In some embodiments, the
microorganism includes deletion of one or more endogenous gene sequence that encodes an enzyme that degrades taurine or an intermediate in taurine biosynthesis (e.g. , cysteate or sulfoacetaldehyde), thus enhancing accumulation of taurine in the microorganism. Taurine and cysteate degradation pathways are shown schematically in Fig. 13. Examples of enzymes in taurine degradation pathways include, but are not limited to, taurine
dehydrogenase (TDH), taurine dioxygenase (TDO/TauD), gamma-glutamyltransferase, and taurine-pyruvate aminotransferase (Tpa). A non-limiting example of an enzyme in a cysteate degradation pathway is cysteate sulfo-lyase (CuyA). A non-limiting example of an enzyme in a sulfoacetaldehyde degradation pathway is sulfoacetaldehyde acetyltransferase (Xsc).
[214] In some embodiments, the non-naturally occurring microorganism includes one or more mutation(s) or deletion of a gene sequence that encodes taurine dehydrogenase (TDH) (EC 1.4.99.2), thus reducing or eliminating activity of TDH in the microorganism in comparison to the host cell from which the microorganism was derived.
[215] In some embodiments, the non-naturally occurring microorganism includes one or more mutation(s) or deletion of a gene sequence that encodes taurine dioxygenase
(TDO)/TauD (EC 1.14.11.17), thus reducing or eliminating activity of TDO/TauD in the microorganism in comparison the host cell from which the microorganism was derived. In one embodiment, an Escherichia microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes TDO/TauD, thus reducing or eliminating activity of this enzyme in the microorganism. In one embodiment, a Saccharomyces microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes TDO/TauD, thus reducing or eliminating activity of this enzyme in the
microorganism in comparison to the host cell from which the microorganism was derived. In one embodiment, a Bacillus microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes TDO/TauD, thus reducing or eliminating activity
of this enzyme in the microorganism in comparison to the host cell from which the microorganism was derived.
[216] In some embodiments, the non-naturally occurring microorganism includes one or more mutation(s) or deletion of a gene sequence that encodes cysteate sulfo-lyase (CuyA) (EC 4.4.1.25), thus reducing or eliminating activity of CuyA in the microorganism in comparison to the host cell from which the microorganism was derived.
[217] In some embodiments, the non-naturally occurring microorganism includes one or more mutation(s) or deletion of a gene sequence that encodes gamma-glutamyltransferase (EC 2.3.2.2), thus reducing or eliminating activity of gamma-glutamyltransferase in the microorganism in comparison the host cell from which the microorganism was derived. In one embodiment, aMethylobacterium microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes gamma-glutamyltransferase, thus reducing or eliminating activity of this enzyme in the microorganism. In one embodiment, an Escherichia microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes gamma-glutamyltransferase, thus reducing or eliminating activity of this enzyme in the microorganism in comparison to the host cell from which the microorganism was derived. In one embodiment, a Bacillus microorganism is provided with one or more mutation(s) or deletion of a gene sequence that encodes gamma- glutamyltransferase, thus reducing or eliminating activity of this enzyme in the
microorganism in comparison to the host cell from which the microorganism was derived.
[218] In some embodiments, the non-naturally occurring microorganism includes one or more mutations(s) or deletion of a gene sequence that encodes a taurine-pyruvate aminotransferase (Tpa) (EC 2.6.1.77), thus reducing or eliminating activity of taurine- pyruvate aminotransferase in the microorganism in comparison the host cell from which the microorganism was derived.
[219] In some embodiments, the non-naturally occurring microorganism includes one or more mutations(s) or deletion of a gene sequence that encodes a sulfoacetaldehyde acetyltransferase (Xsc) (EC 2.3.3.15), thus reducing or eliminating activity of
sulfoacetaldehyde acetyltransferase in the microorganism in comparison the host cell from which the microorganism was derived.
Transformation of microorganisms
[220] Numerous transformation protocols and constructs for introducing and expressing exogenous polynucleotides in host cells are known in the art.
[221] In certain embodiments, genetic modifications will take advantage of freely replicating plasmid vectors for cloning. These may include small IncP vectors developed for use in Methylobacterium. These vectors may include pCM62, pCM66, or pHC41 for cloning. (Marx, C. J. and M. E. Lidstrom Microbiology (2001) 147: 2065-2075; Chou, H - H. et al. PLoS Genetics (2009) 5: el 000652)
[222] In certain embodiments, genetic modifications will take advantage of freely replicating expression plasmids such as pCM80, pCM160, pHC90, or pHC91. (Marx, C. J. and M. E. Lidstrom Microbiology (2001) 147: 2065-2075; Chou, H.-H. et al. PLoS Genetics (2009) 5: el 000652)
[223] In certain embodiments, genetic modifications will utilize freely replicating expression plasmids that have the ability to respond to levels of inducing molecules such as cumate or anhydrotetracycline. These include pHC115, pLC 290, pLC291. (Chou, H.-H. et al. PLoS Genetics (2009) 5: el000652; Chubiz, L. M. et al. BMC Research Notes (2013) 6: 183)
[224] In certain embodiments, genetic modifications will utilize recyclable antibiotic marker systems such as the cre-lox system. This may include use of the pCM157, pCM158, pCM184, pCM351 series of plasmids developed for use in extorquens. (Marx, C. J. and M. E. Lidstrom BioTechniques (2002) 33: 1062-1067)
[225] In certain embodiments, genetic modifications will utilize recyclable antibiotic marker systems such as the cre-lox system. This may include use of the pCM157, pCM158, pCM184, pCM351 series of plasmids developed for use in M. extorquens. (Marx, C. J. and M. E. Lidstrom BioTechniques (2002) 33: 1062-1067).
[226] In certain embodiments, genetic modifications will utilize transposon mutagenesis. This may include mini-Tn5 delivery systems such as pCM639 (D'Argenio, D. A. et al. Journal of Bacteriology (2001) 183: 1466-1471) demonstrated in M. extorquens. (Marx, C. J. et al. Journal of Bacteriology (2003) 185: 669-673)
[227] In certain embodiments, genetic modifications will utilize expression systems introduced directly into a chromosomal locus. This may include pCM168, pCM172, and pHCOl plasmids developed forM. extorquens. AMI . (Marx, C. J. and M. E. Lidstrom
Microbiology (2001) 147: 2065-2075; Lee, M.-C. et al. Evolution (2009) 63: 2813-2830) [228] In certain embodiments, genetic modifications will utilize a sacB-based system for unmarked exchange of alleles due to the sucrose sensitivity provided by sacB expression. This may include the pCM433 vector originally tested with M. extorquens. (Marx, C. J. et al. BMC Research Notes (2008) 1 : 1)
Microbial cultures
[229] Methods for producing taurine and/or taurine precursors are provided. The methods include culturing a non-naturally occurring microorganism as described herein in a culture medium under conditions suitable for growth of the microorganism and expression of enzymes for taurine biosynthesis as described herein, wherein biomass that includes taurine and/or taurine precursors is produced in the culture. In embodiments in which the microorganism also produces one or more carotenoid compound(s) (e.g., a microorganism that has been genetically modified or artificially pre-selected to produce elevated levels of one or more carotenoid compound(s)), biomass that includes taurine and/or taurine precursors and the one or more carotenoid compound(s) is produced.
[230] The culture medium includes carbon source(s), nitrogen source(s), inorganic substances (e.g., inorganic salts), and any other substances required for the growth of the microorganism (e.g. , vitamins, amino acids, etc.).
[231] The carbon source may include sugars, such as glucose, sucrose, lactose, fructose, trehalose, mannose, mannitol, and maltose; organic acids, such as acetic acid, fumaric acid, citric acid, propionic acid, malic acid, pyruvic acid, malonic acid, and ascorbic acid;
alcohols, such as ethanol, propanol, butanol, pentanol, hexanol, isobutanol, and glycerol; oil or fat, such as soybean oil, rice bran oil, olive oil, corn oil, sesame oil, linseed oil, and the like. The amount of the carbon source added varies according to the kind of the carbon source, for example, about 1 to about 100 g, or about 2 to about 50 g per liter of medium.
[232] In some embodiments, a CI carbon substrate is provided to a microorganism that is capable of converting such a substrate to organic products (e.g. , microorganisms of the genera Methylobacterium, Methylomonas, Methylobacter. Methylococcus, Methylosinus, Methylocyctis, Methylomicrobium). In certain embodiments, the CI carbon substrate is selected from methane, methanol, formaldehyde, formic acid, methylated amines, methylated thiols, and carbon dioxide. In certain embodiments, the CI carbon substrate is
selected from methanol, formaldehyde, and methylated amines. In certain embodiments, the CI carbon substrate is methanol.
[233] The nitrogen source may include potassium nitrate, ammonium nitrate, ammonium chloride, ammonium sulfate, ammonium phosphate, ammonia, urea, and the like, alone or in combination. Amount of the nitrogen source added varies according to the kind of the nitrogen source, for example, about 0.1 to about 30 g, or about 1 to about 10 g per liter of medium.
[234] Inorganic salts may include potassium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate, magnesium sulfate, magnesium chloride, ferric sulfate, ferrous sulfate, ferric chloride, ferrous chloride, manganous sulfate, manganous chloride, zinc sulfate, zinc, chloride, cupric sulfate, calcium chloride, calcium carbonate, sodium carbonate, sodium sulfate, and the like, alone or in combination. Amount of inorganic salt varies according to the kind of the inorganic salt, for example, about 0.001 to about 10 g per liter of medium.
[235] Special required substances, for example, vitamins, nucleic acids, yeast extract, peptone, meat extract, malt extract, corn steep liquor, soybean meal, dried yeast etc., may be included alone or in combination. Amount of the special required substance used varies according to the kind of the substance, for example, about 0.2 g to about 200 g, or about 3 to about 10 g per liter of medium.
[236] In some embodiments, the pH of the culture medium is adjusted to pH about 2 to about 12, or about 6 to about 9. The medium may further include one or more buffer(s) to maintain the culture at the desired pH. Numerous buffers are known in the art and include phosphate, carbonate, acetate, PIPES, HEPES, and Tris buffers. A suitable buffer for a given microorganism can easily be determined by one of ordinary skill in the art. For Methylobacterium, a common medium, described by Lee, et al. (2009) Evolution 63:2813- 2830, is a phosphate buffered medium that consists of 1 mL of trace metal solution (to 1 liter of deionized water the following are added in this order: 12.738 g of EDTA disodium salt dihydrate, 4.4 g of ZnSO -7H20, 1 .466 g of CaCI2-2H20, 1 .012 g of MnCI2-4H20, 0.22 g of (ΝΗ4)6Μθ7θ24-4Η20, 0.314 g of CuSO4-5H20, 0.322 g of CoCl2-6H20, and 0.998 g of Fe3(SO4)2 -7H20; pH 5.0 is maintained after every addition), 100 mL of phosphate buffer (25.3 g of K2HPO4 and 22.5 g of NaH2PO4 in 1 liter of deionized water), 100 mL of sulfate solution (5 g of (NH4)2(SO4) and 0.98 g of Mg(SO4)2 in 1 liter of deionized water), and 799
mL of deionized water. All components are heat sterilized separately and then pooled together. An alternative medium recently developed for use with Methylobacterium extorquens takes advantage of an organic buffer and has a citrate-chelated trace metal mix. Culturing is carried out at temperature of 15° to 40°C, and preferably 20° to 35°C, usually for 1 to 20 days, and preferably 1 to 4 days, under aerobic conditions provided by shaking or aeration/agitation. Common practice with Methylobacterium is at 30°C. The protocol for making M-PIPES medium is described in Table S I of Delaney et al. (2013) PLoS One (8:e62957). Figure 2 in USSN 61/863,701 shows an exemplary recipe for medium optimized for use with extorquens.
[237] In order to generate dense cultures of microorganisms, such as Methylobacterium, it may be advantageous to use a fed-batch method. Methanol can be tolerated well at 0.5-1 % v/v (-120-240 mM), and thus this step size of addition can be used repeatedly. Critically, pH levels drop during culturing on methanol, such that the use of a base such as KOH or NaOH would be important to maintain the pH around 6.5. Aeration can be achieved via physical agitation, such as an impeller, via bubbling of filtered air or pure oxygen, or in combination. In order to reduce production costs, the buffer can be replaced from phosphates or PIPES to a carbonate-buffered medium.
[238] Microbial cells may be separated from the culture, for example, by a conventional means such as centrifugation or filtration. The cells may be isolated whole, or may be lysed to release their contents for extraction or further processing. The cells or the medium may be subjected to an extraction with a suitable solvent.
Intracellular taurine as a molecular chaperone and antioxidant.
[239] Microbial cells engineered to produce high levels of taurine or hypotaurine have increased levels of an important osmolyte known to promote protein folding and decrease oxidation (Warskulat et al. (2007) Methods Enzymol 428:439-58; Abe et al. (2015) Amino acids 47(5):909-15; Fujii et al. (2007) J Biochem 141(5):697-707); Oliveira et al. (2010) Pharmacological Reports 62: 185-193; Aruoma et al. (1988) Biochem J 256:251-55; Bucolo et al. (2016) Acta Ophthalmologic 95(256); Patel et al. (2016) Exp Toxic Pathol 68(2- 3): 103-12; Fontana et al. (2004) Neurochemical Research 29(1): 111-116). When microbial cells are used to express a protein of interest, intracellular taurine or hypotaurine could aid in increasing protein folding or decreasing protein inactivation through oxidation. Thus
the use of microorganisms engineered to accumulate intracellular taurine or hypotaurine could be used to increase the yield and/or specific activity of proteins of interest.
[240] Production of intracellular taurine and/or hypotaurine to aid in protein folding has potential benefits, both for cost and effectiveness. In vivo production of taurine or hypotaurine should be less expensive than when taurine or hypotaurine are added externally. Intracellular protein production may also be more effective if it simultaneously allows for higher levels of taurine or hypotaurine. Transport from the cellular medium into cells generally requires a higher concentration of these substrates in the medium and/or requires cellular energy for active transport.
Compositions containing taurine and taurine precursors
[241] Feed compositions are provided for use in aquaculture, or as animal feed, or as human nutritional supplements containing processed or unprocessed biomass from non- naturally occurring microorganism cells as described herein, as are methods of preparation of the feed compositions.
[242] The feed compositions or nutritional supplements include taurine and/or one or more taurine precursor(s), e.g., cysteate, sulfoacetaldehyde, and/or hypotaurine, produced by the non-naturally occurring microorganism. In some embodiments, taurine and/or taurine precursor(s) produced by the microorganism is encapsulated in the microorganism in the feed composition or supplement, e.g. , encapsulated in the lipid bilayer of the cell membrane of the microorganism. In some embodiments, taurine and/or taurine precursor(s) produced by the microbial biocatalyst is/are excreted into the culture medium and further purified, for example, using chromatographic or other separation and purification procedures. In some embodiments, taurine and/or taurine precursor(s) is/are chemically extracted from the producing microorganism.
[243] Taurine and/or taurine precursor(s) can be accumulated and encapsulated by the microorganism or can be exported outside the cell. Conditions required for export may be continuous during microbial growth or can be stimulated by limitation of nutrients, e.g., biotin, or by the presence of an inhibitor of microbial growth, such as an antibiotic or surfactant.
[244] In some embodiments, methods for separating and purifying taurine and/or taurine precursors from a culture containing microbial cells and microbially produced taurine may
deploy ion exchange, e.g. , ion exchange resins. In some embodiments, microbial cells may be separated by centrifugation, condensed, or filtered, and taurine and/or taurine precursors concentrated to, for example, at least about 80% purity.
[245] In certain embodiments, biomass that is incorporated into a feed or nutritional supplement composition can be in a dry, or substantially dry, form, e.g., containing less than about 20%, 10%, 5%, or 2% of moisture. In certain embodiments, the cultures are isolated by removing substantially all supernatant, such as by filtering, sedimentation, or centrifugation. In certain embodiments, the collection of cultures and further processing of biomass excludes a bacterial lysis step, e.g. , by use of detergents or ultrasound. In certain embodiments, the processed microbial cells maintain substantially whole cell membranes. In some embodiments, a substantial portion (e.g. , more than about 5%, 10%, 20%, 30%, 50%, or 80%) of bacterial cells may maintain viability in the processed biomass.
[246] The feed composition may contain at least about 1% of the biomass by weight. In certain embodiments, the feed composition is optimized for consumption by fish, seafood, humans, or other animals. For example, the feed may include one or more of EPA, DHA, and one or more essential amino acids.
[247] Methods for preparing a feed composition are also provided. In some embodiments, the method includes: (a) culturing in an appropriate medium at least one non-naturally occurring microorganism as described above; (b) concentrating the medium to provide a biomass; (c) optionally providing additional feed components; and (d) producing the feed composition from the biomass. In certain embodiments, step (b) includes centrifugation. In certain embodiments, step (b) includes allowing the biomass to settle. In certain embodiments, step (b) includes filtration. In certain embodiments, the method further includes a pre-treatment of the biomass after step (a) with a chemical agent (e.g. , a surfactant or solvent) to disrupt the cell membranes of the biomass. In certain
embodiments, the method further includes mechanical disruption of the cell membranes of the biomass after step (a).
[248] Examples of feedstuffs into which single cell protein enriched with taurine and/or taurine precursors, produced as described herein, may be incorporated include, for example, pet foods, such as cat foods, dog foods and the like, feeds for aquarium fish, cultured fish or crustaceans, etc., feed for farm-raised animals (including livestock and further including fish or crustaceans raised in aquaculture). The state of the biomass can be in whole cell,
lysed or partially processed. The taurine and/or taurine precursors and/or other caloric or nutritional supplements produced in described herein can also be incorporated into food or vitamin supplements for human consumption. Food or feed material into which taurine and/or taurine precursors produced as described herein is incorporated is preferably palatable to the organism that is the intended recipient. This food or feed material may have any physical properties currently known for a food material (e.g. , solid, liquid, soft). In some embodiments,, feed produced as described herein will undergo a pelletization process, e.g., through a hot or cold extrusion process at an inclusion rate of less than about 1%, 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, or 75%. In other scenarios, the taurine and/or taurine precursors-enriched protein can be consumed directly at 100% or combined with another substance in the form of liquid, baked goods or other to form, including but not limited to, various types of tablets, capsules, drinkable agents, gargles, etc.
[249] Methods of producing fish or seafood are also provided, including farming fish or seafood, and providing a diet, which includes a feed composition as described herein, to the fish or seafood.
[250] The following examples are intended to illustrate, but not limit the invention.
EXAMPLES
Example 1
Methods:
[251] Expression plasmids were constructed utilizing standard molecular cloning techniques and codon optimized, synthetically-derived DNA (see Table 1). These plasmids were transformed into Methylobacterium extorquens or Escherichia coli BL21 (DE3).
[252] M. extorquens strains were grown in a minimal media based on Choi et al(1989) Appl Microbiol Bioeng 17:392-6). This media was amended with 0.5% methanol, lOug/mL trimethylprim, and 50ug/mL Kanamycin. For expression, a saturated M. extorquens culture was diluted 100 fold into 25mL of fresh media in a 250mL Erlenmeyer flask and shaken at 200rpm at 30°C. At 24 hours and 36 hours, cultures were fed an additional 0.5% methanol and induced with 0.0125-0.05ng/uL anhydrotetracycline (ATC). M. extorquens cultures were harvested between 48 and 52 hours. Following centrifugation, the bacterial pellets were washed once with 1/20X phosphate buffered saline (PBS) and frozen at -20°C.
[253] E. coli cultures were grown in LB (lOg Tryptone, lOg NaCl, 5g Yeast extract per
liter) amended with lOOug/mL carbenicillin and 125uM isopropyl β-D-l- thiogalactopyranoside (IPTG). Following a 100-500 fold dilution, E. coli cultures were shaken at 200rpm at 30°C for 12-24 hours. Following centrifugation, the bacterial pellets were washed once with 1/20X PBS and frozen at -20°C.
[254] To induce chaperones to aid in protein folding, Betaine (Bet) or Benzyl alcohol (BA) were added at 5-10mm to cultures of E. coli or extorquens, as described in Marco et al. (2005) Cell Stress & Chaperones 10(4):329-339.
[255] For extraction of intracellular free amino acids, frozen bacterial pellets were resuspended in 1 :1 methanol: water and subjected to 3 to 4 freeze thaw cycles using dry- ice/ethanol slurry and a bath sonicator. Following centrifugation, the extraction supematants were derivatized with the Waters AccQ-Tag Ultra Chemistry kit (176001235) utilizing the provided protocols. Derivatized samples were analyzed on a Waters Acquity H-Class UPLC equipped with a 3100 Mass spectrophotometer. Samples were compared to the included amino acid standard amended with taurine, hypotaurine, and L-cysteate. The presence of taurine or hypotaurine was confirmed by the presence of mass spec ions matching the correct derivatized amino acid mass at the same retention time as in the standard samples. Results are in Table 2.
Results:
[256] Although the foregoing invention has been described in some detail by way of illustration and examples for purposes of clarity of understanding, it will be apparent to those skilled in the art that certain changes and modifications may be practiced without departing from the spirit and scope of the invention, which is delineated in the appended claims. Therefore, the description should not be construed as limiting the scope of the invention.
[257] All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entireties for all purposes and to the same extent as if each individual publication, patent, or patent application were specifically and individually indicated to be so incorporated by reference.
Claims
1. A non-naturally occurring microorganism that produces taurine and/or at least one taurine precursor selected from cysteate, sulfoacetaldehyde, and hypotaurine, wherein said microorganism comprises one or more exogenous polynucleotide(s), and wherein said microorganism expresses one or more enzyme(s) for production of taurine and/or taurine precursor(s) in the microorganism, selected from:
(a) cysteamine (2-aminoethanethiol) dioxygenase (ADO);
(b) cysteine dioxygenase (CDO), and cysteine sulfinic acid decarboxylase (CSAD) or glutamate decarboxylase (GAD);
(c) 3-mercaptopropionate dioxygenase (MDO; p3MDO), and CSAD or GAD;
(d) L-serine dehydratase; adenylyl-sulfate kinase (APSK) and sulfate
adenyltransferase, or 3'-phosphoadenosine 5'-phosphosulfate synthase (PAPSS 1); 3'- phosphoadenylyl sulfate:2-aminoacrylate C-sulfotransferase (PAPS-AS); and CSAD or GAD;
(e) cysteate synthase; optionally, L-serine dehydratase; and CSAD or GAD;
(f) L-cysteine dehydrase (CD); optionally, cystathionine gamma-lyase (CGL); sulfate adenyltransferase and APSK, or PAPSS 1; PAPS-AS; and CSAD or GAD;
(g) CD; optionally CGL; cysteate synthase, and CSAD or GAD;
(h) cysteate sulfo-lyase (CuyA), and CSAD or GAD;
(i) phosphosulfolactate synthase (ComA), 2-phospho-3-sulfolactate
phosphohydrolase (ComB), sulfolactate dehydrogenase (ComC), aspartate aminotransferase (AspAT), and CSAD or GAD;
(j) sulfoacetaldehyde acetyltransferase (Xsc) and taurine-pyruvate aminotransferase
(Tpa);
(k) ComA, ComB, ComC, sulfopyruvate decarboxylase (ComDE), and Tpa; and (1) aspartate aminotransferase, ComDE, and Tpa,
wherein at least one of said enzyme activities is encoded by an exogenous polynucleotide that is expressed in the microorganism.
2. A non-naturally occurring microorganism according to claim 1 , wherein the microorganism is from genera selected from Methylobacterium, Methylomonas ,
Methylobacter . Methylococcus , Methylosinus , Methylocyctis, Methylomicrobium,
Methylomonas, Methylpophilus , Methylobacillus , Methylobacterium, Hyphomicrobium, Xanthobacter , Bacillus, Paracoccus, Nocardia, Arthrobacter, Rhodopseudomonas , Pseudomonas, Candida, Hansenula, Pichia, Torulopsis, Rhodotorula, Escherichia, and Saccharomyces.
3. A non-naturally occurring microorganism according to claim 2, wherein the microorganism is selected from Methylobacterium, Escherichia, Saccharomyces, and Bacillus.
4. A non-naturally occurring microorganism according to claim 1 , wherein the microorganism is a methylotrophic bacterium.
5. A non-naturally occurring microorganism according to claim 1 , wherein said one or more exogenous polynucleotide(s) is codon optimized for expression in the microorganism.
6. A non-naturally occurring microorganism according to claim 1 , wherein said one or more exogenous polynucleotide(s) is operably linked to promoter(s) for expression in the microorganism.
7. A non-naturally occurring microorganism according to claim 1 , comprising deletion of one or more genes that encode enzyme(s) that degrade taurine, cysteate, or
sulfoacetaldehyde or modification of one or more genes that encode enzyme(s) that degrade taurine, cysteate, or sulfoacetaldehyde such that activity of the one or more enzyme(s) is lower than in the microorganism parent strain from which the non-naturally microorganism is derived.
8. A non-naturally occurring microorganism according to claim 7, wherein said one or more enzyme(s) that degrade taurine, cysteate, or sulfoacetaldehyde comprises taurine dehydrogenase, Tpa, taurine dioxygenase, CuyA, sulfoacetaldehyde acetyltransferase, and/or gamma-glutamyltransferase.
9. A non-naturally occurring microorganism according to claim 1, wherein said microorganism is genetically modified or artificially pre-selected to produce elevated levels of a carotenoid compound relative to the corresponding unmodified or unselected microorganism.
10. A non-naturally occurring microorganism according to claim 9, wherein said carotenoid compound is selected from β-carotene, lycopene, rhodopsin, zeaxanthin, lutein, canthaxanthin, astaxanthin, and sprilloxanthin.
11. A method for producing biomass that comprises taurine, comprising culturing the microorganism according to claim 1 in a culture medium under conditions suitable for growth of the microorganism and expression of said enzyme(s) for production of taurine and/or taurine precursor(s), wherein biomass comprising said taurine and/or taurine precursor(s) is produced in the culture.
12. A feed or nutritional supplement composition comprising biomass produced according to claim 11.
13. A method for producing biomass that comprises taurine and a carotenoid compound, comprising culturing the microorganism according to claim 9 in a culture medium under conditions suitable for growth of the microorganism and expression of said enzyme(s) for production of taurine and/or taurine precursor(s), wherein biomass comprising said taurine or taurine precursor(s) and a carotenoid compound is produced in the culture.
14. A feed or nutritional supplement composition comprising biomass produced according to claim 13.
15. A non-naturally occurring microorganism according to claim 1, wherein said microorganism accumulates intracellular taurine and/or hypotaurine, wherein said taurine and/or hypotaurine aids in the folding of one or more native or heterologous protein(s), thereby increasing enzymatic activity and/or protein yield of said one or more native or heterologous protein(s) in comparison to the parent microorganism from which the non- naturally occurring microorganism is derived.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16864890.5A EP3374490A4 (en) | 2015-11-09 | 2016-11-09 | Heterologous expression of taurine in microorganisms |
CN201680076248.3A CN108431205A (en) | 2015-11-09 | 2016-11-09 | Heterogenous expression of the taurine in microorganism |
US15/774,731 US11326171B2 (en) | 2015-11-09 | 2016-11-09 | Heterologous expression of taurine in microorganisms |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562252971P | 2015-11-09 | 2015-11-09 | |
US62/252,971 | 2015-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017083351A1 true WO2017083351A1 (en) | 2017-05-18 |
Family
ID=58695125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/061081 WO2017083351A1 (en) | 2015-11-09 | 2016-11-09 | Heterologous expression of taurine in microorganisms |
Country Status (4)
Country | Link |
---|---|
US (1) | US11326171B2 (en) |
EP (1) | EP3374490A4 (en) |
CN (1) | CN108431205A (en) |
WO (1) | WO2017083351A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017213142A1 (en) * | 2016-06-07 | 2017-12-14 | 味の素株式会社 | Method for producing hypotaurine or taurine |
WO2019094051A1 (en) * | 2017-11-13 | 2019-05-16 | Plant Sensory Systems, Llc | Methods for high taurine production using novel decarboxylases |
US11326171B2 (en) | 2015-11-09 | 2022-05-10 | Knipbio, Inc. | Heterologous expression of taurine in microorganisms |
US11560583B2 (en) | 2017-06-01 | 2023-01-24 | Knipbio, Inc. | Heterologous carotenoid production in microorganisms |
WO2023094010A1 (en) * | 2021-11-29 | 2023-06-01 | Wacker Chemie Ag | Process for producing taurine |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023547024A (en) | 2021-07-05 | 2023-11-09 | ワッカー ケミー アクチエンゲゼルシャフト | Method for enzymatic oxidation of sulfinic acid to sulfonic acid |
WO2023094011A1 (en) | 2021-11-29 | 2023-06-01 | Wacker Chemie Ag | Method for preparing l-cysteic acid |
WO2023232233A1 (en) | 2022-05-31 | 2023-12-07 | Wacker Chemie Ag | Process for producing l-cysteic acid and use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120107360A1 (en) * | 2009-04-14 | 2012-05-03 | The Secetart Of State For Defence | Gamma-glutamyl transpeptidase attenuated francisella |
US20120222148A1 (en) | 2009-11-02 | 2012-08-30 | Plant Sensory Systems Llc | Methods for the biosynthesis of taurine or hypotaurine in cells |
US20150044327A1 (en) * | 2013-08-08 | 2015-02-12 | Knipbio | Methylotrophs for aquaculture and animal feed |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
EP1298200B1 (en) | 2001-09-28 | 2006-03-29 | Ajinomoto Co., Inc. | L-Cysteine producing bacterium and method for producing l-cysteine |
US20050108791A1 (en) * | 2001-12-04 | 2005-05-19 | Edgerton Michael D. | Transgenic plants with improved phenotypes |
CN101454013A (en) * | 2006-04-13 | 2009-06-10 | 阿姆布罗泽有限公司 | Compositions and methods for producing fermentation products and residuals |
KR101214632B1 (en) * | 2009-06-03 | 2012-12-21 | 한국과학기술원 | Recombinant Microorganism Producing Taurine and Method for Preparing Taurine Using the Same |
CN108431205A (en) | 2015-11-09 | 2018-08-21 | 尼普拜耳股份有限公司 | Heterogenous expression of the taurine in microorganism |
-
2016
- 2016-11-09 CN CN201680076248.3A patent/CN108431205A/en active Pending
- 2016-11-09 US US15/774,731 patent/US11326171B2/en active Active
- 2016-11-09 EP EP16864890.5A patent/EP3374490A4/en not_active Withdrawn
- 2016-11-09 WO PCT/US2016/061081 patent/WO2017083351A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120107360A1 (en) * | 2009-04-14 | 2012-05-03 | The Secetart Of State For Defence | Gamma-glutamyl transpeptidase attenuated francisella |
US20120222148A1 (en) | 2009-11-02 | 2012-08-30 | Plant Sensory Systems Llc | Methods for the biosynthesis of taurine or hypotaurine in cells |
US20150044327A1 (en) * | 2013-08-08 | 2015-02-12 | Knipbio | Methylotrophs for aquaculture and animal feed |
WO2015021352A2 (en) | 2013-08-08 | 2015-02-12 | Knipbio | Methylotrophs for aquaculture and animal feed |
Non-Patent Citations (44)
Title |
---|
ABE ET AL., AMINO ACIDS, vol. 47, no. 5, 2015, pages 909 - 15 |
ABE, Y ET AL.: "Role of the Osmolyte Taurine on the Folding of a Model protein, Hen Egg White Lysozyme, Under a Crowding Condition.", AMINO ACIDS., vol. 47, no. 5, 21 January 2015 (2015-01-21), pages 1 - 7, XP035484440 * |
AGNELLO ET AL., ACS CHEM BIOL., vol. 8, no. 10, 2013, pages 2264 - 2271 |
AGNELLO, G ET AL.: "Discovery of a Substrate Selectivity Motif in Amino Acid Decarboxylases Unveils a Taurine Biosynthesis Pathway in Prokaryotes.", ACS CHEMICAL BIOLOGY., vol. 8, no. 10, 23 August 2013 (2013-08-23), pages 1 - 17, XP055149111 * |
ALTSHUL, J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
ARUOMA ET AL., BIOCHEM J, vol. 256, 1988, pages 251 - 55 |
AWANO ET AL., APPL ENVIRON MICROBIOL, vol. 71, no. 7, 2005, pages 4149 - 52 |
BROSNAN ET AL., J NUTR., vol. 136, no. 6, 2006, pages 16365 - 16405 |
BUCOLO ET AL., ACTA OPHTHALMOLOGIC, vol. 95, 2016, pages 256 |
CHOI ET AL., APPL MICROBIOL BIOENG, vol. 17, 1989, pages 392 - 6 |
CHOU, H.-H. ET AL., PLOS GENETICS, vol. 5, 2009, pages e1000652 |
CHUBIZ, L. M. ET AL., BMC RESEARCH NOTES, vol. 6, 2013, pages 183 |
D'ARGENIO, D. A. ET AL., JOURNAL OF BACTERIOLOGY, vol. 183, 2001, pages 1466 - 1471 |
DELANEY ET AL., PLOS ONE, vol. 8, 2013, pages e62957 |
FONTANA ET AL., NEUROCHEMICAL RESEARCH, vol. 29, no. 1, 2004, pages 111 - 116 |
FRANCIS ET AL., AQUACULTURE, vol. 199, 2001, pages 197 - 227 |
FUJII ET AL., J BIOCHEM, vol. 141, no. 5, 2007, pages 697 - 707 |
FUJII, JBIOCHEM, vol. 141, no. 5, 2007, pages 697 - 707 |
GIBSON ET AL., AQUACULTURE, vol. 269, 2007, pages 514 - 524 |
HALEMARKHAM: "The Harper Collins Dictionary of Biology", 1991, HARPER PERENNIAL |
HENIKOFF ET AL., PROC. NATL. ACAD. SCI., vol. 89, 1989, pages 10915 |
HIGGINS ET AL., GENE, vol. 73, 1988, pages 237 |
HONJOH ET AL., AMINO ACIDS, vol. 38, no. 4, 2010, pages 1173 - 1183 |
KARIN ET AL., PROC. NATL. ACAD. SCI., vol. 90, 1993, pages 5873 |
LANGDON ET AL., AQUACULTURE, vol. 227, 2003, pages 259 - 275 |
LEE, M.-C. ET AL., EVOLUTION, vol. 63, 2009, pages 2813 - 2830 |
MARCO ET AL., CELL STRESS & CHAPERONES, vol. 10, no. 4, 2005, pages 329 - 339 |
MARX, C. J. ET AL., BMC RESEARCH NOTES, vol. 1, 2008, pages 1 |
MARX, C. J. ET AL., JOURNAL OF BACTERIOLOGY, vol. 185, 2003, pages 669 - 673 |
MARX, C. J.M. E. LIDSTROM, BIOTECHNIQUES, vol. 33, 2002, pages 1062 - 1067 |
MARX, C. J.M. E. LIDSTROM, MICROBIOLOGY, vol. 147, 2001, pages 2065 - 2075 |
MATSUNARI ET AL., FISH SCI, vol. 79, no. 5, 2013, pages 815 - 821 |
MCCUSKER ET AL., JNUTR SCI, vol. 3, 2014, pages e39 |
OLIVEIRA ET AL., PHARMACOLOGICAL REPORTS, vol. 62, 2010, pages 185 - 193 |
PATEL ET AL., EXP TOXIC PATHOL, vol. 68, 2016, pages 103 - 12 |
PERSON ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 2444 - 2448 |
RIPPSSHEN, MOLECULAR VISION, vol. 18, 2012, pages 2673 - 2786 |
SALZE ET AL., AQUACULTURE, vol. 437, 2015, pages 215 - 229 |
See also references of EP3374490A4 |
SINGLETON ET AL.: "Dictionary of Microbiology and Molecular Biology", 1994, JOHN WILEY AND SONS |
TAKEUCHI ET AL., BIOCHIM BIOPHYS ACTA, vol. 1464, no. 2, 2000, pages 219 - 230 |
TEVATIA ET AL., ALGAL RES, vol. 9, 2015, pages 21 - 26 |
WARSKULAT ET AL., METHODS ENZYMOL, vol. 428, 2007, pages 439 - 58 |
WU ET AL., AQUAE NUTR., vol. 21, no. 2, 2015, pages 214 - 222 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11326171B2 (en) | 2015-11-09 | 2022-05-10 | Knipbio, Inc. | Heterologous expression of taurine in microorganisms |
WO2017213142A1 (en) * | 2016-06-07 | 2017-12-14 | 味の素株式会社 | Method for producing hypotaurine or taurine |
US11560583B2 (en) | 2017-06-01 | 2023-01-24 | Knipbio, Inc. | Heterologous carotenoid production in microorganisms |
WO2019094051A1 (en) * | 2017-11-13 | 2019-05-16 | Plant Sensory Systems, Llc | Methods for high taurine production using novel decarboxylases |
US11771114B2 (en) | 2017-11-13 | 2023-10-03 | Plant Sensory Systems, Llc | Methods for high taurine production using novel decarboxylases |
WO2023094010A1 (en) * | 2021-11-29 | 2023-06-01 | Wacker Chemie Ag | Process for producing taurine |
Also Published As
Publication number | Publication date |
---|---|
EP3374490A4 (en) | 2019-08-28 |
CN108431205A (en) | 2018-08-21 |
US11326171B2 (en) | 2022-05-10 |
US20190062757A1 (en) | 2019-02-28 |
EP3374490A1 (en) | 2018-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11326171B2 (en) | Heterologous expression of taurine in microorganisms | |
CN110049953B (en) | Microbial production of protein and PHB from alcohol-utilizing bacteria | |
US20230348948A1 (en) | Heterologous Carotenoid Production in Microorganisms | |
US10920230B2 (en) | Methylotrophs for aquaculture and animal feed | |
Waditee-Sirisattha et al. | Halophilic microorganism resources and their applications in industrial and environmental biotechnology | |
US8883969B2 (en) | Method for production of carotenoid-synthesizing microorganism and method for production of carotenoid | |
US20050003474A1 (en) | Carotenoid biosynthesis | |
JP2004528839A (en) | Carotenoid biosynthesis | |
US8373023B2 (en) | Biochemical route to astaxanthin | |
ES2389302T3 (en) | Procedure to obtain microorganisms that produce cantaxanthin and to produce cantaxanthin | |
US20150167041A1 (en) | Astaxanthin production using a recombinant microbial host cell | |
US20230225366A1 (en) | Microbial-based animal feed for modulating off-flavor content in aquaculture | |
JP5023474B2 (en) | Method for producing carotenoid-synthesizing microorganism and method for producing carotenoid | |
KR20090130116A (en) | Astaxanthin-producing bacterium, bacterial culture, astaxanthin-containing composition and method of producing astaxanthin | |
KR20230066973A (en) | Novel strain of Schizochytrium sp. with easy intracellular oil extraction and a method for producing oil containing omega3 using the same | |
WO2023146544A1 (en) | Bio-based taurine production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16864890 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016864890 Country of ref document: EP |